0001477932-13-003954.txt : 20130820 0001477932-13-003954.hdr.sgml : 20130820 20130819215101 ACCESSION NUMBER: 0001477932-13-003954 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20130630 FILED AS OF DATE: 20130820 DATE AS OF CHANGE: 20130819 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sanomedics International Holdings, Inc CENTRAL INDEX KEY: 0001501972 STANDARD INDUSTRIAL CLASSIFICATION: MEASURING & CONTROLLING DEVICES, NEC [3829] IRS NUMBER: 273320809 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54167 FILM NUMBER: 131049610 BUSINESS ADDRESS: STREET 1: 444 BRICKELL AVE. STREET 2: SUITE 415 CITY: MIAMI STATE: FL ZIP: 33131 BUSINESS PHONE: 305-433-7814 MAIL ADDRESS: STREET 1: 444 BRICKELL AVE. STREET 2: SUITE 415 CITY: MIAMI STATE: FL ZIP: 33131 10-Q 1 simh_10q.htm FORM 10-Q simh_10q.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 10-Q
 
(Mark One)
 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended June 30, 2013
 
or
 
¨
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from __________ to __________
 
Commission file number: 000-54167
 
Sanomedics International Holdings, Inc.
(Exact name of registrant as specified in its charter)

Delaware
 
27-3320809
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)

444 Brickell Avenue, Suite 415, Miami, Florida
 
33131
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code (305) 433-7814
 
not applicable
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ¨ No x

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer
¨
Accelerated filer
¨
Non-accelerated filer
¨
Smaller reporting company
x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ¨ No x
 
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date. 26,508,609 shares of common stock are issued and outstanding as of August 16, 2013.
 


 
 

 
 
TABLE OF CONTENTS
 
     
Page No.
 
PART I - FINANCIAL INFORMATION
 
   
Item 1.
Financial Statements.
   
5
 
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations.
   
15
 
Item 3.
Quantitative and Qualitative Disclosures About Market Risk.
   
22
 
Item 4.
Controls and Procedures.
   
22
 
   
PART II - OTHER INFORMATION
 
   
Item 1.
Legal Proceedings.
   
23
 
Item 1A.
Risk Factors.
   
23
 
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds.
   
24
 
Item 3.
Defaults Upon Senior Securities.
   
25
 
Item 4.
Mine Safety Disclosures.
   
25
 
Item 5.
Other Information.
   
25
 
Item 6.
Exhibits.
   
26
 
 
 
2

 
 
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
 
This report includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “likely,” “aim,” “will,” “would,” “could,” and similar expressions or phrases identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and future events and financial trends that we believe may affect our financial condition, results of operation, business strategy and financial needs. Forward-looking statements include, but are not limited to, statements about our:
 
our revenues and profits are not assured,
we may be unable to continue as a going concern,
ability to close pending acquisitions,
our ability to pay our obligations represented by secured notes when they become due,
we may not be able to obtain the substantial additional capital we need,
cost and quality issues might arise from our dependence on a third-party, sole source Chinese manufacturer,
we may be unable to make or successfully integrate acquisitions,
we may not be able to compete effectively,
our research and development may be unsuccessful; our next generation products may not be developed, or if developed, may fail to win commercial acceptance,
we may be unable to develop next generation products if we cannot hire electrical engineers,
growth, if any, could be unmanageable,
product shortages may arise if our contract manufacturer fails to comply with government regulations,
our medical devices may not meet government regulations,
current economic conditions may jeopardize our fund-raising efforts,
our intellectual property may not be protectable,
we face intellectual property risks that may negatively affect our brand names, reputation, revenues, and potential profitability,
our trademarks are valuable, and any inability to protect them could reduce the value of our products and brands,
product warranties and product liabilities could be costly,
we may be unable to replace current management.
we may receive unfavorable results in the outcome of any pending lawsuits.
management actions could cause substantial dilution and stock price declines and discourage a takeover,
we are engaged in a number of related party transactions,
management could terminate employment, and our operations and viability would be hurt, if we cannot fund the 2010 bonuses and accrued salaries which were earned,
our common stock is quoted on the OTC Markets, which may discourage investors from purchasing it more than if it was listed on a national exchange,
our common stock is illiquid,
the application of the “penny stock” rules could adversely affect transactions in our common stock and could increase transaction cost,
the price of our common stock may be very volatile,
a significant portion of our outstanding shares are restricted securities and the sale of those shares will depress our stock price
as an issuer of a “penny stock,” the protection provided by the Federal securities laws relating to forward looking statements does not apply to us, and
we have not paid dividends in the past and do not expect to pay dividends for the foreseeable future. Any return on investment may be limited to the value of our common stock, if any.
 
 
3

 
 
You should read thoroughly this report and the documents that we refer to herein with the understanding that our actual future results may be materially different from and/or worse than what we expect. We qualify all of our forward-looking statements by these cautionary statements including those made in Part I. Item 1A. Risk Factors appearing in our Annual Report on Form 10-K for the year ended December 31, 2012. Other sections of this report include additional factors which could adversely impact our business and financial performance. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Except for our ongoing obligations to disclose material information under the Federal securities laws, we undertake no obligation to release publicly any revisions to any forward-looking statements, to report events or to report the occurrence of unanticipated events. These forward-looking statements speak only as of the date of this report, and you should not rely on these statements without also considering the risks and uncertainties associated with these statements and our business.

OTHER PERTINENT INFORMATION

Unless specifically set forth to the contrary, when used in this report the terms “we,” “our,” “us,” and similar terms refers to Sanomedics International Holdings, Inc., a Delaware corporation, and our wholly-owned subsidiaries. In addition, the “second quarter of 2013” refers to the three months ended June 30, 2013, the “second quarter of 2012” refers to the three months ended June 30, 2012, “2012” refers to the year ended December 31, 2012 and “2013” refers to the year ending December 31, 2013.

Unless specifically set forth to the contrary, the information which appears on our website at www.sanomedics.com is not part of this report.
 
 
4

 
 
PART I – FINANCIAL INFORMATION
 
Item 1. Financial Statements.
 
Sanomedics International Holdings, Inc.
Condensed Consolidated Balance Sheets
 
   
June 30,
   
December 31,
 
   
2013
   
2012
 
   
(Unaudited)
   
(Audited)
 
Assets
             
Current Assets
           
Cash
  $ 72,482     $ 26,084  
Accounts receivable
    49,376       8,117  
Inventory
    2,318       2,171  
Deposit on planned acquisition
    400,000       -  
Prepaid expense
    10,810       -  
                 
Total Current Assets
    534,986       36,372  
                 
Fixed assets, net
    15,741       17,049  
                 
Other Assets
               
Patents, net
    34,306       36,796  
Deposits
    7,999       -  
                 
Total Other Assets
    42,305       36,796  
                 
Total Assets
  $ 593,032     $ 90,217  
                 
Liabilities and Stockholders’ Deficit
                 
Current Liabilities
               
Accrued salaries payable
  $ 656,569     $ 1,290,516  
Accounts payable and other liabilities
    314,786       243,836  
Accrued interest payable
    283,857       217,001  
Convertible notes payable, net
    68,385       4,688  
Derivative liabilities
    1,847,560       40,697  
Due to related parties
    126,597       65,738  
Notes payable - related parties, current portion
    858,132       1,379,427  
                 
Total Current Liabilities
    4,155,886       3,241,903  
                 
Notes payable - related parties
    1,102,787       -  
Convertible note payable, net
    31,250       12,500  
                 
Total Liabilities
    5,289,923       3,254,403  
                 
Commitments and Contingencies
               
                 
Stockholders’ Deficit
               
Preferred stock, $0.001 par value: 1,000 shares authorized,
               
issued and outstanding as of June 30, 2013 and December 31, 2012,
               
respectively
    1       1  
Common stock, $0.001 par value: 250,000,000 shares authorized,
               
20,508,609 and 20,403,586 issued and outstanding as of June 30, 2013
               
and December 31,2012, respectively.
    20,509       20,404  
Additional paid in capital
    6,785,860       5,748,691  
Stock subscription receivable
    (20,000 )     (20,000 )
Accumulated deficit
    (11,483,261 )     (8,913,282 )
                 
Total Stockholders’ Deficit
    (4,696,891 )     (3,164,186 )
                 
Total Liabilities and Stockholders' Deficit
  $ 593,032     $ 90,217  
 
The accompanying notes are an integral part of these condensed consolidated financial statements
 
 
5

 
 
Sanomedics International Holdings, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)

    For the Three Months Ended June 30,    
For the Six Months Ended June 30,
 
   
2013
   
2012
   
2013
   
2012
 
                         
                         
Revenues, net
  $ 63,941       7,101     $ 121,079     $ 35,028  
                                 
Cost of goods sold
    17,021       12,461       33,592       34,692  
                                 
Gross profit (loss)
    46,920       (5,360 )     87,487       336  
                                 
Operating expenses
                               
General and administrative
    269,676       320,987       453,808       547,828  
Research and development
    25,750       -       53,500       8,500  
Stock compensation
    38,842       204,888       255,738       369,751  
Depreciation and amortization
    1,899       1,061       3,798       2,122  
                                 
Total operating expenses
    336,167       526,936       766,844       928,201  
                                 
Loss from operations
    (289,247 )     (532,296 )     (679,357 )     (927,865 )
                                 
Other income (expense)
                               
Amortization of debt discount
    (30,898 )     -       (54,337 )     -  
Derivative expense     (2,830,798     -       (2,830,798     -  
Unrealized gain on fair value of derivatives
    1,047,628       -       1,047,628       -  
Interest expense
    (27,092 )     (54,489 )     (53,115 )     (108,956 )
                                 
Total other income (expense)
    (1,841,160     (54,489 )     (1,890,622     (108,956 )
                                 
Net income (loss) before income taxes
    (2,130,407     (586,785 )     (2,569,979     (1,036,821 )
Income taxes
    -       -       -       -  
                                 
Net income (loss)
  $ (2,130,407   $ (586,785 )   $ (2,569,979   $ (1,036,821 )
                                 
Net income ( loss) per share - basic and diluted
  $ (0.10   $ (0.04 )   $ (0.13   $ (0.07 )
                                 
Weighted average number of shares outstanding during the period - basic and diluted
    20,410,102       14,258,939       20,454,423       14,258,939  
 
The accompanying notes are an integral part of these condensed consolidated financial statements
 
 
6

 
 
Sanomedics International Holdings, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 
   
For the Six Months Ended June 30,
 
   
2013
   
2012
 
             
CASH FLOWS FROM OPERATING ACTIVITIES
           
Net loss
  $ (2,569,979   $ (1,036,821 )
Adjustments to reconcile net income (loss) to net cash used in operating activities
               
Depreciation and amortization
    3,798       2,122  
Stock compensation
    255,738       369,751  
Amortization of debt discount on convertible notes
    54,337       -  
Derivative expenses     2,830,798       -  
Unrealized gain on fair value of derivative liabilities
    (1,047,628 )     -  
Changes in operating assets and liabilities
               
Accounts receivable
    (41,259 )     (4,600 )
Inventory
    (147 )     29,867  
Prepaid expense
    (400,000 )     -  
Other current assets
    (10,810 )     1,926  
Deposits
    (7,999 )     -  
Bank overdraft
    -       (4,522 )
Accrued salaries payable
    69,392       131,539  
Accounts payable and other liabilities
    50,950       (34,240 )
Accrued interest payable
    66,856       108,935  
Due to related parties
    60,859       20,547  
Net Cash Used In Operating Activities
    (685,094 )     (415,496 )
                 
CASH FLOWS FROM INVESTING ACTIVITIES:
               
Purchase of fixed assets
    -       (45 )
Net Cash Used In Investing Activities
    -       (45 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES
               
Proceeds from notes - related parties
    581,492       47,000  
Issuance of stock subscriptions payable
    -       133,500  
Sale of common stock
    -       238,000  
Proceeds from convertible notes payable
    150,000       -  
Net Cash Provided By Financing Activities
    731,492       418,500  
                 
Net increase (decrease) in cash
    46,398       2,959  
                 
Cash - beginning of period
    26,084       -  
                 
Cash - end of period
  $ 72,482     $ 2,959  
                 
Supplemental Disclosure of Cash Flow Information
               
Cash paid during the period for:
               
Income taxes
  $ -     $ -  
Interest
  $ -     $ -  
                 
Non-cash financing transactions:
               
Common stock issued to consultants for services
  $ 96,343     $ -  
Common stock issued for conversion of debt, net of derivative
  $ 78,197     $ -  
Accrued salaries payable converted to convertible promissory note - officer   $ 703,339     $ -  
 
The accompanying notes are an integral part of these condensed consolidated financial statements
 
 
7

 
 
Sanomedics International Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
June 30, 2013
(Unaudited)
 
NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION

Sanomedics International Holdings, Inc. (referred to herein as “we”, “us”, “our” or the “Company”) formerly Grand Niagara Mining and Development Co, Inc. ("Grand Niagara") was originally incorporated in the state of Idaho in 1955 and re-domiciled in the state of Delaware on April 6, 2009. The Company, through its subsidiaries, designs, develops, markets and distributes non-invasive infrared thermometers principally for consumer and pet home health care.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The results for the interim period are not necessarily indicative of the results to be expected for the full year.

The unaudited interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K, which contains the audited consolidated financial statements and notes thereto, together with the Management’s Discussion and Analysis, for the fiscal year ended December 31, 2012. The interim results for the three and six months ended June 30, 2013 are not necessarily indicative of the results for the full fiscal year.

NOTE 2 – LIQUIDITY AND GOING CONCERN

The condensed consolidated financial statements have been prepared on a going concern basis, and do not reflect any adjustments related to the uncertainty surrounding our recurring losses or accumulated deficit.

The Company currently has limited revenue and is experiencing recurring losses. These factors raise substantial doubt about its ability to continue as a going concern. Management has financed the Company's operations principally through loans from an affiliate of the Company’s former CEO, who is also one of the principal shareholders. Through June 30, 2013, the Company obtained its liquidity principally from approximately $582,000 of cash advances from an affiliate of the former Chairman and CEO and the Company's principal shareholder. The Company may need to continue borrowings from an affiliate of the former Chairman and CEO and the Company's principal shareholder and will also need to raise additional capital. However, management cannot provide any assurances that the Company will be successful in completing this financing and accomplishing any of its plans.

The ability of the Company to continue as a going concern is dependent upon continued financial commitments from related parties and eventually secure other sources of financing in addition to those funds provided by its affiliate and attain profitable operations. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
 
 
8

 
 
Sanomedics International Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
June 30, 2013
(Unaudited)

NOTE 3 – NOTES PAYABLE -RELATED PARTIES
 
   
June 30,
   
December 31,
 
   
2013
   
2012
 
             
Notes Payable consists of the following:
           
             
Secured Convertible Promissory Note - CLSS Holdings, LLC, dated September 30,
           
2010. Note accrues interest at 9% per annum, due and payable on October 1, 2013(A)
  $ 181,000     $ 181,000  
Secured Convertible Promissory Note - CLSS Holdings, LLC, dated March 12, 2011.
               
Note accrues interest at 9% per annum, due and payable on October 1, 2013 (A)
    367,000       367,000  
Secured Convertible Promissory Note - CLSS Holdings, LLC, dated September 30,
               
2011. Note accrues interest at 9% per annum, due and payable on September 30, 2013(A)
    220,000       220,000  
Secured Convertible Promissory Note - CLSS Holdings, LLC, dated March 12, 2011.
               
Note accrues interest at 7.5% per annum, due and payable on October 1, 2013 (A)
    334,787       334,787  
Convertible Promissory Note-Officer, dated June 17, 2013. Note accrues interest
               
at 9% per annum, due and payable on March 30, 2015, net of discount of $703,339
               
(B) Refer to Note 5
    -       -  
                 
Total
    1,102,787       1,102,787  
                 
Other advances from CLSS Holdings, LLC, not evidenced by a promissory Note (A)
    858,132       276,640  
      1,960,919       1,379,427  
                 
Less: Current portion
    858,132       1,379,427  
Notes Payable-related parties
  $ 1,102,787     $ -  
 
The secured convertible promissory notes above are collateralized by substantially all the assets of the Company and are convertible, at the holder's option, into common shares of the Company at a fixed conversion price of $0.50 per share. CLSS is wholly owned by the Company's Former CEO who also is a principal shareholder of the Company.
 
(A)  
On May 9, 2013, the Company and an affiliate of the Company’s former CEO agreed to terminate each of the above listed convertible notes and issue a single replacement convertible note that includes the obligations currently provided together with the advances and accrued interest of $238,868. The original convertible notes were not delivered to the Company and accordingly, the replacement note was not issued and voided. On August 13, 2013 an agreement was executed covering these Notes to extend the maturity of these Notes to March 31, 2015.
 
(B)  
On June 17, 2013, the Company and its President and a principal stockholder of the Company and a Director agreed to convert accrued salary totaling $703,339 into a long term convertible note as reflected above. The Note is convertible, at the holder's option, into common shares of the Company at a fixed conversion price of $0.50 per share.
 
 
9

 
 
Sanomedics International Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
June 30, 2013
(Unaudited)
 
NOTE 4 – CONVERTIBLE NOTES PAYABLE

On August 24, 2012, the Company executed a convertible note for $75,000. The convertible note is unsecured and has a maturity date of August 24, 2014. Interest will accrue at 9% per annum until paid or maturity and is convertible into common shares at a fixed convertible price of $0.50 per share. In the event that the Company undertakes financing while this debt is unpaid, the holder shall have the right to convert at the lessor of the offering price or the fixed conversion price. As of June 30, 2013 and December 31, 2012, the convertible note amounted to $31,250 and $12,500, net of unamortized discounts of $43,750 and $62,500, respectively.

On December 6, 2012, the Company entered into a Securities Purchase Agreement and convertible promissory note (“Note”) in the principal amount of $37,500. The Note, which was due on August 29, 2013, bears interest at 8% per annum until paid or to maturity was converted on June 11, 2013 and June 18, 2013 into a total of 29,128 shares of the Company’s common stock at a conversion price equal to a 42% discount to the average of the lowest three closing bid prices of the common stock during the 10 trading days prior to conversion or $1.36 and $1.36 per share. As of June 30, 2013 and December 31, 2012, the convertible note amounted to $ -0- and $4,688, net of unamortized discount of $37,500 and $32,812, respectively.

On June 17, 2013, the Company entered into a Promissory Note (the “Note”) with a third party lender (“Lender”) in the principal amount up to $500,000. On June 19, 2013, the Lender executed the Note and funded the Company an initial tranche of $150,000 pursuant to the terms thereof. The principal sum of the Note carries a $50,000 original issue discount (“OID”) , which is prorated based on the consideration paid by the lender. The maturity date of each tranche funded under the Note is one year from the date of each payment by the Lender. The principal amount of the Note due is prorated based upon the consideration actually paid to us, plus a 10% OID, and we are only obligated to repay the amount of the funded Note, together with interest and fees. The Note may be prepaid by us at any time on or before 90 days from the date of issue interest free. After the initial 90 day period the Note bears a one-time interest charge of 12% applied to the principal sum. All principal and accrued interest on the Note is convertible into shares of the Company’s common stock at the election of the Lender at any time at a conversion price of the lesser of $2.75 or 70% of the lowest trade price in the 25 trading days prior to conversion. At all times while the Note is outstanding we agreed to reserve from our authorized but unissued shares of common stock 550,000 shares for the possible conversion of the Note; plus provide registration rights. As of June 30, 2013, the Note amounted to $68,385 , net of unamortized discount of $81,615.

In accordance with ASC 470-20 Debt with Conversion and Other Options, the Company recorded total discounts of $125,365 and $0 for the beneficial conversion features of the convertible debts incurred during the periods ended June 30, 2013 and June 30, 2012, respectively. The discounts are being amortized to interest expense over the term of the notes using the effective interest method. The Company recorded $54,337 and $-0- of interest expense pursuant to the amortization of the note discounts for the six months ended June 30, 2013 and for the six months  ended June 30, 2012, respectively; and $30,898 and $ -0- for the three months ended June 30, 2013 and June 30, 2012.
 
NOTE 5 – DERIVATIVE LIABILITIES

The Company analyzed the related party convertible note-officer and convertible promissory notes referred to in Notes 3 and 4 based on the provisions of ASC 815-15 and determined that the conversion options of the convertible notes qualify as embedded derivatives.
 
 
10

 
 
Sanomedics International Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
June 30, 2013
(Unaudited)
 
NOTE 5 – DERIVATIVE LIABILITIES (CONTINUED)

The fair value upon inception of the embedded derivatives are determined to total $2,915,188 and recorded as embedded derivative liabilities. The embedded derivatives are revalued at the end of each reporting period and any resulting gain or loss is recognized as a current period charge to the statement of operations.
 
The Company accounts for the embedded conversion features included in its common stock as well as derivative liabilities. The aggregate fair value of derivative liabilities as of June 30, 2013 and December 31, 2012 amounted to $1,847,560 and $40,697, respectively. The net decrease of $1,047,628 in the fair value of the derivative liabilities between the respective periods is included in other income as an unrealized gain on fair value of derivatives.

NOTE 6 – COMMITMENTS AND CONTINGENCIES

Litigation

From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm its business.

On May 21, 2013, Exergen Corporation commenced legal action in the United States District Court for the District of Massachusetts against us, claiming infringement of certain intellectual property. Exergen is seeking various types of relief, including an injunction against further infringement of certain intellectual property. Given the inherent uncertainty and unpredictability of litigation and due to the early status of this legal action, no range of loss or possible loss can be reasonably estimated at this time. However, we do not expect the outcome of this matter to have a material adverse effect on our consolidated financial statements when taken as a whole. As of June 30, 2013 and through the date of this filing, no amount is accrued as a loss is not considered probable or estimable.

NOTE 7 – STOCKHOLDERS’ DEFICIT

Common stock

On February 9, 2013, the Company issued a total of 50,000 shares of common stock to two consultant for services valued at $1.15 per share. As a result, the Company recorded stock compensation in the amount of $57,500 for the three months ended March 31, 2013.

On June 28, 2013, the Company issued a total of 25,895 shares of common stock to a public relations firm as settlement of its services valued at $1.50 per share. As a result, the Company recorded stock compensation in the amount of $38,842 for the three months ended June 30, 2013.

On June 11, 2013 and June 28, 2013, in connection with a Securities Purchase Agreement and convertible promissory note (“Note”) in the principal amount of $37,500, the Company converted the Note into a total of 29,128 shares of the Company’s common stock at a conversion price of $1.36  per share.

Stock Options

On March 7, 2013, the Company granted to its Chief Technology Officer 150,000 seven-year stock options with an exercise price of $0.50 per share. The Company determined that the fair value of the options was approximately $159,000 using the Black Scholes method and recorded as stock compensation in the accompanying condensed consolidated financial statements.
 
 
11

 
 
Sanomedics International Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
June 30, 2013
(Unaudited)
 
NOTE 8 – PENDING ACQUISITION

Prime Time Medical:

On April 26, 2013, the Company entered into a Stock Purchase Agreement (the “Stock Purchase Agreement ”) with Prime Time Medical, Inc., a Florida corporation (“Prime Time”) and Mark R. Miklos, the sole equity holder of Prime Time (“Miklos”). Prime Time is a Durable Medical Equipment provider of home medical equipment servicing consumers throughout West Central Florida.

Pursuant to the Stock Purchase Agreement, at the closing Miklos will transfer to the Company all the outstanding shares of capital stock of Prime Time for an aggregate purchase price of up to $3,100,000, subject to certain adjustments as summarized herein. The purchase price will be paid in a combination of cash, promissory notes and shares of the Company’s common stock
 
On the closing date, the Company will make a total cash payment to Miklos as follows: (a) if the closing occurs on or prior to May 26, 2013, the Company shall pay $950,000 at closing, (b) if the closing occurs after May 26, 2013 but on or prior to June 26, 2013 the Company shall pay to Seller $1,050,000 at closing, and (c) if the closing occurs after June 26, 2013, the Company shall pay to Seller $1,150,000 at closing. The Purchase Agreement requires total deposits of $400,000 to be paid towards the purchase price, to be paid by June 26, 2013. As of June 30, 2013 the Company has paid $300,000 and recorded and accrual for $100,000. Subsequently the company paid an additional $50,000, which has resulted in the seller granting the Company additional time to close.

Additionally, at closing, the Company will issue two additional promissory notes (the “Prime Time Notes A and B”) to Miklos in the aggregate principal amount of $1,000,000.  Prime Time Note A in the principal amount of $500,000 will bear interest at 5% per annum, with monthly payments of principal and interest, and will mature three years after the closing date.  Prime Time Note B in the principal amount of $500,000 will bear interest at 5% per annum, with annual payments of interest and principal payable annually over two years from the date of closing provided; however, that the principal balance of Prime Time Note B (and the respective annual payment) shall be reduced if: (i) the earnings before income taxes, depreciation and amortization (“EBITDA”) for the fiscal year ended December 31, 2013 is less than $975,000; and/or (ii) the EBITDA for the fiscal year ended December 31, 2014 is less than $975,000. At Miklos’ option, Prime Time Note B can be paid in shares of common stock of the Company on terms acceptable to Miklos and the Company.
 
Total consideration also includes $750,000 in the form of shares of restricted common stock of the Company (the “Shares”), with the number of Shares to be issued to be determined at closing by dividing $750,000 by the average of the highest bid and lowest asked prices for the Company’s common stock as quoted on the OTC Bulletin Board, the OTC Pink Sheets or other similar quotation system, as applicable, at the end of the trading day immediately preceding the closing (the “Original Issuance Price”). If as of the first anniversary of the closing Miklos has not received at least $1,500,000 of the purchase price in the form of cash (including from the payment of principal on Prime Time Notes A and B and the sale of Shares in the public market), then, following such first anniversary, Miklos may put, and Company shall promptly purchase from Miklos in cash, such number of Shares equal to the difference between such cash payments and $1,500,000 divided by the Original Issuance Price.

The Purchase Agreement also requires the Company to enter at closing into an employment agreement with the Seller for certain management services and; also contains a covenant of the Seller not to compete with the Company for a two year period.
 
 
12

 
 
Sanomedics International Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
June 30, 2013
(Unaudited)
 
NOTE 8 – PENDING ACQUISITION (CONTINUED)

The Purchase Agreement further provides that the Company will engage its independent registered public accounting firm to prepare an audit of Prime Time’s financial statements for the years ended December 31, 2011 and 2012. If, for any reason the audit cannot be concluded, the Company will not be required to pay any amounts due under Notes A or B and such notes will be cancelled. The Company, however, has no right to receive a refund of the cash portion of the purchase price as tendered or to effect a cancellation of the Shares. In addition, if Prime Time’s total asset value at December 31, 2012 as determined in accordance with the audited financial statements is less than the value set forth on the financial statements previously provided to the Company, the purchase price will be reduced by such amount on a dollar for dollar basis through a return of a number of Shares equal to such deficiency, and, if the deficiency is greater than the Original Issue Price, through a set off of the amount which will be due under Note A.

NOTE 9 – SUBSEQUENT EVENTS
 
Pending Acquisition

On July 10, 2013, the Company entered into an Equity Purchase Agreement (the “Equity Purchase Agreement ”) with Duke Medical Equipment LLC, a Texas limited liability company (“Duke Medical”) and Vann R. Duke, the sole equity holder of Duke (“Duke”). Duke Medical is a Durable Medical Equipment provider of home medical equipment servicing consumers throughout the Houston and Galveston, Texas area.
 
Pursuant to the Equity Agreement, at the closing Duke will transfer to the Company all the membership interest of Duke Medical for an aggregate purchase price of $7,000,000, subject to certain adjustments as summarized herein. The purchase price will be paid in a combination of cash, promissory notes and shares of the Company’s common stock. On the closing date the Company will make a total cash payment to the Seller of $2,000,000.

Additionally, at closing, the Company will issue two additional promissory notes (the “Duke Medical Notes A and B”) to Duke in the aggregate principal amount of $2,000,000. Duke Medical Note A in the principal amount of $1,000,000 will bear interest at 5% per annum, with monthly payments of principal and interest, and will mature eighteen (18) months after the closing date. Duke Medical Note B in the principal amount of $1,000,000 will bear interest at 5% per annum, with annual payments of interest and principal payable annually over two years from the date of closing provided; however, that the principal balance of Duke Medical Note B (and the respective annual payment) shall be reduced if: (i) EBITDA for the fiscal year ended December 31, 2013 is less than $1,500,000; and/or (ii) the EBITDA for the fiscal year ended December 31, 2014 is less than $1,500,000. At Duke’s option, Duke Medical Note B can be paid in shares of common stock of the Buyer on terms acceptable to Duke and the Company.
 
Total consideration also includes $3,000,000 in the form of shares, with the number of shares to be issued to be determined at closing by dividing $3,000,000 by the average of the closing bid price for the Company’s common stock as quoted on the OTC Bulletin Board, the OTC Pink Sheets or other similar quotation system, as applicable, for the five (5) trading days immediately preceding the closing (the “Duke Medical Original Issuance Price”).
 
The Equity Purchase Agreement also requires the Company to enter at closing into employment agreements with Duke and his spouse for certain management services and; also contains a covenant of Duke and his spouse not to compete with the Company for a two year period.
 
 
13

 
 
Sanomedics International Holdings, Inc.
Notes to Condensed Consolidated Financial Statements
June 30, 2013
(Unaudited)
 
NOTE 9 – SUBSEQUENT EVENTS (CONTINUED)
 
The Equity Purchase Agreement further provides that the Company will engage its independent registered public accounting firm to conduct an audit of Duke Medical’s financial statements for the years ended December 31, 2011 and 2012. If, for any reason the audit cannot be concluded, the Company will not be required to pay any amounts due under the Duke Medical Notes A or B and such notes will be cancelled. The Company, however, has no right to receive a refund of the cash portion of the purchase price as tendered or to effect a cancellation of the Shares. In addition, if Duke Medical’s total asset value at December 31, 2012 as determined in accordance with the audited financial statements is less than the value set forth on the financial statements previously provided to the Company, the purchase price will be reduced by such amount on a dollar for dollar basis through a return of a number of Shares equal to such deficiency, and, if the deficiency is greater than the Duke Medical Original Issue Price, through a set off of the amount which will be due under Duke Medical Note A.

Share Issuances:

In August 12, 2013 the Company issued 6,000,000 shares of its common stock upon the conversion of $6,000 portion of Convertible Note due to CLSS originally at $220,000 and sold to six (6) third parties by the original holder, with the shares valued at current fair market totaling $11,940,000.
 
Management has evaluated the subsequent events through August 19, 2013, the date at which the condensed consolidated financial statements were available for issue.
 
 
14

 
 
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
The following discussion of our financial condition and results of operations for the six and three months ended June 30, 2013 and 2012 should be read in conjunction with the financial statements and the notes to those statements that are included elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under Cautionary Notice Regarding Forward-Looking Statements appearing earlier in this report together with Part II, Item 1. of this report and Item 1A. Risk Factors, and the Business section in our Annual Report on Form 10-K for the year ended December 31, 2012. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements.

OVERVIEW

We design, develop and market a line of non-contact infrared thermometers principally for the “professional” market (physician, medical clinics, nursing homes and institutions), a market in which we conducted limited test-marketing during 2010 and 2011. Prior to 2012 we marketed our thermometers to consumer home healthcare for children and, under the “ThermoPet” brand name for pet dogs which, we stopped marketing to these two markets during 2012. Our marketing research led us to redirect our research and development efforts and focus on our second generation product with improved accuracy, and during the second quarter of 2012 we introduced our second generation product line commercially into the “professional” market. 
 
During the first and second quarters of 2013 our focus has been to continue the introduction and selling of our second generation product line. We are also pursuing the growth of our business through strategic acquisitions in the sleep apnea space. As previously reported, on April 26, 2013, we entered into a Stock Purchase Agreement with Prime Time Medical, Inc., a Florida corporation (“Prime Time”) and Mark R. Miklos, the sole equity holder of Prime Time. Prime Time is a durable medical equipment provider of home medical equipment with products such as power wheel chairs and scooters specializing in complex rehab products, respiratory equipment including oxygen concentrators and nebulizer compressors, diabetic supplies, hospital beds, bariatric equipment, walkers, CPMs, commodes, manual wheel chairs and support surface products for wound care management, servicing consumers throughout West Central Florida. Pursuant to the terms of the Stock Purchase Agreement, we agreed to purchase all of the stock of Prime Time from Mr. Miklos for an aggregate purchase price of up to $3,100,000, subject to certain adjustments. The purchase price will be paid in a combination of cash, promissory notes and shares of our common stock. On the closing date, we will make a total cash payment to Mr. Miklos of $1,150,000,

We have tendered $350,000 in deposit towards the purchase price through August 2013. The balance of the purchase price will be paid through a combination of promissory notes and shares of our common stock, all as more fully described in Note 7 of the Notes to Condensed Consolidated Financial Statements appearing earlier in this report. Under the terms of the Stock Purchase Agreement, if the transaction did not close by May 26, 2013, we were obligated to tender an additional $100,000 deposit to Mr. Miklos, and if the transaction did not close by June 26, 2013, we were obligated to tender an additional $100,000 deposit to him. The Purchase Agreement requires total deposits of $400,000 to be paid towards the purchase price, to be paid by June 26, 2013. As of June 30, 2013 the Company has paid $300,000 and subsequently paid an additional $50,000, which has resulted in the seller granting the Company additional time to close.

The parties are presently working to extend the closing date to September 30, 2013 and, if the transaction does not close by September 30, 2013, under the terms of the agreement Mr. Miklos is entitled to terminate the agreement and retain the deposits.

Additionally, on June 10, 2013, the Company entered into an Equity Purchase Agreement with Duke Medical Equipment LLC, a Texas limited liability company (“Duke Medical”) and Vann R. Duke, the sole equity holder of Duke. Duke Medical is a durable medical equipment provider of home medical equipment servicing consumers throughout the Houston and Galveston, Texas area.
 
 
15

 
 
Pursuant to the Equity Purchase Agreement, at the closing the Seller will transfer to the Company all the membership interest of Duke Medical for an aggregate purchase price of $7,000,000, subject to certain adjustments as summarized herein. The purchase price will be paid in a combination of cash, promissory notes and shares of the Company’s common stock. On the closing date which is contemplated to be 90 days from the Equity Purchase Agreement, the Company will make a total cash payment to the Seller of $2,000,000.
 
We will need to raise additional capital to close these acquisitions. Although we are currently in various discussions with several investment bankers and lending institutions, we do not have any firm commitments for the capital and there are no assurances we will be able to raise the funds prior to closing dates. As a result, there are no assurances that these transactions will close and we may forfeit any deposits rendered.
 
Critical Accounting Policies and Estimates
 
The methods, estimates and judgments we use in applying our accounting policies have a significant impact on the results we report in our consolidated financial statements. Some of our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. We believe our critical accounting policies are those described below.

Revenue Recognition
 
The Company recognizes revenue at the time the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured.
 
Certain product sales are subject to rights of return. Such rights include the right to return defective items within 30 days and with certain large accounts a right to return unsold products. For products sold where the buyer has the right to return the product, the Company recognizes revenue at the time of sale only if (1) the Company’s price to the buyer is substantially fixed or determinable at the date of sale, (2) the buyer has paid the Company, or the buyer is obligated to pay the seller and the obligation is not contingent on resale of the product, (3) the buyer’s obligation to the Company would not be changed in the event of theft or physical destruction or damage of the product, (4) the buyer acquiring the product for resale has economic substance apart from that provided by the seller, (5) the Company does not have significant obligations for future performance to directly bring about resale of the product by the buyer, and (6) the amount of future returns can be reasonably estimated. The Company recognizes such product revenues when either it has met all the above criteria, including the ability to reasonably estimate future returns, when it can reasonably estimate that the return privilege has expired.
 
Revenue from sales of the Company’s products is recorded when title and risk of loss have passed to the buyer and provided the criteria for revenue recognition are met. The Company sells its products to individual consumers and resellers upon receipt of a written order. The Company has a limited return policy for defective items that requires that the customer give the Company notice within 30 days after receipt of the product; however, such risk is passed to the manufacturer and therefore, the Company recognizes revenue at the time of delivery without providing any reserve. For sales made by certain large accounts with a right to return unsold items, the Company provides for a reserve for the estimated amount of unsold items.
 
 
16

 

Inventories
 
Inventories are stated at the lower of cost (on a first-in, first-out basis) or market value. The stated cost is comprised of finished goods of non-invasive medical devices. Reserves, if necessary, are recorded to reduce inventory to market value based on assumptions about consumer demand, current inventory levels and product life cycles for the various inventory items, as follows:
 
Consumer demand – our first generation products have been discontinued and have been written down to lower of cost or market.
 
Current inventory levels – we have approximately 62 units remaining as of June 30, 2013.
 
Product life cycles – although we continue to improve on the design and manufacturing of our 2nd generation professional models, we believe our products are still readily marketable consumer products and demanded by professional healthcare practitioners.
 
Derivative Liability

The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging.” The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument on the reclassification date. We analyzed the derivative financial instruments (the Convertible Notes), in accordance with ASC 815. The objective is to provide guidance for determining whether an equity-linked financial instrument is indexed to an entity’s own stock. This determination is needed for a scope exception which would enable a derivative instrument to be accounted for under the accrual method. The classification of a non-derivative instrument that falls within the scope of ASC 815-40-05 “Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock” also hinges on whether the instrument is indexed to an entity’s own stock. A non-derivative instrument that is not indexed to an entity’s own stock cannot be classified as equity and must be accounted for as a liability. There is a two-step approach in determining whether an instrument or embedded feature is indexed to an entity’s own stock. First, the instrument's contingent exercise provisions, if any, must be evaluated, followed by an evaluation of the instrument's settlement provisions. The Company utilized multinomial lattice models that value the derivative liability within the notes based on a probability weighted discounted cash flow model. The Company utilized the fair value standard set forth by the Financial Accounting Standards Board, defined as the amount at which the assets (or liability) could be bought (or incurred) or sold (or settled) in a current transaction between willing parties, that is, other than in a forced or liquidation sale.

Stock-Based Compensation
 
The Company applies the fair value method stipulated by ASC Topic 718, Compensation - Stock Compensation in accounting for its stock based compensation. This standard states that compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period, if any. During 2012 as the Company does not have sufficient, reliable and readily determinable values relating to its common stock, the Company has used the stock value pursuant to its most recent private sale of stock by an affiliate of our CEO, for purposes of valuing stock based compensation. The Company believes that the market price of the Company's stock is not indicative of value as the stock is not widely held. During 2013 the fair value of restricted stock is estimated on the date of grant and is generally equal to the closing price of our common stock on that date.
 
Income Taxes

Income taxes are accounted for under the asset and liability method as stipulated by the ASC Topic 740 Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC Topic 740, the effect on deferred tax assets and liabilities or a change in tax rate is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced to estimated amounts to be realized by the use of a valuation allowance. A valuation allowance is applied when in management's view it is more likely than not (50%) that such deferred tax will not be utilized.
 
 
17

 

The Company adopted certain provisions under ASC Topic 740, which provide interpretative guidance for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Effective with the Company's adoption of these provisions, interest related to the unrecognized tax benefits is recognized in the consolidated financial statements as a component of income taxes.

In the unlikely event that an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by the taxing authorities. Reserves for uncertain tax positions would be recorded if the Company determined it is probable that a position would not be sustained upon examination or if payment would have to be made to a taxing authority and the amount is reasonably estimated. As of June 30, 2013, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to the taxing authorities. The Company's tax returns are subject to examination by the federal and state tax authorities for the tax years ended 2008 through 2012.
 
The following table summarizes our consolidated operating results as a percentage of net sales revenue for the periods indicated:
                                         
   
Three Months Ended
June 30
   
Six Months Ended
June 30
 
   
2013
   
2012
   
2013
   
2012
 
                         
Revenues, net
    100 %     100 %     100 %     100 %
                                 
Costs and Expenses:
                               
Cost of goods sold
    27 %     176 %     28 %     99 %
General and administrative
    422 %     4,520 %     375 %     1,564 %
Research and development
    40 %     0 %     44 %     24 %
Stock compensation
    61 %     2,885 %     211 %     1,056 %
Depreciation and amortization
    3 %     15 %     3 %     6 %
      553 %     7,596 %     661 %     2,749 %
Loss from operations
    -453 %     -7,496       -561 %     2,649 %
                                 
Other income (expenses):
                               
Amortization of debt discount
    -48 %     0 %     -45 %     0 %
Derivative expense     -4,427 %     -       -2,337        
Unrealized gain on fair value of derivatives
    1,638 %     0 %     865 %     0 %
Interest expense
    -43 %     -767 %     -44 %     -311 %
Total other expense
    2,880 %     -767 %     -1,561 %     -311 %
                                 
Net income (loss) before taxes
    -3,333 %     -8,263 %     -2,122 %     -2,960 %
Income taxes
    0 %     0 %     0 %     0 %
Net income (loss)
    -3,333 %     -8,263 %     -2,122 %     -2,960  
 
 
18

 
 
Results of Operations

Three Months Ended June 30, 2013 compared to the Three Months Ended June 30, 2012
 
Revenues, net: The increase was attributable to the introduction and continued launch of our new professional model the “Caregiver” compared to the sales of our previous first generation products.
 
Cost of goods sold: Cost of goods sold consists of product, shipping and other costs. Cost of goods sold as a percentage of revenues, net decreased in the second quarter of 2013 as compared to the second quarter of 2012 due to the additional sales generated of the newer professional models during the 2013 period. We anticipate our costs of goods sold as a percentage of revenues, net will remain the same throughout the balance of 2013, although there are no assurances that it will.
 
Gross Profit: Gross profit was approximately $47,000 for the second quarter of 2013 as compared to approximately negative $5,400 during the same period in 2012, due primarily to the favorable change to our new higher margin product.
 
Operating Expenses: Operating expenses consist of general and administrative expenses, research and development, stock compensation and depreciation and amortization. For the second quarter of 2013, operating expenses decreased primarily as a result of decreases in officer payroll, legal and professional fees and rent expense. Although we expect our future general and administrative expenses to increase as we continue with our sales growth and acquisition plans. Research and development expenses increased for the second quarter of 2013 from second quarter of primarily due to an increase in consulting and contractor expenses. We expect our future research and development expenses to scale down as our existing products require minimal development
 
Other income (expense): The Company recorded derivative expense of $2,830,798 and a net unrealized gain of $1,064,837 for the three months in 2013 from the decrease in carrying value of the derivative liabilities associated with convertible promissory notes issued to an officer of the company and third party lenders.
 
Net Loss: Net loss for the second quarter of 2013 compared to a net loss in the second quarter of 2012 increased primarily as a result of the increases in gross profit combined with reductions in operating expenses and the derivative expense and unrealized gain in fair value of derivatives as described above.
 
Six Months Ended June 30, 2013 compared to the Six Months Ended June 30, 2012

Revenues, net: The increase in revenues, net for the six months ended June 30, 2013 was attributable to the continued selling and marketing of our “ Caregiver” professional thermometer model.
 
Cost of goods sold: Cost of goods sold as a percentage of revenues, net also decreased in six months ended June 30, 2013 from the comparable period in 2012 due to the favorable change to our new higher margin product.

Gross Profit: Gross profit was $87,000 for the six months ended June 30, 2013 as compared to $336 during the same period in 2012, due primarily to the reasons stated above.

Operating Expenses: The approximate $161,000 decrease in operating expenses for the six months ended June 30, 2013 from the comparable period in 2012 was primarily a result of a decrease in stock compensation amounting to $152,000 relating to the issuance of warrants to investors and for stock issued to consultants.
 
 
19

 

Other income (expense): The Company recorded a net unrealized gain of $1,064,837 for the three months in 2013 from the decrease in carrying value of the derivative liabilities associated with convertible promissory notes issued to an officer of the company and third party lenders.

Net Loss : Net loss for the six months ended June 30, 2013 compared to a net loss for the six months ended June 30, 2012 increased primarily from the derivative expense and the unrealized gain in fair value of derivatives and as a result of decreases in operating expenses as described above.

Financial Condition
 
June 30, 2013 (unaudited) compared to December 31, 2012

Assets: At June 30, 2013 as compared to December 31, 2012, our total assets increased by approximately $503,000 or 557%, to approximately $593,000. This was primarily attributable to an increase of approximately $300,000 in our deposits paid towards our planned acquisition of Prime Time combined with increases in accounts receivable, prepaid expenses and cash.

Liabilities : At June 30, 2013, our total liabilities increased by approximately $2,035,000 or 62%, to approximately $5.3 million, attributable primarily due to $2.5 million derivative recognition, an increase of approximately $650,000 in borrowings from an affiliate of a former director and principal shareholder, borrowings of approximately $150,000 from third parties, an increase in accrued interest payable of $67,000 and an increase in accounts payable and other liabilities of approximately $51,000.
 
Stockholders’ Deficit : At June 30, 2013, our stockholders’ deficit increased by approximately $2.2 million, or 70%, to approximately $5.4 million, primarily due to $2.8 million in computed debt discount on convertible notes offset by an increases in paid in capital of approximately $334,000 that resulted from the issuance of stock compensation and debt conversion to equity and net income of approximately $278,000.
 
Liquidity and Capital Resources

At June 30, 2013 our cash on hand was approximately $72,000. Working capital was approximately negative $3,600,000 and negative $3,206,000 at June 30, 2013 and December 31, 2012, respectively.

Since our inception in 2009, we obtained our liquidity principally from approximately $2.1 million principal amount of cash advances from an affiliate of our former Chairman and CEO and one of our principal shareholders. The Company has executed promissory notes totaling approximately $1.1 million as of June 30, 2013, with CLSS Holdings, LLC (“CLSS”). Each note (a) bears annual interest at 9.0% (20% upon the occurrence, and during the continuance, of an event of default), is convertible into our common stock at a fixed conversion price of $0.50, and is not pre-payable by us, and (b) is subject to a security agreement under which all of our assets secure our loan repayment obligation. As previously reported, on May 9, 2013, the Company and CLSS agreed to terminate the pending convertible notes and issue a single replacement convertible note that includes the obligations currently provided together with the advances and accrued interest of $238,868. The original convertible notes were not delivered to the Company and accordingly, the replacement note was not issued and has been voided. On August 13, 2013 an addendum was executed covering these notes to extend the maturity of these notes to March 30, 2015. As additional consideration for the extension of the maturity date, the addendum provided for an additional 5,000,000 shares of common stock to be issued at the earlier of the consideration date or maturity..

Although we intend to increase our revenue by engaging in more aggressive sales, marketing and advertising activity designed to increase awareness of our products, there are no assurances our efforts will be successful. In addition, even if we succeed in substantially increasing our revenues, we still need substantial additional capital to pay our obligations as they become due and finance our business activities on an ongoing basis, as our revenue is insufficient to fund our operations. We have approximately $1,100,000 in secured obligations to related parties which mature in March 2015 which are secured by substantially all of our assets, and we do not have sufficient funds to pay those obligations. In addition, we also need to raise approximately $2,800,000 of capital to fund the cash portions of the purchase price of the pending acquisitions of Prime Time and Duke Medical.
 
 
20

 

At June 30, 2013, we had approximately $72,000 in cash on hand; and unless and until we receive additional financing from third parties, which we may never achieve, in the absence of on-going cash infusions on an as needed basis by an affiliate of our former Chairman and CEO and one of our principal shareholders, we would be unable to continue to operate. If we are unable to pay our obligations as they become due, the related parties who are holders of the secured notes could seek to foreclose on our assets. In that event, we would be unable to continue our business and operations as they are now conducted and investors could lose their entire investments in our company.
 
Even if we are successful in raising the equity financing noted above we will require substantial additional funds to finance our business activities and acquisition strategy on an ongoing basis. There is no assurance that the additional financing we require would be available on reasonable terms, if at all; and if available, any such financing likely would result in a material and substantial dilution of the equity interests of our current shareholders. The unavailability of such additional financing could require us to delay, scale back or terminate our business activities, which would have a material adverse effect on our viability and prospects.
 
Summary of Cash Flow for the three months ended June 30, 2013
 
Our cash flows for the six months ended June 30, 2013 and 2012 were as follows:
 
 
 
Six Months Ended June 30,
 
 
 
2013
 
 
2012
 
                 
Net cash used in operating activities
 
$
(685,094
)
 
$
(415,496
)
Net cash used in investing activities
 
$
 -0-
 
 
$
(45)
 
Net cash provided by financing activities
 
$
731,492
 
 
$
418,500
 
 
Operating Activities
 
Our total cash used by operating activities increased by approximately $270,000 or 65% for the six months ended June 30, 2013, compared to the six months ended June 30, 2012. The increase is primarily due to the decreased loss, offset by the increase in non-cash items and deposit paid on the planned acquisition.

Financing Activities
 
Our total cash provided for financing activities increased by approximately $313,000, or 75%, to approximately $732,000 for the six months ended June 30, 2013, compared to approximately $418,000 for the six months ended June 30, 2012. The increase is primarily due to $584,000 in borrowings from an affiliate of our former Chairman and CEO and one of our principal shareholders, $150,000 in borrowings from a third party lender, offset by $371,000 raised in the Company's offering during the 2012 period.

Current Commitments for Expenditures
 
Our current cash commitments for expenditures are mainly operational and SEC compliance in nature. We seek to use current revenue to pay vendors for materials for contracts, for payroll, and related employment expenditures (i.e. benefits).
 
 
21

 

Off-Balance Sheet Arrangements
 
We do not have any off-balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, and results of operations, liquidity or capital expenditures.
 
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
 
Not applicable to smaller reporting companies.
 
Item 4. Controls and Procedures.
 
Evaluation of Disclosure Controls and Procedures. We maintain “disclosure controls and procedures” as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. In designing and evaluating our disclosure controls and procedures, our management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Based on their evaluations as of the end of the period covered by this report, our President, who serves as our Principal Executive Officer, and our Chief Financial Officer have concluded that our disclosure controls and procedures were not effective such that the information relating to our company, required to be disclosed in our Securities and Exchange Commission reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) is accumulated and communicated to our management, including our Principal Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure, as a result of our failure to timely file several Current Reports on Form 8-K. Subsequent to the end of the period, we expect to institute enhanced procedures to ensure that we comply with the proper reporting procedures in future periods.
 
Changes in Internal Control over Financial Reporting. There have been no changes in our internal control over financial reporting during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
 
 
22

 
 
PART II – OTHER INFORMATION

Item 1. Legal Proceedings.
 
On May 21, 2013, Exergen Corporation commenced legal action in the United States District Court for the District of Massachusetts entitled Exergen Corp. v. Thermomedics, Inc.,etal.,Civ. Action No. 13-cv-11243, against us, claiming infringement of certain intellectual property. Exergen is seeking various types of relief, including an injunction against further infringement of certain intellectual property. While we intend to vigorously defend against the allegations set forth in the complaint, the case is still at an early stage, and we have not yet answered or otherwise responded to the complaint.

Item 1A. Risk Factors.

In addition to the risk factors disclosed in Item 1A. of our Annual Report on Form 10-K for year ended December 31, 2012, the following are additional risk factors facing our company:
 
If we fail to pay secured convertible notes when due, or if the holders do not elect to convert those notes, our ability to continue our business and operations could be in jeopardy.

In 2010 and 2011 we issued secured convertible notes in the aggregate principal amount of approximately $1,100,000 to a related party which originally matured between September 30, 2013 and October 1, 2013. In August 2013 we extended the maturity dates of those notes to March 30, 2015. These notes are collateralized by substantially all of our assets. We do not have the funds necessary to satisfy these obligations and there are no assurances the holders will convert the notes at or before maturity into shares of our common stock. In the event we should be unable to pay these obligations when they become due, and the holders do not convert the notes, the holders could seek to foreclose on our assets. If they are successful, we would be unable to continue our business and operations as they are presently conducted and it is possible that our stockholders would lose their entire investment in our company.

We need to raise significant capital to consummate two pending acquisitions. There are no assurances these acquisitions will be consummated
 
We have entered into agreements to acquire two companies, Prime Time and Duke Medical, which require us to pay a material portion of the purchase price for each transaction in cash. The terms of the Prime Time acquisition provided that if we did not close the transaction by June 26, 2013, subsequently to be extended to September 30, 2013, we were required to increase our initial deposit to a total of $400,000 and pay an additional $750,000 at closing. We have paid a total of $350,000 towards this deposit. In addition, the seller is entitled to cancel this agreement at any time and retain the $350,000 funds we have tendered to date. We are required to pay $2,000,000 in cash at the closing of the Duke Medical acquisition. We need to raise capital to fund these acquisitions, but so far we have been unable to obtain commitments for the necessary capital. Accordingly, there are no assurances we will close one of both of these pending acquisitions, and it is possible that we will forfeit the $350,000 deposit paid to date in connection with the Prime Time acquisition.
 
 
23

 

From time to time we engage in related party transactions, the terms of which are not negotiated on an arms length basis.

In June 2013 we issued a $703,339 principal amount convertible promissory note to Mr. Houlihan, our President, in satisfaction of accrued but unpaid salary due him. This note, which bears interest at 9% per annum, is due on March 30, 2105. The note is convertible at Mr. Houlihan’ s option into shares of our common stock at the lesser of (a) the average of the lowest three closing bid prices for the 10 trading days prior to the notice of conversion, or (b) $0.50 per share. This conversion price is subject to reduction if we should issue or sell shares of our common stock or common stock equivalents at a price less than the then conversion price to such lower price.
 
In August 2013 CLSS, a related party, agreed to extend the maturity date of secured convertible notes representing approximately $1.1 million in obligations from September 2013 and October 2013 to March 2015. As additional consideration, we agreed to issue the lender 5,000,000 shares of our common stock at the conversion date or maturity date of those notes. We will recognize an expense equal to the fair market value of these shares when issued. While these transactions were approved by our Board of Directors, Mr. Houlihan is one of our two directors and these transactions were not negotiated on an arms-length basis. There are no assurances that the terms of these transactions are as fair to our company as we might receive from unaffiliated third parties.
 
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
 
On June 28, 2013, the Company issued a total of 25,895 shares of common stock to a public relations firm as settlement of its services valued at $1.50 per share. As a result, the Company recorded stock compensation in the amount of $38,842 for the three months ended June 30, 2013. The recipients were accredited or otherwise sophisticated investors who had access to financial and business information concerning the Company. The issuances were exempt from registration under the Securities Act of 1933 in reliance on an exemption provided by Section 4(2) of that act.

As previously disclosed, on December 6, 2012, the Company entered into a Securities Purchase Agreement and convertible promissory note in the principal amount of $37,500. The note, which was due on August 29, 2013, bore interest at 8% per annum until paid or to maturity and was convertible into shares of the Company’s common stock, at the election of the lender, at any time after 180 days from issuance date of the note at a conversion price equal to a 42% discount to the average of the lowest three closing bid prices of the common stock during the 10 trading days prior to conversion. On June 11, 2013 and June 28, 2013 the holder converted the note into a total of 29,128 shares of the Company’s common stock at a conversion price of $1.36 per share. The recipient was an accredited investor and the issuances were exempt from registration under the Securities Act of 1933 in reliance on an exemption provided by Section 3(a)(9) of that act.

On June 17, 2013, we issued Mr. Keith Houlihan, our President, a promissory note in the principal amount of $703,339.33 in satisfaction of all amounts due him for accrued but unpaid salary. The recipient was an accredited investor and the issuance was exempt from registration under the Securities Act of 1933 in reliance on an exemption provided by Section 4(2) of that act.

This note bears interest at the rate of 9% per annum and is due on March 30, 2015. At Mr. Houlihan’ s option, the note is convertible into shares of our common stock at the lesser of (a) the variable conversion price equal to the average of the lowest three closing bid prices for the 10 trading days prior to the notice of conversion, or (b) $0.50 per share. This conversion price is subject to adjustment in the event we should issue or sell shares of our common stock or common stock equivalents, other than issuances under employee stock option plans) at a price less than the then conversion price. In that event, the conversion price of the note will be reduced to this lesser amount. The principal and accrued interest become immediately due in the event of certain events, including our failure to pay any amounts due under the note, our dissolution, insolvency, or bankruptcy, among other events. We agreed to indemnify the holder against and claims or losses arising out of our obligations under the note.

The description of the terms and conditions of this note is qualified in its entirety by reference to such note which is filed as Exhibit 10.43 to this report.
 
 
24

 
 
Item 3. Defaults Upon Senior Securities.
 
None.
 
Item 4. Mine Safety Disclosures.
 
Not applicable to our company’s operations.
 
Item 5. Other Information.
 
As previously disclosed, we owed CLSS, a related party, approximately $1.1 million under secured convertible promissory notes which were originally due on September 30, 2013 and October 1, 2013. The secured convertible promissory notes are collateralized by substantially all of our assets and are convertible, at the holder's option, into shares of our common stock at a fixed conversion price ranging of $0.50 per share. CLSS is wholly owned by our former CEO who also is a principal shareholder of our company and a former director. In May 2013, the Company and CLSS agreed to terminate the individual convertible notes and issue a single replacement convertible note that included the obligations currently provided together with the advances and accrued interest of $238,868. The replacement note was for a total of $1,740,786. Additionally the replacement note extended the maturity date to March 30, 2015. Subsequently, CLSS was unable to delivery the original convertible notes for exchange, and we did not issue the replacement note, which has been voided. Thereafter, on August 13, 2013 an agreement was executed covering these notes to extend the maturity of these notes to March 31, 2015.
 
In August 12, 2013 the Company issued 6,000,000 shares of its common stock upon the conversion of $6,000 portion of Convertible Note due to CLSS originally at $220,000 and sold to six (6) third parties by the original holder, with the shares valued at current fair market totaling $11,940,000.
 
 
25

 
 
Item 6. Exhibits.
 
No.
 
Description
 
 
 
10.41
 
$500,000 Promissory Note dated June 19, 2013 payable to JMJ Financial Duke (incorporated by reference to the Current Report on Form 8-K as filed on June 24, 2013).
 
 
 
10.42
 
Equity Purchase Agreement dated July 10, 2013 by and among Sanomedics International Holdings, Inc., Anovent, Inc., Duke Medical Equipment LLC and Vann R. Duke (incorporated by reference to the Current Report on Form 8-K as filed on July 16, 2013).
 
 
 
10.43
 
$703,339.33 principal amount Promissory Note dated June 17, 2013 payable to Keith Houlihan.*
     
10.44
 
[EXTENSION OF CLSS NOTES]
     
10.45
 
[EXTENSION OF PRIME MEDICAL AGREEMENT]
     
31.1
 
Rule 13a-14(a)/ 15d-14(a) Certification of principal executive officer*
 
 
 
31.2
 
Rule 13a-14(a)/ 15d-14(a) Certification of principal financial and accounting officer *
 
 
 
32.1
 
Section 1350 Certifications of President and Chief Financial Officer*
 
 
 
101.INS
 
XBRL INSTANCE DOCUMENT **
 
 
 
101.SCH
 
XBRL TAXONOMY EXTENSION SCHEMA **
 
 
 
101.CAL
 
XBRL TAXONOMY EXTENSION CALCULATION LINKBASE **
 
 
 
101.DEF
 
XBRL TAXONOMY EXTENSION DEFINITION LINKBASE **
 
 
 
101.LAB
 
XBRL TAXONOMY EXTENSION LABEL LINKBASE **
     
101.PRE
 
XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE **
____________
filed herewith

**
In accordance with Regulation S-T, the XBRL-formatted interactive data files that comprise Exhibit 101 in this Quarterly Report on Form 10-Q shall be deemed “furnished” and not “filed”.
 
 
26

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
Sanomedics International Holdings, Inc.
 
 
 
Dated: August 19, 2013
By:
/s/ Keith Houlihan
 
 
 
Keith Houlihan, President
 
 
 
     
 
By:
/s/ David C. Langle
 
 
 
David C. Langle, Chief Financial Officer
 
 
 
27

EX-10.43 2 simh_ex1043.htm PROMISSORY NOTE simh_ex1043.htm
EXHIBIT 10.43

PROMISSORY NOTE
 
$703,339.33
June 17, 2013
Miami, Florida
                                                            
WHEREAS, Keith Houlihan (“Houlihan”) is a member of the Board and President of Sanomedics International Holdings, Inc., a Delaware corporation (the “Company”), is owed accrued, unpaid salary from the Company in the aggregage amount of $703,339.33;

WHEREAS, the Company and Houlihan wish to issue a convertible note that includes the obligations currently represented as accrued salary pursuant to the terms as set forth in this note.

FOR VALUE RECEIVED, the undersigned, Sanomedics International Holdings, Inc., a Delaware corporation ("Maker" or the “Company”), hereby promises to pay to the order of Keith Houlihan, a director and officer of Maker ("Holder") the principal sum of Seven Hundred Three Thousand Three Hundred Thirty Nine and 33/100 Dollars ($703,339.33)(the “Principal Amount”), on or by March 30, 2015 (the "Maturity Date"), plus accrued and unpaid interest as set forth below.

1.  Principal and interest shall be payable in lawful money of the United States of America in immediately available funds, without any deduction, setoff or counterclaim, at the address of Holder specified herein.

2. This Note shall bear interest on the unpaid principal amount hereof commencing on the date hereof at a rate of 9% per annum. Upon the occurrence and during the continuance of an Event of Default, interest shall accrue on the unpaid principal amount of this Note, from the date of such default until the earlier of the date the principal sum is paid in full or, if applicable, the date such default is cured, at the rate of 15% per annum (but not higher than the applicable maximum rate provided by law).  Accrued interest on the outstanding principal amount of this Note shall be payable on the Maturity Date, unless accelerated as a result of the occurrence of an Event of Default as set forth below. The principal amount of this Note may not be prepaid without the prior written consent of the Holder which may be withheld for any reason.

3. This Note and any ancillary documents entered into in connection therewith, each as amended, extended or modified from time to time, are referred to collectively herein as the "Transaction Documents".
 
 
1

 

4. (a) Prepayment Conversion.  Notwithstanding anything contained in this Note to the contrary, Holder of this Note is entitled, at his option, at any time after the issuance of this Note, to convert all or any lesser portion of the Principal Amount and accrued but unpaid interest into common stock of the Maker (“Common Stock”) at a conversion price for each share of Common Stock equal to at a price (the “Conversion Price”) which is equal to the lesser of: (i) the Variable Conversion Price (as defined herein); and (ii) the Fixed Conversion Price (as defined herein) (subject, in each case, to equitable adjustments for stock splits, stock dividends or rights offerings by the Maker relating to the Maker’s securities or the securities of any subsidiary of the Maker, combinations, recapitalization, reclassifications, extraordinary distributions and similar events).  The “Variable Conversion Price” shall mean the Applicable Percentage (as defined herein) multiplied by the Market Price (as defined herein).  “Market Price” means the average of the lowest three (3) Trading Prices (as defined below) for the Common Stock during the ten (10) Trading Day period ending one Trading Day prior to the date the Conversion Notice is sent by the Holder to the Maker via facsimile (the “Conversion Date”).  “Trading Price” means, for any security as of any date, the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCBB”) as reported by a reliable reporting service (“Reporting Service”) mutually acceptable to Maker and Holder, or, if the OTCBB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc.  If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Maker and the holders of a majority in interest of the Notes being converted for which the calculation of the Trading Price is required in order to determine the Conversion Price of such Notes.  “Trading Day” shall mean any day on which the Common Stock is traded for any period on the OTCBB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded.  “Applicable Percentage” shall mean 50%. “Fixed Conversion Price” shall mean $0.50. (The Common stock into which the Note is converted shall be referred to in this agreement as “Conversion Shares”),

(b) The Company will not issue fractional shares or scrip representing fractions of shares of Common Stock on conversion, but the Company will round the number of shares of Common Stock issuable up to the nearest whole share.  The date on which a Notice of Conversion is given shall be deemed to be the date on which the Holder notifies the Company of its intention to so convert by delivery, by facsimile transmission or otherwise, of a copy of the Notice of Conversion.  Notice of Conversion may be sent by facsimile to the Company, Attn: Keith Houlihan, Fax.: 305-433-5129.  Upon receipt of the Notice of Conversion, the Company shall immediately cause the issuance of the shares of common stock subject to the notice.  The Holder will deliver this Note, together with original executed copy of the Notice of Conversion, to the Company within three (3) business days following the Conversion Date.  At the Maturity Date, the Company will pay any unconverted Outstanding Principal Amount and accrued Interest thereon, at the option of the Holder, in either (a) cash or (b) Common Stock valued at a price equal to the Conversion Price determined as if the Note was converted in accordance with its terms into Common Stock on the Maturity Date.

(c) Adjustment Due to Dilutive Issuance.  If, at any time when the Note is issued and outstanding, the Company issues or sells, or in accordance with this Section 4(c) hereof is deemed to have issued or sold, any shares of Common Stock for no consideration or for a consideration per share (before deduction of reasonable expenses or commissions or underwriting discounts or allowances in connection therewith) less than the Conversion Price in effect on the date of such issuance (or deemed issuance) of such shares of Common Stock (a “Dilutive Issuance”), then immediately upon the Dilutive Issuance, the Conversion Price will be reduced to the amount of the consideration per share received by the Company in such Dilutive Issuance.
 
 
2

 

The Company shall be deemed to have issued or sold shares of Common Stock if the Company in any manner issues or grants any warrants, rights or options (not including employee stock option plans), whether or not immediately exercisable, to subscribe for or to purchase Common Stock or other securities convertible into or exchangeable for Common Stock (“Convertible Securities”) (such warrants, rights and options to purchase Common Stock or Convertible Securities are hereinafter referred to as “Options”) and the price per share for which Common Stock is issuable upon the exercise of such Options is less than the Conversion Price then in effect, then the Conversion Price shall be equal to such price per share.  For purposes of the preceding sentence, the “price per share for which Common Stock is issuable upon the exercise of such Options” is determined by dividing (i) the total amount, if any, received or receivable by the Company as consideration for the issuance or granting of all such Options, plus the minimum aggregate amount of additional consideration, if any, payable to the Company upon the exercise of all such Options, plus, in the case of Convertible Securities issuable upon the exercise of such Options, the minimum aggregate amount of additional consideration payable upon the conversion or exchange thereof at the time such Convertible Securities first become convertible or exchangeable, by (ii) the maximum total number of shares of Common Stock issuable upon the exercise of all such Options (assuming full conversion of Convertible Securities, if applicable).  No further adjustment to the Conversion Price will be made upon the actual issuance of such Common Stock upon the exercise of such Options or upon the conversion or exchange of Convertible Securities issuable upon exercise of such Options.

Additionally, the Company shall be deemed to have issued or sold shares of Common Stock if the Company in any manner issues or sells any Convertible Securities, whether or not immediately convertible (other than where the same are issuable upon the exercise of Options), and the price per share for which Common Stock is issuable upon such conversion or exchange is less than the Conversion Price then in effect, then the Conversion Price shall be equal to such price per share.  For the purposes of the preceding sentence, the “price per share for which Common Stock is issuable upon such conversion or exchange” is determined by dividing (i) the total amount, if any, received or receivable by the Company as consideration for the issuance or sale of all such Convertible Securities, plus the minimum aggregate amount of additional consideration, if any, payable to the Company upon the conversion or exchange thereof at the time such Convertible Securities first become convertible or exchangeable, by (ii) the maximum total number of shares of Common Stock issuable upon the conversion or exchange of all such Convertible Securities.  No further adjustment to the Conversion Price will be made upon the actual issuance of such Common Stock upon conversion or exchange of such Convertible Securities.

5. The unpaid principal amount of this Note, the accrued interest thereon and all other obligations of Maker hereunder (collectively, the "Obligations"), at the option of Holder, shall become immediately due and payable upon the occurrence of any of the following events of default ("Events of Default"):

(a) Maker shall fail to pay: (i) any principal or accrued interest under this Note within ten (10) days after the Maturity Date; or (ii) any of the other monetary Obligations to be paid by it under this Note within ten (10) days of the due date for payment of same.

(b) Maker shall default in the observance or performance of any material agreements, covenants or conditions contained in: (i) this Note, the Transaction Documents or in any other document or instrument referred to herein or therein (except the failure to pay monetary Obligations); or (ii) any agreement by and between the Maker and the Holder; and fail to cure such default within ten (10) business days of the date Maker obtains notice thereof whether from Holder or otherwise.
 
 
3

 
 
(c) Any present or future representation or warranty made by or on behalf of Maker whether contained herein or in any of the other document shall be false or incorrect in any material respect when such representation or warranty is made.

(d) The occurrence of any of the following with respect to Maker: dissolution; termination of existence; insolvency; business cessation; calling of a meeting of creditors; appointment of a receiver for any property; assignment for the benefit of creditors or admit in writing its inability to pay its debts as they become due; voluntary commencement of any proceeding under any bankruptcy or insolvency law; commencement of any involuntary proceeding under any bankruptcy or insolvency law and if any such involuntary proceeding is not dismissed within 45 days or the relief requested is granted; entry of a court order which enjoins or restrains the conduct of business in the ordinary course.

6. Maker shall reimburse Holder for all costs and expenses incurred by Holder and shall pay the reasonable fees, disbursements and out of pocket expenses of counsel to Holder in connection with the enforcement of Holder's rights hereunder.  Maker shall also pay any and all taxes (other than taxes on or measured by net income of the holder of this Note) recording fees, filing charges, search fees or similar items incurred or payable in connection with the execution and delivery of this Note.

7. Maker waives demand, presentment, protest and notice of any kind and consents to the release, surrender or substitution of any and all security or guarantees for the Obligations evidenced hereby or other indulgence with respect to this Note, all without notice.

8. Maker shall indemnify, defend and save Holder harmless from and against any and all claims, liabilities, losses, costs and expenses (including, without limitation, reasonable attorneys' fees, disbursements and out of pocket expenses) of any nature whatsoever which may be asserted against or incurred by Holder arising out of or in any manner occasioned by or any failure by Maker to perform any of its Obligations hereunder.

9. Maker agrees to do such further acts and to execute and deliver to Holder such additional agreements, instruments and documents as Holder may reasonably require or deem advisable to effectuate the purposes of this Note, or to confirm to Holder its rights, powers and remedies under this Note.

10. (a)  Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered or transmitted personally by messenger, by recognized overnight courier, telecopied or mailed (by registered or certified mail, postage prepaid) as follows:  
 
 
4

 

(i) If to Maker, one copy to:

Sanomedics International Holdings, Inc.
444 Brickell Avenue, Suite 415
Miami, Florida 33131

(ii)  If to the Holder:

Keith Houlihan
c/o Sanomedics International Holdings, Inc.
444 Brickell Avenue, Suite 415
Miami, Florida 33131

(b) Each such notice or other communication shall be effective: (i) if given by telecopier, when such telecopy is transmitted to the telecopier number specified in Section 10(a) (with confirmation of transmission received by the sender); or (ii) if given by any other means, when received at the address specified in Section 10(a).  Any party by notice given in accordance with this Section 10 to the other party may designate another address (or telecopier number) or person for receipt of notices hereunder.
 
11. This Note contain the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements, written or oral, with respect thereto including the Convertible Notes which upon the execution and delivery of this Note shall be terminated and of no further force or effect.

12. This Note may be amended, superseded, cancelled, renewed or extended only by a written instrument signed by Holder and Maker.  Any provisions hereof may be waived by a party but any such waiver must be in writing signed by such party and any such waiver shall be effective only in the specific instance and for the specific purpose for which given.  No delay on the part of any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any waiver on the part of any party of any such right, power or privilege, nor any single or partial exercise of any such right, power or privilege, preclude any further exercise thereof or the exercise of any other such right, power or privilege.  The rights and remedies herein provided are cumulative and are not exclusive of any rights or remedies that any party may otherwise have at law or in equity.
 
 
5

 

13. This Agreement shall be governed by and construed in accordance with the laws of the State of Florida applicable to agreements made and to be performed entirely within such State, without regard to the conflict of laws rules thereof.

14. Maker irrevocably: (a) agrees that any suit, action or other legal proceeding arising out of this Agreement may be brought in the courts of the State of Florida or the courts of the United States located in Dade County, Florida; (b) consents to the jurisdiction of each court in any such suit, action or proceeding; (c) waives any objection which it may have to the laying of venue of any such suit, action or proceeding in any of such courts; (d) waives the right to assert any counterclaim in any such suit, action and proceeding; and (e) waives the right to a trial by jury in any such suit, action or other legal proceeding.  

15. This Note and all of its provisions, rights and Obligations shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors, assigns and legal representatives.  Nothing herein express or implied is intended or shall be construed to confer upon or to give anyone other than the parties hereto and their respective heirs, legal representatives and successors any rights or benefits under or by reason of this Agreement and no other party shall have any right to enforce any of the provisions of this Agreement.  This note may be transferred or assigned by the Holder, in full or in part.

16. If any provision of this Note for any reason shall be held to be illegal, invalid or unenforceable, such illegality shall not affect any other provision of this Note, but this Note shall be construed as if such illegal, invalid or unenforceable provision had never been included herein.
 
 
6

 
 
IN WITNESS WHEREOF, the undersigned has executed this Promissory Note as of the date first written above.
 
 
ATTEST:
MAKER:
Sanomedics International Holdings, Inc.,
 
       
/s/  Miriam Sardinas  
By:
/s/ David Langle  
    Name: David Langle  
    Title: Chief Financial Officer and by resolution of the members of the Board of Directors)  
       
 
 
 
 
7

 

Exhibit A
Conversion Notice
NOTICE OF CONVERSION
 
The undersigned hereby elects to convert $____________ principal amount of the Note (defined below) into that number of shares of Common Stock to be issued pursuant to the conversion of the Note (“Common Stock”) as set forth below, of Sanomedics International Holdings, Inc., a Delaware corporation (the “Borrower”) according to the conditions of the convertible note of the Borrower dated as of [insert date of note] (the “Note”), as of the date written below.  No fee will be charged to the Holder for any conversion, except for transfer taxes, if any.  

Box Checked as to applicable instructions:

[ ]
The Borrower shall electronically transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its nominee with DTC through its Deposit Withdrawal Agent Commission system (“DWAC Transfer”).

Name of DTC Prime Broker:   
Account Number:  

[  ]
The undersigned hereby requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth below (which numbers are based on the Holder’s calculation attached hereto) in the name(s) specified immediately below or, if additional space is necessary, on an attachment hereto:
 
Date of Conversion:  
Applicable Conversion Price:
Number of Shares of Common Stock to be Issued Pursuant to
Conversion of the Notes:  
Amount of Principal Balance Due on Note being Converted:


BY_____________________________
Name:

Date: _________
Address:

 
 8

EX-31.1 3 simh_ex311.htm CERTIFICATION simh_ex311.htm
EXHIBIT 31.1
 
Rule 13a-14(a)/15d-14(a) Certification
 
I, Keith Houlihan, certify that:

1.
I have reviewed this report on Form 10-Q for the period ended June 30, 2013 of Sanomedics International Holdings, Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
 
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
 
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
 
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
 
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
     
 
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
 
Dated: August 19, 2013
By:
/s/ Keith Houlihan
 
 
 
Keith Houlihan
President, principal executive officer
EX-31.2 4 simh_ex312.htm CERTIFICATION simh_ex312.htm
EXHIBIT 31.2
 
Rule 13a-14(a)/15d-14(a) Certification
 
I, David C. Langle, certify that:

1.
I have reviewed this report on Form 10-Q for the period ended June 30, 2013 of Sanomedics International Holdings, Inc.;

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
 
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
 
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
 
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
     
 
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
 
Dated: August 19, 2013
By:
/s/ David C. Langle
 
   
David C. Langle
Chief Financial Officer, principal financial and accounting officer
EX-32.1 5 simh_ex321.htm CERTIFICATION simh_ex321.htm
EXHIBIT 32.1
 
Section 1350 Certification
 
In connection with the Quarterly Report of Sanomedics International Holdings, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2013 as filed with the Securities and Exchange Commission (the “Report”), I, Keith Houlihan, President, and David C. Langle, Chief Financial Officer, of the Company, certify, pursuant to 18 U.S.C. SS. 1350, as adopted pursuant to SS. 906 of the Sarbanes-Oxley Act of 2002, that:
 
1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and
 
2.
The information contained in the Report fairly presents, in all material respects, the financial conditions and results of operations of the Company.
 
 
Dated: August 19, 2013
By:
/s/ Keith Houlihan
 
 
 
Keith Houlihan
President, principal executive officer
 
 
 
     
Dated: August 19, 2013
By:
/s/ David C. Langle
 
   
David C. Langle
Chief Financial Officer, principal financial and accounting officer
 
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
EX-101.INS 6 simh-20130630.xml XBRL INSTANCE DOCUMENT 0001501972 2013-01-01 2013-06-30 0001501972 2013-08-16 0001501972 2012-12-31 0001501972 2013-06-30 0001501972 2012-01-01 2012-06-30 0001501972 simh:On24August2012Member 2012-12-31 0001501972 simh:On6December2012Member 2012-12-31 0001501972 simh:SecuredConvertiblePromissoryNote30Septemberl2010Member 2012-12-31 0001501972 simh:SecuredConvertiblePromissoryNote30Septemberl2010Member 2013-06-30 0001501972 simh:SecuredConvertiblePromissoryNote12March2011Member 2012-12-31 0001501972 simh:SecuredConvertiblePromissoryNote12March2011Member 2013-06-30 0001501972 simh:SecuredConvertiblePromissoryNote30September2011Member 2012-12-31 0001501972 simh:SecuredConvertiblePromissoryNote30September2011Member 2013-06-30 0001501972 simh:SecuredConvertiblePromissoryNoteOne12March2011Member 2012-12-31 0001501972 simh:SecuredConvertiblePromissoryNoteOne12March2011Member 2013-06-30 0001501972 2011-12-31 0001501972 simh:On24August2012Member 2013-06-30 0001501972 simh:On6December2012Member 2013-06-30 0001501972 2013-04-01 2013-06-30 0001501972 2012-04-01 2012-06-30 0001501972 2012-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 0.09 0.08 0.09 0.08 Sanomedics International Holdings, Inc 0001501972 10-Q 2013-06-30 2013 Q2 26508609 Smaller Reporting Company false --12-31 No No Yes 12500 31250 12500 4688 31250 0 54337 0 30898 0 62500 32812 43750 37500 0.001 0.001 1000 1000 1000 1000 1000 1000 0.001 0.001 250000000 250000000 20403586 20508609 20403586 20508609 582000 1102787 1102787 181000 181000 367000 367000 220000 220000 334787 334787 276640 858132 1379427 1960919 238868 1102787 1379427 858132 125365 0 40697 1847560 38842 50000 300000 90217 593032 36796 42305 7999 36796 34306 17049 15741 36372 534986 10810 2171 2318 8117 49376 3254403 5289923 3241903 4155886 65738 126597 40697 1847560 4688 68385 217001 283857 243836 314786 1290516 656569 90217 593032 -3164186 -4696891 -8913282 -11483261 20000 20000 5748691 6785860 20404 20509 1 1 1379427 858132 121079 35028 63941 7101 33592 34692 17021 12461 87487 336 46920 -5360 453808 547828 269676 320987 53500 8500 25750 255738 369751 38842 204888 3798 2122 1899 1061 766844 928201 336167 526936 -679357 -927865 -289247 -532296 54337 30898 1047628 1047628 53115 108956 27092 54489 -1890622 -108956 -1841160 -54489 -2569979 -1036821 -2130407 -586785 -2569979 -1036821 -2130407 -586785 -0.13 -0.07 -0.10 -0.04 20454423 14258939 20410102 14258939 3798 2122 255738 369751 337 -1047628 -41259 -4600 -147 29867 -7999 -4522 69392 131539 50950 -34240 66856 108935 60859 20547 -685094 -415496 45 -45 581492 47000 -133500 238000 150000 731492 418500 46398 2959 26084 72482 2959 96343 78197 -400000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sanomedics International Holdings, Inc. (referred to herein as &#147;we&#148;, &#147;us&#148;, &#147;our&#148; or the &#147;Company&#148;) formerly Grand Niagara Mining and Development Co, Inc. (&#34;Grand Niagara&#34;) was originally incorporated in the state of Idaho in 1955 and re-domiciled in the state of Delaware on April 6, 2009. The Company, through its subsidiaries, designs, develops, markets and distributes non-invasive infrared thermometers principally for consumer and pet home health care.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed&#160;consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The results for the interim period are not necessarily indicative of the results to be expected for the full year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited interim financial statements should be read in conjunction with the Company&#146;s Annual Report on Form 10-K, which contains the audited consolidated financial statements and notes thereto, together with the Management&#146;s Discussion and Analysis, for the fiscal year ended December 31, 2012. The interim results for the three and six months ended June 30, 2013 are not necessarily indicative of the results for the full fiscal year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The condensed consolidated financial statements have been prepared on a going concern basis, and do not reflect any adjustments related to the uncertainty surrounding our recurring losses or accumulated deficit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently has limited revenue and is experiencing recurring losses. These factors raise substantial doubt about its ability to continue as a going concern. Management has financed the Company's operations principally through loans from an affiliate of the Company&#146;s former CEO, who is also one of the principal shareholders. Through June 30, 2013, the Company obtained its liquidity principally from approximately $582,000 of cash advances from an affiliate of the former Chairman and CEO and the Company's principal shareholder. The Company may need to continue borrowings from an affiliate of the former Chairman and CEO and the Company's principal shareholder and will also need to raise additional capital. However, management cannot provide any assurances that the Company will be successful in completing this financing and accomplishing any of its plans.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ability of the Company to continue as a going concern is dependent upon continued financial commitments from related parties and eventually secure other sources of financing in addition to those funds provided by its affiliate and attain profitable operations. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>June 30,</b></font></td> <td nowrap="nowrap" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2013</b></font></td> <td nowrap="nowrap" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2012</b></font></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 10pt">Notes Payable consists of the following:</font></td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%; text-align: justify"><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated September 30, 2010. Note accrues interest at 9% per annum, due and payable on October 1, 2013(A)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">181,000</font></td> <td nowrap="nowrap" style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">181,000</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated March 12, 2011. Note accrues interest at 9% per annum, due and payable on October 1, 2013 (A)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">367,000</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">367,000</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated September 30, 2011. Note accrues interest at 9% per annum, due and payable on September 30, 2013(A)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">220,000</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">220,000</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated March 12, 2011. Note accrues interest at 7.5% per annum, due and payable on October 1, 2013 (A)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">334,787</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">334,787</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Convertible Promissory Note-Officer, dated June 17, 2013. Note accrues interest at 9% per annum, due and payable on March 30, 2015, net of discount of $703,339 (B) Refer to Note 5</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Total</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,102,787</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,102,787</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other advances from CLSS Holdings, LLC, not evidenced by a promissory Note (A)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">858,132 </font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">276,640 </font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,960,919</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,379,427</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Less: Current portion</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">858,132</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,379,427</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Notes Payable-related parties</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,102,787</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The secured convertible promissory notes above are collateralized by substantially all the assets of the Company and are convertible, at the holder's option, into common shares of the Company at a fixed conversion price of $0.50 per share. CLSS is wholly owned by the Company's Former CEO who also is a principal shareholder of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: right"><font style="font-size: 10pt">(A)&#160;&#160;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">On May 9, 2013, the Company and an affiliate of the Company&#146;s former CEO agreed to terminate each of the above listed convertible notes and issue a single replacement convertible note that includes the obligations currently provided together with the advances and accrued interest of $238,868. The original convertible notes were not delivered to the Company and accordingly, the replacement note was not issued and voided. On August 13, 2013 an agreement was executed covering these Notes to extend the maturity of these Notes to March 31, 2015.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: right"><font style="font-size: 10pt">(B)&#160;&#160;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">On June 17, 2013, the Company and its President and a principal stockholder of the Company and a Director agreed to convert accrued salary totaling $703,339 into a long term convertible note as reflected above<font style="color: red">. </font>The Note is<font style="color: red">&#160;</font>convertible, at the holder's option, into common shares of the Company at a fixed conversion price of $0.50 per share.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 24, 2012, the Company executed a convertible note for $75,000. The convertible note is unsecured and has a maturity date of August 24, 2014. Interest will accrue at 9% per annum until paid or maturity and is convertible into common shares at a fixed convertible price of $0.50 per share. In the event that the Company undertakes financing while this debt is unpaid, the holder shall have the right to convert at the lessor of the offering price or the fixed conversion price. As of June 30, 2013 and December 31, 2012, the convertible note amounted to $31,250 and $12,500, net of unamortized discounts of $43,750 and $62,500, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 6, 2012, the Company entered into a Securities Purchase Agreement and convertible promissory note (&#147;Note&#148;) in the principal amount of $37,500. The Note, which was due on August 29, 2013, bears interest at 8% per annum until paid or to maturity was converted on June 11, 2013 and June 18, 2013 into a total of 29,128 shares of the Company&#146;s common stock at a conversion price equal to a 42% discount to the average of the lowest three closing bid prices of the common stock during the 10 trading days prior to conversion or $1.36 and $1.36 per share. As of June 30, 2013 and December 31, 2012, the convertible note amounted to $ -0- and $4,688, net of unamortized discount of $37,500 and $32,812, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 17, 2013, the Company entered into a Promissory Note (the &#147;Note&#148;) with a third party lender (&#147;Lender&#148;) in the principal amount up to $500,000. On June 19, 2013, the Lender executed the Note and funded the Company an initial tranche of $150,000 pursuant to the terms thereof. The principal sum of the Note carries a $50,000 original issue discount (&#147;OID&#148;) , which is prorated based on the consideration paid by the lender. The maturity date of each tranche funded under the Note is one year from the date of each payment by the Lender. The principal amount of the Note due is prorated based upon the consideration actually paid to us, plus a 10% OID, and we are only obligated to repay the amount of the funded Note, together with interest and fees. The Note may be prepaid by us at any time on or before 90 days from the date of issue interest free. After the initial 90 day period the Note bears a one-time interest charge of 12% applied to the principal sum. All principal and accrued interest on the Note is convertible into shares of the Company&#146;s common stock at the election of the Lender at any time at a conversion price of the lesser of $2.75 or 70% of the lowest trade price in the 25 trading days prior to conversion. At all times while the Note is outstanding we agreed to reserve from our authorized but unissued shares of common stock 550,000 shares for the possible conversion of the Note; plus provide registration rights. As of June 30, 2013, the Note amounted to $68,385 , net of unamortized discount of $81,615.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 470-20 <i>Debt with Conversion and Other Options</i>, the Company recorded total discounts of $125,365 and $0 for the beneficial conversion features of the convertible debts incurred during the periods ended June 30, 2013 and June 30, 2012, respectively. The discounts are being amortized to interest expense over the term of the notes using the effective interest method. The Company recorded $54,337 and $-0- of interest expense pursuant to the amortization of the note discounts for the six months ended June 30, 2013 and for the six months&#160;&#160;ended June 30, 2012, respectively; and $30,898 and $ -0- for the three months ended June 30, 2013 and June 30, 2012.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company analyzed the related party convertible note-officer and convertible promissory notes referred to in Notes 3 and 4 based on the provisions of ASC 815-15 and determined that the conversion options of the convertible notes qualify as embedded derivatives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value upon inception of the embedded derivatives are determined to total $2,915,188 and recorded as embedded derivative liabilities. The embedded derivatives are revalued at the end of each reporting period and any resulting gain or loss is recognized as a current period charge to the statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for the embedded conversion features included in its common stock as well as derivative liabilities. The aggregate fair value of derivative liabilities as of June 30, 2013 and December 31, 2012 amounted to $1,847,560 and $40,697, respectively. The net decrease of $1,047,628 in the fair value of the derivative liabilities between the respective periods is included in other income as an unrealized gain on fair value of derivatives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Litigation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm its business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 21, 2013, Exergen Corporation commenced legal action in the United States District Court for the District of Massachusetts against us, claiming infringement of certain intellectual property. Exergen is seeking various types of relief, including an injunction against further infringement of certain intellectual property. Given the inherent uncertainty and unpredictability of litigation and due to the early status of this legal action, no range of loss or possible loss can be reasonably estimated at this time.&#160;However, we do not expect the outcome of this matter to have a material adverse effect on our consolidated financial statements when taken as a whole. As of June&#160;30, 2013 and through the date of this filing, no amount is accrued as a loss is not considered probable or estimable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Common stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 9, 2013, the Company issued a total of 50,000 shares of common stock to two consultant for services valued at $1.15 per share. As a result, the Company recorded stock compensation in the amount of $57,500 for the three months ended March 31, 2013.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 28, 2013, the Company issued a total of 25,895 shares of common stock to a public relations firm as settlement of its services valued at $1.50 per share. As a result, the Company recorded stock compensation in the amount of $38,842 for the three months ended June 30, 2013.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 11, 2013 and June 28, 2013, in connection with a Securities Purchase Agreement and convertible promissory note (&#147;Note&#148;) in the principal amount of $37,500, the Company converted the Note into a total of 29,128 shares of the Company&#146;s common stock at a conversion price of $1.36&#160;&#160;per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 7, 2013, the Company granted to its Chief Technology Officer 150,000 seven-year stock options with an exercise price of&#160;$0.50 per share. The Company determined that the fair value of the options was approximately $159,000 using the Black Scholes method and recorded as stock compensation in the accompanying condensed consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Prime Time Medical:</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 26, 2013, the Company entered into a Stock Purchase Agreement (the &#147;Stock Purchase Agreement &#148;) with Prime Time Medical, Inc., a Florida corporation (&#147;Prime Time&#148;) and Mark R. Miklos, the sole equity holder of Prime Time (&#147;Miklos&#148;). Prime Time is a Durable Medical Equipment provider of home medical equipment servicing consumers throughout West Central Florida.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Stock Purchase Agreement, at the closing Miklos will transfer to the Company all the outstanding shares of capital stock of Prime Time for an aggregate purchase price of up to $3,100,000, subject to certain adjustments as summarized herein. The purchase price will be paid in a combination of cash, promissory notes and shares of the Company&#146;s common stock</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On the closing date, the Company will make a total cash payment to Miklos as follows: (a) if the closing occurs on or prior to May 26, 2013, the Company shall pay $950,000 at closing, (b) if the closing occurs after May 26, 2013 but on or prior to June 26, 2013 the Company shall pay to Seller $1,050,000 at closing, and (c) if the closing occurs after June 26, 2013, the Company shall pay to Seller $1,150,000 at closing. The Purchase Agreement requires total deposits of $400,000 to be paid towards the purchase price, to be paid by June 26, 2013. As of June 30, 2013 the Company has paid $300,000 and recorded an accrual for $100,000. Subsequently the company paid an additional $50,000, which has resulted in the seller granting the Company additional time to close.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, at closing, the Company will issue two additional promissory notes (the &#147;Prime Time Notes A and B&#148;) to Miklos in the aggregate principal amount of $1,000,000.&#160;&#160;Prime Time Note A in the principal amount of $500,000 will bear interest at 5% per annum, with monthly payments of principal and interest, and will mature three years after the closing date.&#160;&#160;Prime Time Note B in the principal amount of $500,000 will bear interest at 5% per annum, with annual payments of interest and principal payable annually over two years from the date of closing provided; however, that the principal balance of Prime Time Note B (and the respective annual payment) shall be reduced if: (i) the earnings before income taxes, depreciation and amortization (&#147;EBITDA&#148;) for the fiscal year ended December 31, 2013 is less than $975,000; and/or (ii) the EBITDA for the fiscal year ended December 31, 2014 is less than $975,000. At Miklos&#146; option, Prime Time Note B can be paid in shares of common stock of the Company on terms acceptable to Miklos and the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total consideration also includes $750,000 in the form of shares of restricted common stock of the Company (the &#147;Shares&#148;), with the number of Shares to be issued to be determined at closing by dividing $750,000 by the average of the highest bid and lowest asked prices for the Company&#146;s common stock as quoted on the OTC Bulletin Board, the OTC Pink Sheets or other similar quotation system, as applicable, at the end of the trading day immediately preceding the closing (the &#147;Original Issuance Price&#148;). If as of the first anniversary of the closing Miklos has not received at least $1,500,000 of the purchase price in the form of cash (including from the payment of principal on Prime Time Notes A and B and the sale of Shares in the public market), then, following such first anniversary, Miklos may put, and Company shall promptly purchase from Miklos in cash, such number of Shares equal to the difference between such cash payments and $1,500,000 divided by the Original Issuance Price.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Purchase Agreement also requires the Company to enter at closing into an employment agreement with the Seller for certain management services and; also contains a covenant of the Seller not to compete with the Company for a two year period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Purchase Agreement further provides that the Company will engage its independent registered public accounting firm to prepare an audit of Prime Time&#146;s financial statements for the years ended December 31, 2011 and 2012. If, for any reason the audit cannot be concluded, the Company will not be required to pay any amounts due under Notes A or B and such notes will be cancelled. The Company, however, has no right to receive a refund of the cash portion of the purchase price as tendered or to effect a cancellation of the Shares. In addition, if Prime Time&#146;s total asset value at December 31, 2012 as determined in accordance with the audited financial statements is less than the value set forth on the financial statements previously provided to the Company, the purchase price will be reduced by such amount on a dollar for dollar basis through a return of a number of Shares equal to such deficiency, and, if the deficiency is greater than the Original Issue Price, through a set off of the amount which will be due under Note A.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Pending Acquisition</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 10, 2013, the Company entered into an Equity Purchase Agreement (the &#147;Equity Purchase Agreement &#148;) with Duke Medical Equipment LLC, a Texas limited liability company (&#147;Duke Medical&#148;) and Vann R. Duke, the sole equity holder of Duke (&#147;Duke&#148;). Duke Medical is a Durable Medical Equipment provider of home medical equipment servicing consumers throughout the Houston and Galveston, Texas area.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Equity Agreement, at the closing Duke will transfer to the Company all the membership interest of Duke Medical for an aggregate purchase price of $7,000,000, subject to certain adjustments as summarized herein. The purchase price will be paid in a combination of cash, promissory notes and shares of the Company&#146;s common stock. On the closing date the Company will make a total cash payment to the Seller of $2,000,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, at closing, the Company will issue two additional promissory notes (the &#147;Duke Medical Notes A and B&#148;) to Duke in the aggregate principal amount of $2,000,000. Duke Medical Note A in the principal amount of $1,000,000 will bear interest at 5% per annum, with monthly payments of principal and interest, and will mature eighteen (18) months after the closing date. Duke Medical Note B in the principal amount of $1,000,000 will bear interest at 5% per annum, with annual payments of interest and principal payable annually over two years from the date of closing provided; however, that the principal balance of Duke Medical Note B (and the respective annual payment) shall be reduced if: (i) EBITDA for the fiscal year ended December 31, 2013 is less than $1,500,000; and/or (ii) the EBITDA for the fiscal year ended December 31, 2014 is less than $1,500,000. At Duke&#146;s option, Duke Medical Note B can be paid in shares of common stock of the Buyer on terms acceptable to Duke and the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total consideration also includes $3,000,000 in the form of shares, with the number of shares to be issued to be determined at closing by dividing $3,000,000 by the average of the closing bid price for the Company&#146;s common stock as quoted on the OTC Bulletin Board, the OTC Pink Sheets or other similar quotation system, as applicable, for the five (5) trading days immediately preceding the closing (the &#147;Duke Medical Original Issuance Price&#148;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Equity Purchase Agreement also requires the Company to enter at closing into employment agreements with Duke and his spouse for certain management services and; also contains a covenant of Duke and his spouse not to compete with the Company for a two year period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Equity Purchase Agreement further provides that the Company will engage its independent registered public accounting firm to conduct an audit of Duke Medical&#146;s financial statements for the years ended December 31, 2011 and 2012. If, for any reason the audit cannot be concluded, the Company will not be required to pay any amounts due under the Duke Medical Notes A or B and such notes will be cancelled. The Company, however, has no right to receive a refund of the cash portion of the purchase price as tendered or to effect a cancellation of the Shares. In addition, if Duke Medical&#146;s total asset value at December 31, 2012 as determined in accordance with the audited financial statements is less than the value set forth on the financial statements previously provided to the Company, the purchase price will be reduced by such amount on a dollar for dollar basis through a return of a number of Shares equal to such deficiency, and, if the deficiency is greater than the Duke Medical Original Issue Price, through a set off of the amount which will be due under Duke Medical Note A.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Share Issuances:</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 12, 2013 the Company issued 6,000,000 shares of its common stock upon the conversion of $6,000 portion of Convertible Note due to CLSS originally at $220,000 and sold to six (6) third parties by the original holder, with the shares valued at current fair market totaling $11,940,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has evaluated the subsequent events through August 19, 2013, the date at which the condensed consolidated financial statements were available for issue.</p> <p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>June 30,</b></font></td> <td nowrap="nowrap" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2013</b></font></td> <td nowrap="nowrap" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2012</b></font></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 10pt">Notes Payable consists of the following:</font></td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%; text-align: justify"><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated September 30, 2010. Note accrues interest at 9% per annum, due and payable on October 1, 2013(A)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">181,000</font></td> <td nowrap="nowrap" style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">181,000</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated March 12, 2011. Note accrues interest at 9% per annum, due and payable on October 1, 2013 (A)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">367,000</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">367,000</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated September 30, 2011. Note accrues interest at 9% per annum, due and payable on September 30, 2013(A)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">220,000</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">220,000</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated March 12, 2011. Note accrues interest at 7.5% per annum, due and payable on October 1, 2013 (A)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">334,787</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">334,787</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Convertible Promissory Note-Officer, dated June 17, 2013. Note accrues interest at 9% per annum, due and payable on March 30, 2015, net of discount of $703,339 (B) Refer to Note 5</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Total</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,102,787</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,102,787</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other advances from CLSS Holdings, LLC, not evidenced by a promissory Note (A)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">858,132 </font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">276,640 </font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,960,919</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,379,427</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Less: Current portion</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">858,132</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,379,427</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Notes Payable-related parties</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,102,787</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td></tr> </table> <p style="margin: 0pt"></p> 400000 100000 2830798 2830798 10810 -1926 703339 EX-101.SCH 7 simh-20130630.xsd XBRL TAXONOMY EXTENSION SCHEMA 0001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0005 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0006 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 0007 - Disclosure - LIQUIDITY AND GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 0008 - Disclosure - NOTES PAYABLE -RELATED PARTY link:presentationLink link:calculationLink link:definitionLink 0009 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 0010 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 0011 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0012 - Disclosure - STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 0013 - Disclosure - PENDING ACQUISITION link:presentationLink link:calculationLink link:definitionLink 0014 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 0015 - Disclosure - NOTES PAYABLE -RELATED PARTY (Tables) link:presentationLink link:calculationLink link:definitionLink 0016 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0017 - Disclosure - NOTES PAYABLE -RELATED PARTY (Details) link:presentationLink link:calculationLink link:definitionLink 0018 - Disclosure - NOTES PAYABLE -RELATED PARTY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0019 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0020 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0021 - Disclosure - STOCKHOLDERS' DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 0022 - Disclosure - PENDING ACQUISITION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 simh-20130630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 simh-20130630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 simh-20130630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Affiliate Of Former Chief Executive Officer [Member] Related Party [Axis] Secured Convertible Promissory Note Of Clss Holdings, Llc, Dated March 12, 2012 [Member] Short-Term Debt, Type [Axis] Minimum Range [Axis] Maximum Patents [Member] Finite-Lived Intangible Assets By Major Class [Axis] Chief Executive Officer [Member] Common Stock Equity Components [Axis] Deferred Bonus and Profit Sharing Plan by Title of Individual [Axis] Two customers [Member] Major Customers [Axis] One customer [Member] Decrease [Member] Valuation Allowance by Deferred Tax Asset [Axis] Increase [Member] Minimum [Member] Maximum [Member] Exercise price 0.05 to $1.50 [Member] Exercise Price Range [Axis] Warrant [Member] Exercise price 1.50 - 3.75 [Member] Former CEO and Chairman [Member] On August 24, 2012 [Member] Report Date [Axis] On December 6, 2012 [Member] Secured Convertible Promissory Note September 8, 2009 [Member] Debt Instrument [Axis] Secured Convertible Promissory Note December 7, 2009 [Member] Secured Convertible Promissory Note April 6, 2010 [Member] Secured Convertible Promissory Note September 30, 2010 [Member] Convertible Promissory Note September 30, 2010 [Member] Convertible Promissory Note President September 30, 2010 [Member] Convertible Promissory Note One September 30, 2010 [Member] Secured Convertible Promissory Note March 12, 2011 [Member] Secured Convertible Promissory Note September 30, 2011 [Member] Secured Convertible Promissory Note One March 12, 2011 [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current Assets Cash Accounts receivable Inventory Deposit on planned acquisition Prepaid expense Total Current Assets Fixed assets, net Other Assets Patents, net Deposit Total Other Assets Total Assets Liabilities and Stockholders' Deficit Current Liabilities Accrued salaries payable Accounts payable and other liabilities Accrued interest payable Convertible note payable, net Derivative liabilities Due to related parties Notes payable - related parties, current portion Total Current Liabilities Notes payable - related parties Convertible note payable, net Total Liabilities Commitments and Contingencies Stockholders' Deficit Preferred stock, $0.001 par value: 1,000 shares authorized, issued and outstanding as of June 30, 2013 and December 31, 2012, respectively Common stock, $0.001 par value: 250,000,000 shares authorized, 20,508,609 and 20,403,586 issued and outstanding as of June 30, 2013 and December 31,2012, respectively. Additional paid in capital Stock subscription receivable Accumulated deficit Total Stockholders' Deficit Total Liabilities and Stockholders' Deficit Consolidated Balance Sheets Parenthetical Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Consolidated Statements Of Operations Revenues, net Cost of goods sold Gross profit (loss) Operating expenses General and administrative Research and development Stock compensation Depreciation and amortization Total operating expenses Loss from operations Other income (expense) Amortization of debt discount Derivative expense Unrealized gain on fair value of derivatives Interest expense Total other income (expense) Net income (loss) before income taxes Income taxes Net income (loss) Net income (loss) per share - basic and diluted Weighted average number of shares outstanding during the period - basic and diluted Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net income (loss) to net cash used in operating activities Depreciation and amortization Stock compensation Amortization of debt discount on convertible notes Derivative expense Unrealized gain on fair value of derivative liabilities Changes in operating assets and liabilities Accounts receivable Inventory Deposit on planned acquisition Prepaid expense Deposits Bank overdraft Accrued salaries payable Accounts payable and other liabilities Accrued interest payable Due to related parties Net Cash Used In Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of fixed assets Net Cash Used In Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from notes - related party Issuance of stock subscriptions payable Sale of common stock Proceeds from convertible notes payable Net Cash Provided By Financing Activities Net increase in cash Cash - beginning of period Cash - end of period Supplemental Disclosure of Cash Flow Information Cash paid during the period for: Income taxes Cash paid during the period for: Interest Non-cash Financing transactions: Common stock issued to consultants for services Common stock issued for conversion of debt, net of derivative Accrued salaries payable converted to convertible promissory note - officer Notes to Financial Statements NOTE 1 - ORGANIZATION AND BASIS OF PRESENTATION NOTE 2 - LIQUIDITY AND GOING CONCERN NOTE 3 - NOTES PAYABLE -RELATED PARTY NOTE 4 - CONVERTIBLE NOTES PAYABLE NOTE 5 - DERIVATIVE LIABILITIES NOTE 6 - COMMITMENTS AND CONTINGENCIES NOTE 7 - STOCKHOLDERS' DEFICIT NOTE 8 - PENDING ACQUISITION NOTE 9 - SUBSEQUENT EVENTS Notes Payable -Related Party Tables Schedule of Notes payable Liquidity And Going Concern Details Narrative Due to Officers or Stockholders Statement [Table] Statement [Line Items] Total Notes Other advances from CLSS Holdings, Inc, LLC, not evidenced by a promissory Note Notes payable - related party Less: Current portion Notes Payable-related parties Notes Payable -Related Party Details Narrative Advances and accrued interest Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Convertible note payable Percentage of interest rate on convertible note Unamortized discounts Beneficial conversion features of convertible debts Interest expense Derivative Liabilities Details Narrative Fair value of derivative liabilities Stockholders Deficit Details Narrative Stock compensation Pending Acquisition Details Narrative Purchase price paid Accrual amount Purchase price paid an additional Affiliate Of Former Chief Executive Officer [Member] Custom Element. Custom Element. Custom Element. Custom Element. Custom Element Custom Element. Custom Element Custom Element Custom Element Custom Element Custom Element Custom Element. Custom Element. Custom Element Custom Element. Custom Element Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Custom Element. Secured Convertible Promissory Note Of Clss Holdings, Llc, Dated March 12, 2012 [Member] Custom Element. Custom Element Stock Subscription Receivable Custom Element Custom Element Custom Element Custom Element Custom Element Custom Element Custom Element Custom Element Custom Element Custom Element Planned acquisition deposit. Accrual salaries payable converted to convertible promissory note - officer. Assets, Current Other Assets, Current Assets [Default Label] Liabilities, Current Liabilities StockSubscriptionReceivable Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Amortization of Financing Costs and Discounts Interest Expense Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Depreciation, Depletion and Amortization StockCompensation Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories DepositOnPlannedAcquisition Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accrued Salaries Increase (Decrease) in Accounts Payable and Other Operating Liabilities Increase (Decrease) in Interest Payable, Net Increase (Decrease) in Due to Related Parties, Current Net Cash Provided by (Used in) Operating Activities, Continuing Operations Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities IssuanceOfStockSubscriptionsPayable Net Cash Provided by (Used in) Financing Activities, Continuing Operations Cash, Period Increase (Decrease) Stock Issued During Period, Value, Share-based Compensation, Gross EX-101.PRE 11 simh-20130630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R8.xml IDEA: NOTES PAYABLE -RELATED PARTY 2.4.0.80008 - Disclosure - NOTES PAYABLE -RELATED PARTYtruefalsefalse1false falsefalseFrom2013-01-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-01-01T00:00:002013-06-30T00:00:001true 1simh_NotesToFinancialStatementsAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2simh_NotesPayableRelatedPartyTextBlocksimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>June 30,</b></font></td> <td nowrap="nowrap" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2013</b></font></td> <td nowrap="nowrap" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2012</b></font></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 10pt">Notes Payable consists of the following:</font></td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%; text-align: justify"><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated September 30, 2010. Note accrues interest at 9% per annum, due and payable on October 1, 2013(A)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">181,000</font></td> <td nowrap="nowrap" style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">181,000</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated March 12, 2011. Note accrues interest at 9% per annum, due and payable on October 1, 2013 (A)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">367,000</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">367,000</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated September 30, 2011. Note accrues interest at 9% per annum, due and payable on September 30, 2013(A)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">220,000</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">220,000</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated March 12, 2011. Note accrues interest at 7.5% per annum, due and payable on October 1, 2013 (A)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">334,787</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">334,787</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Convertible Promissory Note-Officer, dated June 17, 2013. Note accrues interest at 9% per annum, due and payable on March 30, 2015, net of discount of $703,339 (B) Refer to Note 5</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Total</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,102,787</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,102,787</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other advances from CLSS Holdings, LLC, not evidenced by a promissory Note (A)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">858,132 </font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">276,640 </font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,960,919</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,379,427</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Less: Current portion</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">858,132</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,379,427</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Notes Payable-related parties</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,102,787</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The secured convertible promissory notes above are collateralized by substantially all the assets of the Company and are convertible, at the holder's option, into common shares of the Company at a fixed conversion price of $0.50 per share. CLSS is wholly owned by the Company's Former CEO who also is a principal shareholder of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: right"><font style="font-size: 10pt">(A)&#160;&#160;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">On May 9, 2013, the Company and an affiliate of the Company&#146;s former CEO agreed to terminate each of the above listed convertible notes and issue a single replacement convertible note that includes the obligations currently provided together with the advances and accrued interest of $238,868. The original convertible notes were not delivered to the Company and accordingly, the replacement note was not issued and voided. On August 13, 2013 an agreement was executed covering these Notes to extend the maturity of these Notes to March 31, 2015.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: right"><font style="font-size: 10pt">(B)&#160;&#160;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">On June 17, 2013, the Company and its President and a principal stockholder of the Company and a Director agreed to convert accrued salary totaling $703,339 into a long term convertible note as reflected above<font style="color: red">. </font>The Note is<font style="color: red">&#160;</font>convertible, at the holder's option, into common shares of the Company at a fixed conversion price of $0.50 per share.</font></td></tr> </table>falsefalsefalsenonnum:textBlockItemTypenaCustom ElementNo definition available.false0falseNOTES PAYABLE -RELATED PARTYUnKnownUnKnownUnKnownUnKnowntruefalsefalseNoteshttp://sanomedics.com/role/NotesPayable-RelatedParty12 XML 13 R6.xml IDEA: ORGANIZATION AND BASIS OF PRESENTATION 2.4.0.80006 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATIONtruefalsefalse1false falsefalseFrom2013-01-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-01-01T00:00:002013-06-30T00:00:001true 1simh_NotesToFinancialStatementsAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sanomedics International Holdings, Inc. (referred to herein as &#147;we&#148;, &#147;us&#148;, &#147;our&#148; or the &#147;Company&#148;) formerly Grand Niagara Mining and Development Co, Inc. (&#34;Grand Niagara&#34;) was originally incorporated in the state of Idaho in 1955 and re-domiciled in the state of Delaware on April 6, 2009. The Company, through its subsidiaries, designs, develops, markets and distributes non-invasive infrared thermometers principally for consumer and pet home health care.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed&#160;consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The results for the interim period are not necessarily indicative of the results to be expected for the full year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited interim financial statements should be read in conjunction with the Company&#146;s Annual Report on Form 10-K, which contains the audited consolidated financial statements and notes thereto, together with the Management&#146;s Discussion and Analysis, for the fiscal year ended December 31, 2012. The interim results for the three and six months ended June 30, 2013 are not necessarily indicative of the results for the full fiscal year.</p>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).No definition available.false0falseORGANIZATION AND BASIS OF PRESENTATIONUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://sanomedics.com/role/OrganizationAndBasisOfPresentation12 XML 14 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTES PAYABLE -RELATED PARTY (Details) (USD $)
Jun. 30, 2013
Dec. 31, 2012
Total Notes $ 1,102,787 $ 1,102,787
Other advances from CLSS Holdings, Inc, LLC, not evidenced by a promissory Note 858,132 276,640
Notes payable - related party 1,960,919 1,379,427
Less: Current portion 858,132 1,379,427
Notes Payable-related parties 1,102,787   
Secured Convertible Promissory Note September 30, 2010 [Member]
   
Total Notes 181,000 181,000
Secured Convertible Promissory Note March 12, 2011 [Member]
   
Total Notes 367,000 367,000
Secured Convertible Promissory Note September 30, 2011 [Member]
   
Total Notes 220,000 220,000
Secured Convertible Promissory Note One March 12, 2011 [Member]
   
Total Notes $ 334,787 $ 334,787
XML 15 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Operations (Unaudited) (USD $)
3 Months Ended 6 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Consolidated Statements Of Operations        
Revenues, net $ 63,941 $ 7,101 $ 121,079 $ 35,028
Cost of goods sold 17,021 12,461 33,592 34,692
Gross profit (loss) 46,920 (5,360) 87,487 336
Operating expenses        
General and administrative 269,676 320,987 453,808 547,828
Research and development 25,750    53,500 8,500
Stock compensation 38,842 204,888 255,738 369,751
Depreciation and amortization 1,899 1,061 3,798 2,122
Total operating expenses 336,167 526,936 766,844 928,201
Loss from operations (289,247) (532,296) (679,357) (927,865)
Other income (expense)        
Amortization of debt discount (30,898)    (54,337)   
Derivative expense (2,830,798)    (2,830,798)   
Unrealized gain on fair value of derivatives 1,047,628    1,047,628   
Interest expense (27,092) (54,489) (53,115) (108,956)
Total other income (expense) (1,841,160) (54,489) (1,890,622) (108,956)
Net income (loss) before income taxes (2,130,407) (586,785) (2,569,979) (1,036,821)
Income taxes            
Net income (loss) $ (2,130,407) $ (586,785) $ (2,569,979) $ (1,036,821)
Net income (loss) per share - basic and diluted $ (0.10) $ (0.04) $ (0.13) $ (0.07)
Weighted average number of shares outstanding during the period - basic and diluted 20,410,102 14,258,939 20,454,423 14,258,939
XML 16 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8
DERIVATIVE LIABILITIES
6 Months Ended
Jun. 30, 2013
Notes to Financial Statements  
NOTE 5 - DERIVATIVE LIABILITIES

The Company analyzed the related party convertible note-officer and convertible promissory notes referred to in Notes 3 and 4 based on the provisions of ASC 815-15 and determined that the conversion options of the convertible notes qualify as embedded derivatives.

 

The fair value upon inception of the embedded derivatives are determined to total $2,915,188 and recorded as embedded derivative liabilities. The embedded derivatives are revalued at the end of each reporting period and any resulting gain or loss is recognized as a current period charge to the statement of operations.

 

The Company accounts for the embedded conversion features included in its common stock as well as derivative liabilities. The aggregate fair value of derivative liabilities as of June 30, 2013 and December 31, 2012 amounted to $1,847,560 and $40,697, respectively. The net decrease of $1,047,628 in the fair value of the derivative liabilities between the respective periods is included in other income as an unrealized gain on fair value of derivatives.

XML 17 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 18 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTES PAYABLE -RELATED PARTY (Details Narrative) (USD $)
Jun. 30, 2013
Notes Payable -Related Party Details Narrative  
Advances and accrued interest $ 238,868
XML 19 R19.xml IDEA: CONVERTIBLE NOTES PAYABLE (Details Narrative) 2.4.0.80019 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative)truefalsefalse1false USDfalsefalse$From2013-04-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-04-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$From2012-04-01to2012-06-30http://www.sec.gov/CIK0001501972duration2012-04-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$From2013-01-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-01-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$From2012-01-01to2012-06-30http://www.sec.gov/CIK0001501972duration2012-01-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDfalsefalse$AsOf2012-12-31http://www.sec.gov/CIK0001501972instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_DebtInstrumentLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 4us-gaap_ConvertibleLongTermNotesPayableus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse3125031250USD$falsetruefalse2falsefalsefalse00falsefalsefalse3truefalsefalse3125031250USD$falsetruefalse4falsefalsefalse00falsefalsefalse5truefalsefalse1250012500USD$falsetruefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 false23false 4us-gaap_DebtInstrumentConvertibleBeneficialConversionFeatureus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse125365125365USD$falsefalsefalse4truefalsefalse00USD$falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Beneficial Conversion Feature -URI http://asc.fasb.org/extlink&oid=6505963 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 98-5 -Paragraph 7 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 00-27 -Paragraph 56 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false24false 4us-gaap_InterestExpenseDebtus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse3089830898USD$falsefalsefalse2truefalsefalse00USD$falsefalsefalse3truefalsefalse5433754337USD$falsefalsefalse4truefalsefalse00USD$falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the portion of interest incurred in the period on debt arrangements that was charged against earnings.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 34 -Paragraph 21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false25false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6false USDtruefalse$AsOf2013-06-30_custom_On24August2012Memberhttp://www.sec.gov/CIK0001501972instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseOn August 24, 2012 [Member]us-gaap_CreationDateAxisxbrldihttp://xbrl.org/2006/xbrldisimh_On24August2012Memberus-gaap_CreationDateAxisexplicitMemberpureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse06true 3us-gaap_DebtInstrumentLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse07false 4us-gaap_ConvertibleLongTermNotesPayableus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse3125031250USD$falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse3125031250USD$falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse1250012500USD$falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 false28false 4us-gaap_DebtInstrumentInterestRateStatedPercentageus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalse1truetruefalse0.090.09falsefalsefalse2falsefalsefalse00falsefalsefalse3truetruefalse0.090.09falsefalsefalse4falsefalsefalse00falsefalsefalse5truetruefalse0.090.09falsefalsefalsenum:percentItemTypepureInterest rate stated in the contractual debt agreement.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false09false 4us-gaap_DebtInstrumentUnamortizedDiscountus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse4375043750USD$falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse4375043750USD$falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse6250062500USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number APB14-1 -Paragraph 31 -Subparagraph b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 21 -Paragraph 16, 20 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false210false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse8false USDtruefalse$AsOf2013-06-30_custom_On6December2012Memberhttp://www.sec.gov/CIK0001501972instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseOn December 6, 2012 [Member]us-gaap_CreationDateAxisxbrldihttp://xbrl.org/2006/xbrldisimh_On6December2012Memberus-gaap_CreationDateAxisexplicitMemberpureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse011true 3us-gaap_DebtInstrumentLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse012false 4us-gaap_ConvertibleLongTermNotesPayableus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse00USD$falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse00USD$falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse46884688USD$falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 false213false 4us-gaap_DebtInstrumentInterestRateStatedPercentageus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalse1truetruefalse0.080.08falsefalsefalse2falsefalsefalse00falsefalsefalse3truetruefalse0.080.08falsefalsefalse4falsefalsefalse00falsefalsefalse5truetruefalse0.080.08falsefalsefalsenum:percentItemTypepureInterest rate stated in the contractual debt agreement.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false014false 4us-gaap_DebtInstrumentUnamortizedDiscountus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse3750037500USD$falsetruefalse2falsefalsefalse00falsefalsefalse3truefalsefalse3750037500USD$falsetruefalse4falsefalsefalse00falsefalsefalse5truefalsefalse3281232812USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number APB14-1 -Paragraph 31 -Subparagraph b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6584090&loc=d3e28878-108400 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 21 -Paragraph 16, 20 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2falseCONVERTIBLE NOTES PAYABLE (Details Narrative) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseNoteshttp://sanomedics.com/role/ConvertibleNotesPayableDetailsNarrative514 XML 20 R9.xml IDEA: CONVERTIBLE NOTES PAYABLE 2.4.0.80009 - Disclosure - CONVERTIBLE NOTES PAYABLEtruefalsefalse1false falsefalseFrom2013-01-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-01-01T00:00:002013-06-30T00:00:001true 1simh_NotesToFinancialStatementsAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2us-gaap_DebtDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 24, 2012, the Company executed a convertible note for $75,000. The convertible note is unsecured and has a maturity date of August 24, 2014. Interest will accrue at 9% per annum until paid or maturity and is convertible into common shares at a fixed convertible price of $0.50 per share. In the event that the Company undertakes financing while this debt is unpaid, the holder shall have the right to convert at the lessor of the offering price or the fixed conversion price. As of June 30, 2013 and December 31, 2012, the convertible note amounted to $31,250 and $12,500, net of unamortized discounts of $43,750 and $62,500, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 6, 2012, the Company entered into a Securities Purchase Agreement and convertible promissory note (&#147;Note&#148;) in the principal amount of $37,500. The Note, which was due on August 29, 2013, bears interest at 8% per annum until paid or to maturity was converted on June 11, 2013 and June 18, 2013 into a total of 29,128 shares of the Company&#146;s common stock at a conversion price equal to a 42% discount to the average of the lowest three closing bid prices of the common stock during the 10 trading days prior to conversion or $1.36 and $1.36 per share. As of June 30, 2013 and December 31, 2012, the convertible note amounted to $ -0- and $4,688, net of unamortized discount of $37,500 and $32,812, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 17, 2013, the Company entered into a Promissory Note (the &#147;Note&#148;) with a third party lender (&#147;Lender&#148;) in the principal amount up to $500,000. On June 19, 2013, the Lender executed the Note and funded the Company an initial tranche of $150,000 pursuant to the terms thereof. The principal sum of the Note carries a $50,000 original issue discount (&#147;OID&#148;) , which is prorated based on the consideration paid by the lender. The maturity date of each tranche funded under the Note is one year from the date of each payment by the Lender. The principal amount of the Note due is prorated based upon the consideration actually paid to us, plus a 10% OID, and we are only obligated to repay the amount of the funded Note, together with interest and fees. The Note may be prepaid by us at any time on or before 90 days from the date of issue interest free. After the initial 90 day period the Note bears a one-time interest charge of 12% applied to the principal sum. All principal and accrued interest on the Note is convertible into shares of the Company&#146;s common stock at the election of the Lender at any time at a conversion price of the lesser of $2.75 or 70% of the lowest trade price in the 25 trading days prior to conversion. At all times while the Note is outstanding we agreed to reserve from our authorized but unissued shares of common stock 550,000 shares for the possible conversion of the Note; plus provide registration rights. As of June 30, 2013, the Note amounted to $68,385 , net of unamortized discount of $81,615.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 470-20 <i>Debt with Conversion and Other Options</i>, the Company recorded total discounts of $125,365 and $0 for the beneficial conversion features of the convertible debts incurred during the periods ended June 30, 2013 and June 30, 2012, respectively. The discounts are being amortized to interest expense over the term of the notes using the effective interest method. The Company recorded $54,337 and $-0- of interest expense pursuant to the amortization of the note discounts for the six months ended June 30, 2013 and for the six months&#160;&#160;ended June 30, 2012, respectively; and $30,898 and $ -0- for the three months ended June 30, 2013 and June 30, 2012.</p>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20, 22 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20,22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false0falseCONVERTIBLE NOTES PAYABLEUnKnownUnKnownUnKnownUnKnowntruefalsefalseNoteshttp://sanomedics.com/role/CONVERTIBLENOTESPAYABLERELATEDPARTY12 XML 21 R12.xml IDEA: STOCKHOLDERS' DEFICIT 2.4.0.80012 - Disclosure - STOCKHOLDERS' DEFICITtruefalsefalse1false falsefalseFrom2013-01-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-01-01T00:00:002013-06-30T00:00:001true 1simh_NotesToFinancialStatementsAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2us-gaap_StockholdersEquityNoteDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Common stock</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 9, 2013, the Company issued a total of 50,000 shares of common stock to two consultant for services valued at $1.15 per share. As a result, the Company recorded stock compensation in the amount of $57,500 for the three months ended March 31, 2013.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 28, 2013, the Company issued a total of 25,895 shares of common stock to a public relations firm as settlement of its services valued at $1.50 per share. As a result, the Company recorded stock compensation in the amount of $38,842 for the three months ended June 30, 2013.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 11, 2013 and June 28, 2013, in connection with a Securities Purchase Agreement and convertible promissory note (&#147;Note&#148;) in the principal amount of $37,500, the Company converted the Note into a total of 29,128 shares of the Company&#146;s common stock at a conversion price of $1.36&#160;&#160;per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Stock Options</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 7, 2013, the Company granted to its Chief Technology Officer 150,000 seven-year stock options with an exercise price of&#160;$0.50 per share. The Company determined that the fair value of the options was approximately $159,000 using the Black Scholes method and recorded as stock compensation in the accompanying condensed consolidated financial statements.</p>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Article 4 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section B -Paragraph 7, 11A -Chapter 1 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Preferred Stock -URI http://asc.fasb.org/extlink&oid=6521494 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(d),(e)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 17: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 18: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 19: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644 Reference 20: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644 Reference 21: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644 Reference 22: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644 Reference 23: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph d -Article 4 false0falseSTOCKHOLDERS' DEFICITUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://sanomedics.com/role/StockholdersDeficit12 XML 22 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
ORGANIZATION AND BASIS OF PRESENTATION
6 Months Ended
Jun. 30, 2013
Notes to Financial Statements  
NOTE 1 - ORGANIZATION AND BASIS OF PRESENTATION

Sanomedics International Holdings, Inc. (referred to herein as “we”, “us”, “our” or the “Company”) formerly Grand Niagara Mining and Development Co, Inc. ("Grand Niagara") was originally incorporated in the state of Idaho in 1955 and re-domiciled in the state of Delaware on April 6, 2009. The Company, through its subsidiaries, designs, develops, markets and distributes non-invasive infrared thermometers principally for consumer and pet home health care.

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The results for the interim period are not necessarily indicative of the results to be expected for the full year.

 

The unaudited interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K, which contains the audited consolidated financial statements and notes thereto, together with the Management’s Discussion and Analysis, for the fiscal year ended December 31, 2012. The interim results for the three and six months ended June 30, 2013 are not necessarily indicative of the results for the full fiscal year.

XML 23 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTES PAYABLE -RELATED PARTY
6 Months Ended
Jun. 30, 2013
Notes to Financial Statements  
NOTE 3 - NOTES PAYABLE -RELATED PARTY

    June 30,     December 31,
    2013     2012
           
Notes Payable consists of the following:          
           
Secured Convertible Promissory Note - CLSS Holdings, LLC, dated September 30, 2010. Note accrues interest at 9% per annum, due and payable on October 1, 2013(A)   $ 181,000     $ 181,000
Secured Convertible Promissory Note - CLSS Holdings, LLC, dated March 12, 2011. Note accrues interest at 9% per annum, due and payable on October 1, 2013 (A)     367,000       367,000
Secured Convertible Promissory Note - CLSS Holdings, LLC, dated September 30, 2011. Note accrues interest at 9% per annum, due and payable on September 30, 2013(A)     220,000       220,000
Secured Convertible Promissory Note - CLSS Holdings, LLC, dated March 12, 2011. Note accrues interest at 7.5% per annum, due and payable on October 1, 2013 (A)     334,787       334,787
Convertible Promissory Note-Officer, dated June 17, 2013. Note accrues interest at 9% per annum, due and payable on March 30, 2015, net of discount of $703,339 (B) Refer to Note 5     -       -
               
Total     1,102,787       1,102,787
               
Other advances from CLSS Holdings, LLC, not evidenced by a promissory Note (A)     858,132       276,640
      1,960,919       1,379,427
               
Less: Current portion     858,132       1,379,427
Notes Payable-related parties   $ 1,102,787     $ -

 

The secured convertible promissory notes above are collateralized by substantially all the assets of the Company and are convertible, at the holder's option, into common shares of the Company at a fixed conversion price of $0.50 per share. CLSS is wholly owned by the Company's Former CEO who also is a principal shareholder of the Company.

 

(A)   On May 9, 2013, the Company and an affiliate of the Company’s former CEO agreed to terminate each of the above listed convertible notes and issue a single replacement convertible note that includes the obligations currently provided together with the advances and accrued interest of $238,868. The original convertible notes were not delivered to the Company and accordingly, the replacement note was not issued and voided. On August 13, 2013 an agreement was executed covering these Notes to extend the maturity of these Notes to March 31, 2015.

 

(B)   On June 17, 2013, the Company and its President and a principal stockholder of the Company and a Director agreed to convert accrued salary totaling $703,339 into a long term convertible note as reflected above. The Note is convertible, at the holder's option, into common shares of the Company at a fixed conversion price of $0.50 per share.
XML 24 R11.xml IDEA: COMMITMENTS AND CONTINGENCIES 2.4.0.80011 - Disclosure - COMMITMENTS AND CONTINGENCIEStruefalsefalse1false falsefalseFrom2013-01-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-01-01T00:00:002013-06-30T00:00:001true 1simh_NotesToFinancialStatementsAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2us-gaap_CommitmentsAndContingenciesDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Litigation</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm its business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 21, 2013, Exergen Corporation commenced legal action in the United States District Court for the District of Massachusetts against us, claiming infringement of certain intellectual property. Exergen is seeking various types of relief, including an injunction against further infringement of certain intellectual property. Given the inherent uncertainty and unpredictability of litigation and due to the early status of this legal action, no range of loss or possible loss can be reasonably estimated at this time.&#160;However, we do not expect the outcome of this matter to have a material adverse effect on our consolidated financial statements when taken as a whole. As of June&#160;30, 2013 and through the date of this filing, no amount is accrued as a loss is not considered probable or estimable.</p>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for commitments and contingencies.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Interpretation (FIN) -Number 14 -Paragraph 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 9, 10, 11, 12 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false0falseCOMMITMENTS AND CONTINGENCIESUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://sanomedics.com/role/CommitmentsAndContingencies12 XML 25 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Jun. 30, 2013
Notes to Financial Statements  
NOTE 6 - COMMITMENTS AND CONTINGENCIES

Litigation

 

From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm its business.

 

On May 21, 2013, Exergen Corporation commenced legal action in the United States District Court for the District of Massachusetts against us, claiming infringement of certain intellectual property. Exergen is seeking various types of relief, including an injunction against further infringement of certain intellectual property. Given the inherent uncertainty and unpredictability of litigation and due to the early status of this legal action, no range of loss or possible loss can be reasonably estimated at this time. However, we do not expect the outcome of this matter to have a material adverse effect on our consolidated financial statements when taken as a whole. As of June 30, 2013 and through the date of this filing, no amount is accrued as a loss is not considered probable or estimable.

XML 26 R14.xml IDEA: SUBSEQUENT EVENTS 2.4.0.80014 - Disclosure - SUBSEQUENT EVENTStruefalsefalse1false falsefalseFrom2013-01-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-01-01T00:00:002013-06-30T00:00:001true 1simh_NotesToFinancialStatementsAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2us-gaap_SubsequentEventsTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Pending Acquisition</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 10, 2013, the Company entered into an Equity Purchase Agreement (the &#147;Equity Purchase Agreement &#148;) with Duke Medical Equipment LLC, a Texas limited liability company (&#147;Duke Medical&#148;) and Vann R. Duke, the sole equity holder of Duke (&#147;Duke&#148;). Duke Medical is a Durable Medical Equipment provider of home medical equipment servicing consumers throughout the Houston and Galveston, Texas area.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Equity Agreement, at the closing Duke will transfer to the Company all the membership interest of Duke Medical for an aggregate purchase price of $7,000,000, subject to certain adjustments as summarized herein. The purchase price will be paid in a combination of cash, promissory notes and shares of the Company&#146;s common stock. On the closing date the Company will make a total cash payment to the Seller of $2,000,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, at closing, the Company will issue two additional promissory notes (the &#147;Duke Medical Notes A and B&#148;) to Duke in the aggregate principal amount of $2,000,000. Duke Medical Note A in the principal amount of $1,000,000 will bear interest at 5% per annum, with monthly payments of principal and interest, and will mature eighteen (18) months after the closing date. Duke Medical Note B in the principal amount of $1,000,000 will bear interest at 5% per annum, with annual payments of interest and principal payable annually over two years from the date of closing provided; however, that the principal balance of Duke Medical Note B (and the respective annual payment) shall be reduced if: (i) EBITDA for the fiscal year ended December 31, 2013 is less than $1,500,000; and/or (ii) the EBITDA for the fiscal year ended December 31, 2014 is less than $1,500,000. At Duke&#146;s option, Duke Medical Note B can be paid in shares of common stock of the Buyer on terms acceptable to Duke and the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total consideration also includes $3,000,000 in the form of shares, with the number of shares to be issued to be determined at closing by dividing $3,000,000 by the average of the closing bid price for the Company&#146;s common stock as quoted on the OTC Bulletin Board, the OTC Pink Sheets or other similar quotation system, as applicable, for the five (5) trading days immediately preceding the closing (the &#147;Duke Medical Original Issuance Price&#148;).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Equity Purchase Agreement also requires the Company to enter at closing into employment agreements with Duke and his spouse for certain management services and; also contains a covenant of Duke and his spouse not to compete with the Company for a two year period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&#160;&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Equity Purchase Agreement further provides that the Company will engage its independent registered public accounting firm to conduct an audit of Duke Medical&#146;s financial statements for the years ended December 31, 2011 and 2012. If, for any reason the audit cannot be concluded, the Company will not be required to pay any amounts due under the Duke Medical Notes A or B and such notes will be cancelled. The Company, however, has no right to receive a refund of the cash portion of the purchase price as tendered or to effect a cancellation of the Shares. In addition, if Duke Medical&#146;s total asset value at December 31, 2012 as determined in accordance with the audited financial statements is less than the value set forth on the financial statements previously provided to the Company, the purchase price will be reduced by such amount on a dollar for dollar basis through a return of a number of Shares equal to such deficiency, and, if the deficiency is greater than the Duke Medical Original Issue Price, through a set off of the amount which will be due under Duke Medical Note A.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Share Issuances:</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 12, 2013 the Company issued 6,000,000 shares of its common stock upon the conversion of $6,000 portion of Convertible Note due to CLSS originally at $220,000 and sold to six (6) third parties by the original holder, with the shares valued at current fair market totaling $11,940,000.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has evaluated the subsequent events through August 19, 2013, the date at which the condensed consolidated financial statements were available for issue.</p>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.No definition available.false0falseSUBSEQUENT EVENTSUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://sanomedics.com/role/SubsequentEvents12 XML 27 R2.xml IDEA: Consolidated Balance Sheets (Unaudited) 2.4.0.80002 - Statement - Consolidated Balance Sheets (Unaudited)truefalsefalse1false USDfalsefalse$AsOf2013-06-30http://www.sec.gov/CIK0001501972instant2013-06-30T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$AsOf2012-12-31http://www.sec.gov/CIK0001501972instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_AssetsCurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 4us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse7248272482USD$falsetruefalse2truefalsefalse2608426084USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false23false 4us-gaap_AccountsReceivableNetCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse4937649376falsefalsefalse2truefalsefalse81178117falsefalsefalsexbrli:monetaryItemTypemonetaryAmount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 false24false 4us-gaap_InventoryNetus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse23182318falsefalsefalse2truefalsefalse21712171falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 35 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 false25false 4simh_PlannedAcquisitionDepositsimh_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse400000400000falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryPlanned acquisition deposit.No definition available.false26false 4us-gaap_OtherPrepaidExpenseCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse1081010810falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying amount as of the balance sheet date of expenditures made, not otherwise specified in the taxonomy, in advance of the timing of recognition of expenses which are expected to be charged against earnings within one year or the normal operating cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 4 -Chapter 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6787-107765 false27false 4us-gaap_AssetsCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse534986534986falsefalsefalse2truefalsefalse3637236372falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 9 -Article 5 true28false 3us-gaap_PropertyPlantAndEquipmentNetus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse1574115741falsefalsefalse2truefalsefalse1704917049falsefalsefalsexbrli:monetaryItemTypemonetaryAmount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 12 -Paragraph 5 -Subparagraph b, c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false29false 3simh_PatentsNetsimh_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse3430634306falsefalsefalse2truefalsefalse3679636796falsefalsefalsexbrli:monetaryItemTypemonetaryCustom ElementNo definition available.false210false 3simh_Depositsimh_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse79997999falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryCustom Element.No definition available.false211false 3us-gaap_OtherAssetsCurrentus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse4230542305falsefalsefalse2truefalsefalse3679636796falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 8 -Article 5 true212false 3us-gaap_Assetsus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse593032593032falsefalsefalse2truefalsefalse9021790217falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 18 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Concepts (CON) -Number 6 -Paragraph 25 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true213true 3us-gaap_LiabilitiesCurrentAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse014false 4us-gaap_AccruedSalariesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse656569656569falsefalsefalse2truefalsefalse12905161290516falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 7 -Chapter 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6911-107765 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 8 -Chapter 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false215false 4us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse314786314786falsefalsefalse2truefalsefalse243836243836falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, and other costs not separately disclosed in the balance sheet that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.No definition available.false216false 4us-gaap_InterestPayableCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse283857283857falsefalsefalse2truefalsefalse217001217001falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 7 -Chapter 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e7018-107765 false217false 4us-gaap_ConvertibleNotesPayableCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse6838568385falsefalsefalse2truefalsefalse46884688falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false218false 4us-gaap_DerivativeLiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse18475601847560falsefalsefalse2truefalsefalse4069740697falsefalsefalsexbrli:monetaryItemTypemonetaryFair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 43 -Section A -Paragraph 7 -Chapter 3 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13495-108611 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number FIN39-1 -Paragraph 10A, 10B -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 4, 17 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false219false 4us-gaap_DueToRelatedPartiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse126597126597falsefalsefalse2truefalsefalse6573865738falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 2 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 false220false 4us-gaap_NotesPayableCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse858132858132falsefalsefalse2truefalsefalse13794271379427falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20 -Article 5 false221false 4us-gaap_LiabilitiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse41558864155886falsefalsefalse2truefalsefalse32419033241903falsefalsefalsexbrli:monetaryItemTypemonetaryTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 21 -Article 5 true222false 3us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse11027871102787falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount for notes payable (written promise to pay), due to related parties.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 2 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.17) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 17 -Article 7 false223false 3us-gaap_ConvertibleLongTermNotesPayableus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse3125031250falsefalsefalse2truefalsefalse1250012500falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 false224false 3us-gaap_Liabilitiesus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse52899235289923falsefalsefalse2truefalsefalse32544033254403falsefalsefalsexbrli:monetaryItemTypemonetarySum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 true225false 3us-gaap_CommitmentsAndContingenciesus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00&nbsp;&nbsp;falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 25 -Article 5 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 7 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 17 -Article 9 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.(a),19) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 5 -Paragraph 8, 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false226true 3us-gaap_StockholdersEquityAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse027false 4us-gaap_PreferredStockValueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse11falsefalsefalse2truefalsefalse11falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false228false 4us-gaap_CommonStockValueus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse2050920509falsefalsefalse2truefalsefalse2040420404falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false229false 4us-gaap_AdditionalPaidInCapitalus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse67858606785860falsefalsefalse2truefalsefalse57486915748691falsefalsefalsexbrli:monetaryItemTypemonetaryExcess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false230false 4simh_StockSubscriptionReceivablesimh_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-20000-20000falsefalsefalse2truefalsefalse-20000-20000falsefalsefalsexbrli:monetaryItemTypemonetaryStock Subscription ReceivableNo definition available.false231false 4us-gaap_RetainedEarningsAccumulatedDeficitus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-11483261-11483261falsefalsefalse2truefalsefalse-8913282-8913282falsefalsefalsexbrli:monetaryItemTypemonetaryThe cumulative amount of the reporting entity's undistributed earnings or deficit.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false232false 4us-gaap_StockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-4696891-4696891falsefalsefalse2truefalsefalse-3164186-3164186falsefalsefalsexbrli:monetaryItemTypemonetaryTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A3 -Appendix A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5 true233false 4us-gaap_LiabilitiesAndStockholdersEquityus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse593032593032USD$falsetruefalse2truefalsefalse9021790217USD$falsetruefalsexbrli:monetaryItemTypemonetaryTotal of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.32) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 32 -Article 5 true2falseConsolidated Balance Sheets (Unaudited) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://sanomedics.com/role/ConsolidatedBalanceSheets233 XML 28 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONVERTIBLE NOTES PAYABLE
6 Months Ended
Jun. 30, 2013
Notes to Financial Statements  
NOTE 4 - CONVERTIBLE NOTES PAYABLE

On August 24, 2012, the Company executed a convertible note for $75,000. The convertible note is unsecured and has a maturity date of August 24, 2014. Interest will accrue at 9% per annum until paid or maturity and is convertible into common shares at a fixed convertible price of $0.50 per share. In the event that the Company undertakes financing while this debt is unpaid, the holder shall have the right to convert at the lessor of the offering price or the fixed conversion price. As of June 30, 2013 and December 31, 2012, the convertible note amounted to $31,250 and $12,500, net of unamortized discounts of $43,750 and $62,500, respectively.

 

On December 6, 2012, the Company entered into a Securities Purchase Agreement and convertible promissory note (“Note”) in the principal amount of $37,500. The Note, which was due on August 29, 2013, bears interest at 8% per annum until paid or to maturity was converted on June 11, 2013 and June 18, 2013 into a total of 29,128 shares of the Company’s common stock at a conversion price equal to a 42% discount to the average of the lowest three closing bid prices of the common stock during the 10 trading days prior to conversion or $1.36 and $1.36 per share. As of June 30, 2013 and December 31, 2012, the convertible note amounted to $ -0- and $4,688, net of unamortized discount of $37,500 and $32,812, respectively.

 

On June 17, 2013, the Company entered into a Promissory Note (the “Note”) with a third party lender (“Lender”) in the principal amount up to $500,000. On June 19, 2013, the Lender executed the Note and funded the Company an initial tranche of $150,000 pursuant to the terms thereof. The principal sum of the Note carries a $50,000 original issue discount (“OID”) , which is prorated based on the consideration paid by the lender. The maturity date of each tranche funded under the Note is one year from the date of each payment by the Lender. The principal amount of the Note due is prorated based upon the consideration actually paid to us, plus a 10% OID, and we are only obligated to repay the amount of the funded Note, together with interest and fees. The Note may be prepaid by us at any time on or before 90 days from the date of issue interest free. After the initial 90 day period the Note bears a one-time interest charge of 12% applied to the principal sum. All principal and accrued interest on the Note is convertible into shares of the Company’s common stock at the election of the Lender at any time at a conversion price of the lesser of $2.75 or 70% of the lowest trade price in the 25 trading days prior to conversion. At all times while the Note is outstanding we agreed to reserve from our authorized but unissued shares of common stock 550,000 shares for the possible conversion of the Note; plus provide registration rights. As of June 30, 2013, the Note amounted to $68,385 , net of unamortized discount of $81,615.

 

In accordance with ASC 470-20 Debt with Conversion and Other Options, the Company recorded total discounts of $125,365 and $0 for the beneficial conversion features of the convertible debts incurred during the periods ended June 30, 2013 and June 30, 2012, respectively. The discounts are being amortized to interest expense over the term of the notes using the effective interest method. The Company recorded $54,337 and $-0- of interest expense pursuant to the amortization of the note discounts for the six months ended June 30, 2013 and for the six months  ended June 30, 2012, respectively; and $30,898 and $ -0- for the three months ended June 30, 2013 and June 30, 2012.

XML 29 R10.xml IDEA: DERIVATIVE LIABILITIES 2.4.0.80010 - Disclosure - DERIVATIVE LIABILITIEStruefalsefalse1false falsefalseFrom2013-01-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-01-01T00:00:002013-06-30T00:00:001true 1simh_NotesToFinancialStatementsAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2us-gaap_DerivativesAndFairValueTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company analyzed the related party convertible note-officer and convertible promissory notes referred to in Notes 3 and 4 based on the provisions of ASC 815-15 and determined that the conversion options of the convertible notes qualify as embedded derivatives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value upon inception of the embedded derivatives are determined to total $2,915,188 and recorded as embedded derivative liabilities. The embedded derivatives are revalued at the end of each reporting period and any resulting gain or loss is recognized as a current period charge to the statement of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for the embedded conversion features included in its common stock as well as derivative liabilities. The aggregate fair value of derivative liabilities as of June 30, 2013 and December 31, 2012 amounted to $1,847,560 and $40,697, respectively. The net decrease of $1,047,628 in the fair value of the derivative liabilities between the respective periods is included in other income as an unrealized gain on fair value of derivatives.</p>falsefalsefalsenonnum:textBlockItemTypenaThe entire disclosure for derivatives and fair value of assets and liabilities.No definition available.false0falseDERIVATIVE LIABILITIESUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://sanomedics.com/role/DerivativeLiabilities12 XML 30 R5.xml IDEA: Consolidated Statements of Cash Flows 2.4.0.80005 - Statement - Consolidated Statements of Cash Flowstruefalsefalse1false USDfalsefalse$From2013-01-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-01-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$From2012-01-01to2012-06-30http://www.sec.gov/CIK0001501972duration2012-01-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 2us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 3us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-2569979-2569979USD$falsetruefalse2truefalsefalse-1036821-1036821USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false23true 3us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse04false 4us-gaap_DepreciationDepletionAndAmortizationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse37983798falsefalsefalse2truefalsefalse21222122falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false25false 4simh_StockCompensationsimh_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse255738255738falsefalsefalse2truefalsefalse369751369751falsefalsefalsexbrli:monetaryItemTypemonetaryCustom ElementNo definition available.false26false 4us-gaap_AmortizationOfDebtDiscountPremiumus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse337337falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 21 -Paragraph 16 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 5 false27false 4us-gaap_DebtInstrumentConvertibleInterestExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse28307982830798falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryInterest expense related to convertible debt instruments which has been recognized for the period, including the contractual interest coupon and amortization of the debt discount, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 6 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6036836-161870 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number APB14-1 -Paragraph 33 -Subparagraph b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false28false 4simh_UnrealizedGainonFairValueOfDerivativeLiabilitiessimh_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-1047628-1047628falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryCustom ElementNo definition available.false29true 3us-gaap_IncreaseDecreaseInOperatingCapitalAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse010false 4us-gaap_IncreaseDecreaseInAccountsReceivableus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-41259-41259falsefalsefalse2truefalsefalse-4600-4600falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false211false 4us-gaap_IncreaseDecreaseInInventoriesus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-147-147falsefalsefalse2truefalsefalse2986729867falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false212false 4simh_DepositOnPlannedAcquisitionsimh_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse-400000-400000falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryCustom ElementNo definition available.false213false 4us-gaap_IncreaseDecreaseInPrepaidExpenseus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-10810-10810falsefalsefalse2truefalsefalse19261926falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false214false 4us-gaap_InterestExpenseDepositsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-7999-7999falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate amount of interest expense on all deposits.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.6) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 6 -Article 9 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher OTS -Name Federal Regulation (FR) -Number Title 12 -Section 563c.102 -Paragraph 6 -Chapter V -Subsection II -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy. It will be removed from future versions of this taxonomy. false215false 4us-gaap_ProceedsFromRepaymentsOfBankOverdraftsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00&nbsp;&nbsp;falsefalsefalse2truefalsefalse-4522-4522falsefalsefalsexbrli:monetaryItemTypemonetaryThe net cash inflow or outflow from the excess drawing from an existing cash balance, which will be honored by the bank but reflected as a loan to the drawer.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3095-108585 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 9 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3098-108585 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Technical Practice Aid (TPA) -Number 1300 -Paragraph 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false216false 4us-gaap_IncreaseDecreaseInAccruedSalariesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse6939269392falsefalsefalse2truefalsefalse131539131539falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the period in accrued salaries.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false217false 4us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse5095050950falsefalsefalse2truefalsefalse-34240-34240falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the aggregate amount of obligations incurred but not paid and other operating obligations not separately disclosed in the statement of cash flows.No definition available.false218false 4us-gaap_IncreaseDecreaseInInterestPayableNetus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse6685666856falsefalsefalse2truefalsefalse108935108935falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false219false 4us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrentus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse6085960859falsefalsefalse2truefalsefalse2054720547falsefalsefalsexbrli:monetaryItemTypemonetaryThe increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false220false 4us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-685094-685094falsefalsefalse2truefalsefalse-415496-415496falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of net cash from (used in) the entity's continuing operations, excluding cash flows derived by the entity from its discontinued operations.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 -Footnote 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true221true 2us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse022false 3us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00&nbsp;&nbsp;falsefalsefalse2truefalsefalse-45-45falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 17 -Subparagraph c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false223false 3us-gaap_NetCashProvidedByUsedInInvestingActivitiesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1falsefalsefalse00&nbsp;&nbsp;falsefalsefalse2truefalsefalse-45-45falsefalsefalsexbrli:monetaryItemTypemonetaryThe net cash inflow or outflow from investing activity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true224true 2us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse025false 3us-gaap_ProceedsFromRelatedPartyDebtus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse581492581492falsefalsefalse2truefalsefalse4700047000falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false226false 3simh_IssuanceOfStockSubscriptionsPayablesimh_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00&nbsp;&nbsp;falsefalsefalse2truefalsefalse133500133500falsefalsefalsexbrli:monetaryItemTypemonetaryCustom ElementNo definition available.false227false 3simh_SaleOfCommonStocksimh_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00&nbsp;&nbsp;falsefalsefalse2truefalsefalse238000238000falsefalsefalsexbrli:monetaryItemTypemonetaryCustom ElementNo definition available.false228false 3us-gaap_ProceedsFromNotesPayableus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse150000150000falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryThe cash inflow from a borrowing supported by a written promise to pay an obligation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false229false 3us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse731492731492falsefalsefalse2truefalsefalse418500418500falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of net cash from (used in) the entity's financing activities, excluding cash flows derived by the entity from its discontinued operations.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585 true230false 3us-gaap_CashPeriodIncreaseDecreaseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse4639846398falsefalsefalse2truefalsefalse29592959falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.No definition available.true231false 3us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsetruefalsefalseperiodStartLabel1truefalsefalse2608426084falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false232false 3us-gaap_CashAndCashEquivalentsAtCarryingValueus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsetruefalseperiodEndLabel1truefalsefalse7248272482falsefalsefalse2truefalsefalse29592959falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash Equivalents -URI http://asc.fasb.org/extlink&oid=6507016 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 8, 9 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7 -Footnote 1 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 1 -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 7, 26 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false233true 2us-gaap_SupplementalCashFlowInformationAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse034false 3us-gaap_IncomeTaxesPaidus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00&nbsp;&nbsp;falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 29 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 27 -Subparagraph f -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585 false235false 3us-gaap_InterestPaidus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00&nbsp;&nbsp;falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of cash paid for interest during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 29 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585 false236true 3us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse037false 4simh_CommonStockIssuedToConsultantsForServicessimh_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse9634396343falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryCustom ElementNo definition available.false238false 4simh_CommonStockIssuedForConversionOfDebtNetOfDerivativesimh_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse7819778197falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryCustom ElementNo definition available.false239false 4simh_AccrualSalariesPayableConvertedToConvertiblePromissoryNotesimh_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse703339703339USD$falsetruefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryAccrual salaries payable converted to convertible promissory note - officer.No definition available.false2falseConsolidated Statements of Cash Flows (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://sanomedics.com/role/Consolidatedstatementsofcashflowsunaudited239 EXCEL 31 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\R,C`V8C$Y,5\Q-#,T7S1D-CA?.#@T-%]E,3`R M-3AB9F(S,CDB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DQ)455)1$E465]!3D1?1T])3D=?0T].0T52 M3CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3E9%4E1)0DQ%7TY/5$537U!!64%"3$4\+W@Z M3F%M93X-"B`@("`\>#I7;W)K#I% M>&-E;%=O#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E!% M3D1)3D=?04-154E3251)3TX\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DY/5$537U!!64%"3$5?4D5,051%1%]0 M05)465]483PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DQ)455)1$E465]!3D1?1T])3D=?0T].0T523E]$93PO>#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DY/5$537U!!64%"3$5?4D5,051% M1%]005)465]$93PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/DY/5$537U!!64%"3$5?4D5,051%1%]005)465]$93$\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I3='EL97-H965T($A2968] M,T0B5V]R:W-H965T&-E;"!84"!O3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\R,C`V8C$Y,5\Q-#,T7S1D-CA?.#@T-%]E,3`R M-3AB9F(S,CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C(P-F(Q M.3%?,30S-%\T9#8X7S@X-#1?93$P,C4X8F9B,S(Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R2!);F9O2!);F9O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^665S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^43(\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,C`V8C$Y,5\Q-#,T7S1D-CA? M.#@T-%]E,3`R-3AB9F(S,CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,C(P-F(Q.3%?,30S-%\T9#8X7S@X-#1?93$P,C4X8F9B,S(Y+U=O'0O:'1M;#L@ M8VAA'!E;G-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PX,3`\'0^)FYB'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA6%B;&4@86YD(&]T M:&5R(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XS,30L-S@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M6%B M;&4@+2!R96QA=&5D('!A'0^)FYB6%B;&4L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S2X\+W1D M/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,C`V8C$Y,5\Q-#,T7S1D-CA?.#@T M-%]E,3`R-3AB9F(S,CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,C(P-F(Q.3%?,30S-%\T9#8X7S@X-#1?93$P,C4X8F9B,S(Y+U=O'0O:'1M;#L@8VAA M'0^)FYB'!E;G-E*3PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'!E;G-E*3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#$S,"PT M,#&5S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\ M'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XS+#'0^)FYB3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'!E M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,"PX,3`I/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5D(&%S'0^)FYB'0^)FYB'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)FYB'0^)FYB'0^)FYB'0^)FYB M'0^)FYB'0^)FYB'0^)FYB'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'`@ M2!I;F-O2!F;W(@8V]N6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^5&AE(&%C8V]M<&%N>6EN9R!U;F%U9&ET M960@8V]N9&5N2!D;R!N;W0@:6YC M;'5D92!A;&P@=&AE(&EN9F]R;6%T:6]N(&%N9"!F;V]T;F]T97,@;F5C97-S M87)Y(&9O'!E8W1E9"!F;W(@=&AE(&9U;&P@>65A M6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU28C,30V.W,@06YN=6%L(%)E<&]R="!O;B!&;W)M M(#$P+4LL('=H:6-H(&-O;G1A:6YS('1H92!A=61I=&5D(&-O;G-O;&ED871E M9"!F:6YA;F-I86P-"G-T871E;65N=',@86YD(&YO=&5S('1H97)E=&\L('1O M9V5T:&5R('=I=&@@=&AE($UA;F%G96UE;G0F(S$T-CMS($1I7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^5&AE(&-O;F1E M;G-E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',-"FAA=F4@ M8F5E;B!P'0M86QI9VXZ(&IU2!C=7)R96YT;'D@:&%S(&QI;6ET960@2!T M:')O=6=H(&QO86YS(&9R;VT@86X@869F:6QI871E(&]F('1H92!#;VUP86YY M)B,Q-#8[2!N965D#0IT;R!C;VYT:6YU92!B;W)R;W=I M;F=S(&9R;VT@86X@869F:6QI871E(&]F('1H92!F;W)M97(@0VAA:7)M86X@ M86YD($-%3R!A;F0@=&AE($-O;7!A;GDG2!W:6QL(&)E('-U8V-E6QE/3-$)V9O M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E M'0M86QI9VXZ(&IU2!S96-U7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'`@6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$ M)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0G/CQB/C(P M,3,\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!S M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO=&0^#0H@("`@ M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9EF4Z M(#$P<'0G/E-E8W5R960@0V]N=F5R=&EB;&4@4')O;6ES2!.;W1E("T@ M0TQ34R!(;VQD:6YG6QE/3-$)V9O;G0M M'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F M;VYT+7-I>F4Z(#$P<'0G/C$X,2PP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@ M;F]W6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T M9#X-"B`@("`\=&0@6QE/3-$)V9O M;G0M'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#$P<'0G/C$X,2PP,#`\+V9O;G0^/"]T9#X\+W1R/@T* M/'1R('-T>6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C,V-RPP,#`\+V9O;G0^/"]T9#X- M"B`@("`\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M+7-I>F4Z(#$P<'0G/C,V-RPP,#`\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T M>6QE/3-$)W9EF4Z(#$P<'0G/E-E8W5R960@0V]N=F5R=&EB;&4@4')O;6ES2!.;W1E M("T@0TQ34R!(;VQD:6YG6QE/3-$)V9O;G0M6QE/3-$)V9O M;G0MF4Z(#$P<'0G/E-E8W5R960@0V]N=F5R=&EB;&4@4')O;6ES2!.;W1E M("T@0TQ34R!(;VQD:6YG6%B;&4@;VX@3V-T;V)E'0M86QI9VXZ(')I9VAT)SX\9F]N M="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/BT\+V9O;G0^/"]T9#X-"B`@ M("`\=&0@;F]W6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\ M+W1D/CPO='(^#0H\='(@6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$ M)W9EF4Z(#$P M<'0G/D]T:&5R(&%D=F%N8V5S(&9R;VT@0TQ34R!(;VQD:6YG2!.;W1E("A!*3PO9F]N=#X\ M+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9"<^)B,Q-C`[/"]T9#X- M"B`@("`\=&0@'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT M+7-I>F4Z(#$P<'0G/C@U."PQ,S(@/"]F;VYT/CPO=&0^#0H@("`@/'1D(&YO M=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P M="!S;VQI9"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@'0M86QI9VXZ(')I9VAT M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C(W-BPV-#`@/"]F M;VYT/CPO=&0^/"]T6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C$L.38P+#DQ.3PO9F]N M=#X\+W1D/@T*("`@(#QT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X- M"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@ M("`\=&0@6QE M/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V)O'0M86QI9VXZ(')I9VAT)SX\ M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C$L,S6QE/3-$)V9O;G0M6QE/3-$)V)O6QE/3-$ M)V)O'0M86QI M9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/BT\ M+V9O;G0^/"]T9#X\+W1R/@T*/"]T86)L93X-"@T*#0H-"@T*/'`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`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/D]N($IU;F4@,32!A;F0@82!$:7)E M8W1O2!T;W1A;&EN M9R`D-S`S+#,S.2!I;G1O(&$@;&]N9R!T97)M(&-O;G9E2!A="!A M(&9I>&5D(&-O;G9E7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'`@2!A;F0@:7,@8V]N=F5R=&EB;&4@:6YT;R!C M;VUM;VX@2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM M97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU2!W87,@8V]N=F5R=&5D(&]N($IU;F4@ M,3$L(#(P,3,@86YD($IU;F4-"C$X+"`R,#$S(&EN=&\@82!T;W1A;"!O9B`R M.2PQ,C@@2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU&5C=71E M9"!T:&4@3F]T92!A;F0@9G5N9&5D('1H92!#;VUP86YY(&%N(&EN:71I86P@ M=')A;F-H92!O9B`D,34P+#`P,"!P=7)S=6%N="!T;R!T:&4@=&5R;7,@=&AE M65A2!T:&4@ M3&5N9&5R+@T*5&AE('!R:6YC:7!A;"!A;6]U;G0@;V8@=&AE($YO=&4@9'5E M(&ES('!R;W)A=&5D(&)A0T*;V)L:6=A=&5D('1O(')E<&%Y('1H92!A;6]U;G0@;V8@=&AE(&9U M;F1E9"!.;W1E+"!T;V=E=&AE2!U7,@9G)O;2!T:&4@9&%T92!O9B!I6QE/3-$ M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\ M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L M(%-E'0M86QI9VXZ(&IUF5D('1O(&EN M=&5R97-T(&5X<&5N2!R96-O"!M;VYT:',F(S$V,#LF(S$V,#ME;F1E9"!* M=6YE(#,P+"`R,#$R+"!R97-P96-T:79E;'D[(&%N9"`D,S`L.#DX(&%N9"`D M("TP+2!F;W(@=&AE('1H3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\R,C`V8C$Y,5\Q-#,T7S1D-CA?.#@T-%]E M,3`R-3AB9F(S,CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C(P M-F(Q.3%?,30S-%\T9#8X7S@X-#1?93$P,C4X8F9B,S(Y+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0M86QI9VXZ(&IUF5D M('1H92!R96QA=&5D('!A'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I;B<^ M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU2!R97-U;'1I;F<@9V%I;B!O6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^5&AE($-O;7!A;GD@86-C;W5N=',@9F]R('1H92!E;6)E9&1E9"!C M;VYV97)S:6]N#0IF96%T=7)E2X@5&AE(&YE="!D96-R96%S92!O9B`D,2PP-#3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\R,C`V8C$Y,5\Q-#,T7S1D-CA?.#@T-%]E,3`R-3AB M9F(S,CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C(P-F(Q.3%? M,30S-%\T9#8X7S@X-#1?93$P,C4X8F9B,S(Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M6QE M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^3&ET:6=A=&EO;CPO M<#X-"@T*/'`@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE2<^1G)O;2!T:6UE('1O('1I;64L('1H92!#;VUP86YY(&UA M>2!B96-O;64@:6YV;VQV960-"FEN('9A6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU2`R,2P@,C`Q,RP@17AE2X@17AE2X@1VEV96X@=&AE(&EN M:&5R96YT('5N8V5R=&%I;G1Y(&%N9"!U;G!R961I8W1A8FEL:71Y(&]F(&QI M=&EG871I;VX@86YD(&1U92!T;R!T:&4@96%R;'D@'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI M9VXZ(&IU6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2<^ M3VX@2G5N92`Q,2P@,C`Q,R!A;F0@2G5N92`R."P@,C`Q,RP@:6X@8V]N;F5C M=&EO;@T*=VET:"!A(%-E8W5R:71I97,@4'5R8VAA2!C;VYV97)T960@=&AE($YO=&4@:6YT;R!A('1O=&%L(&]F(#(Y M+#$R."!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO;B!S=&]C M:R!A="!A(&-O;G9E6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&D^4W1O8VL@3W!T:6]N6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N M+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI M9VXZ(&IU&5R8VES92!P M2`D,34Y+#`P,"!U6EN9R!C;VYD96YS960@8V]N'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^/&D^4')I;64@5&EM92!-961I8V%L.CPO M:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M M86QI9VXZ(&IU2!E;G1E'0M86QI9VXZ(&IUF5D(&AE0T*=VEL;"!M86ME(&$@=&]T86P@ M8V%S:"!P87EM96YT('1O($UI:VQO2`R-BP@,C`Q,RP@ M=&AE($-O;7!A;GD@2`D.34P+#`P,"!A="!C;&]S:6YG+"`H M8BD@:68@=&AE(&-L;W-I;F<@;V-C=7)S(&%F=&5R($UA>2`R-BP@,C`Q,R!B M=70@;VX@;W(@<')I;W(@=&\@2G5N92`R-BP@,C`Q,R!T:&4@0V]M<&%N>2!S M:&%L;"!P87D-"G1O(%-E;&QE2!T;R!396QL97(-"B0Q+#$U,"PP M,#`@870@8VQO2!*=6YE(#(V M+"`R,#$S+B!!2!T:&4@8V]M<&%N>2!P86ED(&%N(&%D9&ET M:6]N86P@)#4P+#`P,"P@=VAI8V@@:&%S(')E6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W M(%)O;6%N+"!4:6UE2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU2P@870@8VQO2!N;W1E6UE;G1S(&]F('!R:6YC:7!A;"!A;F0@:6YT97)E2!O;B!T97)M2`H=&AE("8C,30W.U-H87)E28C,30V.W,-"F-O;6UO;B!S=&]C:R!A7-T96TL(&%S M(&%P<&QI8V%B;&4L(&%T('1H90T*96YD(&]F('1H92!T2!I M;6UE9&EA=&5L>2!P6UE;G0-"F]F('!R:6YC:7!A;"!O;B!02!T M:&4@3W)I9VEN86P@27-S=6%N8V4@4')I8V4N/"]P/@T*#0H\<"!S='EL93TS M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU6QE/3-$)V9O;G0Z(#$P M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE2<^5&AE(%!U2!W:6QL(&YO="!B92!R97%U M:7)E9"!T;R!P87D@86YY#0IA;6]U;G1S(&1U92!U;F1E2P@86YD+"!I9B!T:&4@ M9&5F:6-I96YC>2!I7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`P+C5I;CL@=&5X="UA;&EG M;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ(&IU2!D:79I9&EN9R`D,RPP,#`L,#`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`T*8F4@2!A;6]U;G1S M(&1U92!U;F1E2!P2P@=&AE('!U6QE/3-$)V9O;G0Z(#$P<'0@ M5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4 M:6UE2<^ M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E'0M86QI9VXZ M(&IU2!A="`D,C(P+#`P,"!A M;F0@6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE3L@=&5X="UI M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE2<^36%N86=E;65N="!H87,@979A;'5A M=&5D('1H92!S=6)S97%U96YT(&5V96YT3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\R,C`V8C$Y,5\Q-#,T7S1D-CA?.#@T-%]E,3`R-3AB9F(S,CD- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C(P-F(Q.3%?,30S-%\T M9#8X7S@X-#1?93$P,C4X8F9B,S(Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0G M/CQB/DIU;F4@,S`L/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!N;W=R87`] M,T1N;W=R87`@6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1EF4Z(#$P<'0G/CQB/C(P,3(\+V(^/"]F;VYT/CPO=&0^/"]T6QE/3-$)W=I9'1H.B`W-R4[('1E>'0M86QI9VXZ(&IU6QE/3-$)V9O;G0M6QE/3-$)W=I M9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA M;&EG;CH@6QE/3-$)V9O;G0M6QE/3-$ M)W=I9'1H.B`Q)2<^/&9O;G0@6QE/3-$)W=I9'1H.B`Y)3L@=&5X M="UA;&EG;CH@6QE/3-$)V9O;G0MF4Z(#$P<'0G/E-E M8W5R960@0V]N=F5R=&EB;&4@4')O;6ES2!.;W1E("T@0TQ34R!(;VQD M:6YG6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0G/C,S-"PW.#<\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C,S-"PW M.#<\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9EF4Z(#$P<'0G/D-O;G9E6%B;&4@;VX@36%R8V@@,S`L(#(P,34L(&YE="!O9B!D:7-C M;W5N="!O9B`D-S`S+#,S.2`H0BD@4F5F97(@=&\@3F]T92`U/"]F;VYT/CPO M=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O M6QE/3-$)V9O;G0M M6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF(S$V,#L\+W1D/@T*("`@ M(#QT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q M-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C$L,3`R M+#6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT)SXF M(S$V,#L\+W1D/CPO='(^#0H\='(@6QE/3-$)V9O;G0M6QE/3-$)V)O6QE/3-$)V9O;G0M6QE M/3-$)V)O6QE/3-$ M)V9O;G0M6QE/3-$)W9E6QE/3-$)V9O M;G0M6QE/3-$ M)W9E6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@F4Z(#$P<'0G/DQE M'0M86QI9VXZ M(')I9VAT)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C@U."PQ M,S(\+V9O;G0^/"]T9#X-"B`@("`\=&0@;F]W6QE/3-$ M)V)O6QE/3-$)V9O M;G0MF4Z(#$P<'0G/B0\+V9O;G0^/"]T9#X-"B`@ M("`\=&0@6QE/3-$)V9O;G0M MF4Z(#$P<'0G/B0\ M+V9O;G0^/"]T9#X-"B`@("`\=&0@6QE/3-$)V9O;G0M6QE/3-$)VUA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,C`V M8C$Y,5\Q-#,T7S1D-CA?.#@T-%]E,3`R-3AB9F(S,CD-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,C(P-F(Q.3%?,30S-%\T9#8X7S@X-#1?93$P M,C4X8F9B,S(Y+U=O'0O:'1M;#L@8VAA3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,C`V8C$Y,5\Q-#,T7S1D-CA?.#@T M-%]E,3`R-3AB9F(S,CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,C(P-F(Q.3%?,30S-%\T9#8X7S@X-#1?93$P,C4X8F9B,S(Y+U=O'0O:'1M;#L@8VAA M2!.;W1E/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XX-3@L,3,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^)FYB'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!.;W1E(%-E<'1E;6)E'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!.;W1E M($]N92!-87)C:"`Q,BP@,C`Q,2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R,C`V8C$Y,5\Q-#,T7S1D M-CA?.#@T-%]E,3`R-3AB9F(S,CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO,C(P-F(Q.3%?,30S-%\T9#8X7S@X-#1?93$P,C4X8F9B,S(Y+U=O M'0O:'1M M;#L@8VAA2!$971A:6QS($YA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\R,C`V8C$Y,5\Q-#,T7S1D-CA?.#@T-%]E,3`R-3AB9F(S M,CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C(P-F(Q.3%?,30S M-%\T9#8X7S@X-#1?93$P,C4X8F9B,S(Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6%B;&4\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S MF5D(&1I'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6%B;&4\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%SF5D(&1I M3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\R,C`V8C$Y,5\Q-#,T7S1D-CA?.#@T-%]E,3`R-3AB M9F(S,CD-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,C(P-F(Q.3%? M,30S-%\T9#8X7S@X-#1?93$P,C4X8F9B,S(Y+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B M=7)N.G-C:&5M87,M;6EC XML 32 R4.xml IDEA: Consolidated Statements of Operations (Unaudited) 2.4.0.80004 - Statement - Consolidated Statements of Operations (Unaudited)truefalsefalse1false USDfalsefalse$From2013-04-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-04-01T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$From2012-04-01to2012-06-30http://www.sec.gov/CIK0001501972duration2012-04-01T00:00:002012-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$From2013-01-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-01-01T00:00:002013-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$From2012-01-01to2012-06-30http://www.sec.gov/CIK0001501972duration2012-01-01T00:00:002012-06-30T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1simh_StatementConsolidatedStatementsOfOperationsAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2us-gaap_SalesRevenueNetus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse6394163941USD$falsetruefalse2truefalsefalse71017101USD$falsetruefalse3truefalsefalse121079121079USD$falsetruefalse4truefalsefalse3502835028USD$falsetruefalsexbrli:monetaryItemTypemonetaryTotal revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 false23false 2us-gaap_CostOfGoodsSoldus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse1702117021falsefalsefalse2truefalsefalse1246112461falsefalsefalse3truefalsefalse3359233592falsefalsefalse4truefalsefalse3469234692falsefalsefalsexbrli:monetaryItemTypemonetaryTotal costs related to goods produced and sold during the reporting period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 2 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 false24false 2us-gaap_GrossProfitus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse4692046920falsefalsefalse2truefalsefalse-5360-5360falsefalsefalse3truefalsefalse8748787487falsefalsefalse4truefalsefalse336336falsefalsefalsexbrli:monetaryItemTypemonetaryAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 true25true 2us-gaap_OperatingExpensesAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse06false 3us-gaap_GeneralAndAdministrativeExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse269676269676falsefalsefalse2truefalsefalse320987320987falsefalsefalse3truefalsefalse453808453808falsefalsefalse4truefalsefalse547828547828falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 false27false 3us-gaap_ResearchAndDevelopmentExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse2575025750falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalse3truefalsefalse5350053500falsefalsefalse4truefalsefalse85008500falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph g -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 86 -Paragraph 11, 12 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false28false 3us-gaap_ShareBasedCompensationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse3884238842falsefalsefalse2truefalsefalse204888204888falsefalsefalse3truefalsefalse255738255738falsefalsefalse4truefalsefalse369751369751falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false29false 3us-gaap_DepreciationAndAmortizationus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse18991899falsefalsefalse2truefalsefalse10611061falsefalsefalse3truefalsefalse37983798falsefalsefalse4truefalsefalse21222122falsefalsefalsexbrli:monetaryItemTypemonetaryThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 5 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 false210false 3us-gaap_OperatingExpensesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse336167336167falsefalsefalse2truefalsefalse526936526936falsefalsefalse3truefalsefalse766844766844falsefalsefalse4truefalsefalse928201928201falsefalsefalsexbrli:monetaryItemTypemonetaryGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.No definition available.true211false 2us-gaap_OperatingIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-289247-289247falsefalsefalse2truefalsefalse-532296-532296falsefalsefalse3truefalsefalse-679357-679357falsefalsefalse4truefalsefalse-927865-927865falsefalsefalsexbrli:monetaryItemTypemonetaryThe net result for the period of deducting operating expenses from operating revenues.No definition available.true212true 2us-gaap_NonoperatingIncomeExpenseAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse013false 3us-gaap_AmortizationOfFinancingCostsAndDiscountsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-30898-30898falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalse3truefalsefalse-54337-54337falsefalsefalse4falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false214false 3us-gaap_DebtInstrumentConvertibleInterestExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-2830798-2830798falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalse3truefalsefalse-2830798-2830798falsefalsefalse4falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryInterest expense related to convertible debt instruments which has been recognized for the period, including the contractual interest coupon and amortization of the debt discount, if any.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 6 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6036836-161870 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name FASB Staff Position (FSP) -Number APB14-1 -Paragraph 33 -Subparagraph b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false215false 3us-gaap_DerivativeGainLossOnDerivativeNetus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse10476281047628falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalse3truefalsefalse10476281047628falsefalsefalse4falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryNet Increase or Decrease in the fair value of the derivative or group of derivatives included in earnings.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959 false216false 3us-gaap_InterestExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1truefalsefalse-27092-27092falsefalsefalse2truefalsefalse-54489-54489falsefalsefalse3truefalsefalse-53115-53115falsefalsefalse4truefalsefalse-108956-108956falsefalsefalsexbrli:monetaryItemTypemonetaryThe cost of borrowed funds accounted for as interest that was charged against earnings during the period.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 34 -Paragraph 21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 9 -Article 9 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher OTS -Name Federal Regulation (FR) -Number Title 12 -Section 563c.102 -Paragraph 9 -Chapter V -Subsection II -LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy. It will be removed from future versions of this taxonomy. false217false 3us-gaap_NonoperatingIncomeExpenseus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-1841160-1841160falsefalsefalse2truefalsefalse-54489-54489falsefalsefalse3truefalsefalse-1890622-1890622falsefalsefalse4truefalsefalse-108956-108956falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 7 -Article 5 true218false 2us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-2130407-2130407falsefalsefalse2truefalsefalse-586785-586785falsefalsefalse3truefalsefalse-2569979-2569979falsefalsefalse4truefalsefalse-1036821-1036821falsefalsefalsexbrli:monetaryItemTypemonetaryThis element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 10 -Article 5 true219false 2us-gaap_IncomeTaxExpenseBenefitus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00&nbsp;&nbsp;falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;falsefalsefalse3falsefalsefalse00&nbsp;&nbsp;falsefalsefalse4falsefalsefalse00&nbsp;&nbsp;falsefalsefalsexbrli:monetaryItemTypemonetaryThe sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(h)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph h -Article 4 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Income Tax Expense (or Benefit) -URI http://asc.fasb.org/extlink&oid=6515339 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 9 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 109 -Paragraph 45 -Subparagraph a, b -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false220false 2us-gaap_NetIncomeLossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1truefalsefalse-2130407-2130407USD$falsetruefalse2truefalsefalse-586785-586785USD$falsetruefalse3truefalsefalse-2569979-2569979USD$falsetruefalse4truefalsefalse-1036821-1036821USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 28, 29, 30 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 130 -Paragraph 10, 15 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=6519514 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=6518256 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph A7 -Appendix A Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Research Bulletin (ARB) -Number 51 -Paragraph 38 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 Reference 15: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913 Reference 16: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 87-21 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. true221false 2us-gaap_EarningsPerShareBasicAndDilutedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse-0.10-0.10USD$falsetruefalse2truefalsefalse-0.04-0.04USD$falsetruefalse3truefalsefalse-0.13-0.13USD$falsetruefalse4truefalsefalse-0.07-0.07USD$falsetruefalsenum:perShareItemTypedecimalThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.No definition available.false322false 2us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDilutedus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse2041010220410102falsefalsefalse2truefalsefalse1425893914258939falsefalsefalse3truefalsefalse2045442320454423falsefalsefalse4truefalsefalse1425893914258939falsefalsefalsexbrli:sharesItemTypesharesAverage number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).No definition available.false1falseConsolidated Statements of Operations (Unaudited) (USD $)NoRoundingNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://sanomedics.com/role/Consolidatedstatementsofoperationsunaudited422 XML 33 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 HtmlAndXml 21 123 1 false 6 0 false 4 false false R1.htm 0001 - Document - Document and Entity Information Sheet http://sanomedics.com/role/Documentandentityinformation Document and Entity Information R1.xml true false R2.htm 0002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://sanomedics.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets (Unaudited) R2.xml false false R3.htm 0003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://sanomedics.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) R3.xml false false R4.htm 0004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://sanomedics.com/role/Consolidatedstatementsofoperationsunaudited Consolidated Statements of Operations (Unaudited) R4.xml false false R5.htm 0005 - Statement - Consolidated Statements of Cash Flows Sheet http://sanomedics.com/role/Consolidatedstatementsofcashflowsunaudited Consolidated Statements of Cash Flows R5.xml false false R6.htm 0006 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION Sheet http://sanomedics.com/role/OrganizationAndBasisOfPresentation ORGANIZATION AND BASIS OF PRESENTATION R6.xml false false R7.htm 0007 - Disclosure - LIQUIDITY AND GOING CONCERN Sheet http://sanomedics.com/role/LiquidityAndGoingConcern LIQUIDITY AND GOING CONCERN R7.xml false false R8.htm 0008 - Disclosure - NOTES PAYABLE -RELATED PARTY Notes http://sanomedics.com/role/NotesPayable-RelatedParty NOTES PAYABLE -RELATED PARTY R8.xml false false R9.htm 0009 - Disclosure - CONVERTIBLE NOTES PAYABLE Notes http://sanomedics.com/role/CONVERTIBLENOTESPAYABLERELATEDPARTY CONVERTIBLE NOTES PAYABLE R9.xml false false R10.htm 0010 - Disclosure - DERIVATIVE LIABILITIES Sheet http://sanomedics.com/role/DerivativeLiabilities DERIVATIVE LIABILITIES R10.xml false false R11.htm 0011 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://sanomedics.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES R11.xml false false R12.htm 0012 - Disclosure - STOCKHOLDERS' DEFICIT Sheet http://sanomedics.com/role/StockholdersDeficit STOCKHOLDERS' DEFICIT R12.xml false false R13.htm 0013 - Disclosure - PENDING ACQUISITION Sheet http://sanomedics.com/role/PendingAcquisition PENDING ACQUISITION R13.xml false false R14.htm 0014 - Disclosure - SUBSEQUENT EVENTS Sheet http://sanomedics.com/role/SubsequentEvents SUBSEQUENT EVENTS R14.xml false false R15.htm 0015 - Disclosure - NOTES PAYABLE -RELATED PARTY (Tables) Notes http://sanomedics.com/role/NotesPayable-RelatedPartyTables NOTES PAYABLE -RELATED PARTY (Tables) R15.xml false false R16.htm 0016 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative) Sheet http://sanomedics.com/role/LiquidityAndGoingConcernDetailsNarrative LIQUIDITY AND GOING CONCERN (Details Narrative) R16.xml false false R17.htm 0017 - Disclosure - NOTES PAYABLE -RELATED PARTY (Details) Notes http://sanomedics.com/role/NotesPayable-RelatedPartyDetails NOTES PAYABLE -RELATED PARTY (Details) R17.xml false false R18.htm 0018 - Disclosure - NOTES PAYABLE -RELATED PARTY (Details Narrative) Notes http://sanomedics.com/role/NotesPayable-RelatedPartyDetailsNarrative NOTES PAYABLE -RELATED PARTY (Details Narrative) R18.xml false false R19.htm 0019 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) Notes http://sanomedics.com/role/ConvertibleNotesPayableDetailsNarrative CONVERTIBLE NOTES PAYABLE (Details Narrative) R19.xml false false R20.htm 0020 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative) Sheet http://sanomedics.com/role/DerivativeLiabilitiesDetailsNarrative DERIVATIVE LIABILITIES (Details Narrative) R20.xml false false R21.htm 0021 - Disclosure - STOCKHOLDERS' DEFICIT (Details Narrative) Sheet http://sanomedics.com/role/StockholdersDeficitDetailsNarrative STOCKHOLDERS' DEFICIT (Details Narrative) R21.xml false false R22.htm 0022 - Disclosure - PENDING ACQUISITION (Details Narrative) Sheet http://sanomedics.com/role/PendingAcquisitionDetailsNarrative PENDING ACQUISITION (Details Narrative) R22.xml false false All Reports Book All Reports Process Flow-Through: 0002 - Statement - Consolidated Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Jun. 30, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 0003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Process Flow-Through: 0004 - Statement - Consolidated Statements of Operations (Unaudited) Process Flow-Through: 0005 - Statement - Consolidated Statements of Cash Flows simh-20130630.xml simh-20130630.xsd simh-20130630_cal.xml simh-20130630_def.xml simh-20130630_lab.xml simh-20130630_pre.xml true true XML 34 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)
Jun. 30, 2013
Dec. 31, 2012
Stockholders' Deficit    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 1,000 1,000
Preferred stock, shares issued 1,000 1,000
Preferred stock, shares outstanding 1,000 1,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 250,000,000 250,000,000
Common stock, shares issued 20,508,609 20,403,586
Common stock, shares outstanding 20,508,609 20,403,586
XML 35 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2013
Notes to Financial Statements  
NOTE 9 - SUBSEQUENT EVENTS

Pending Acquisition

 

On July 10, 2013, the Company entered into an Equity Purchase Agreement (the “Equity Purchase Agreement ”) with Duke Medical Equipment LLC, a Texas limited liability company (“Duke Medical”) and Vann R. Duke, the sole equity holder of Duke (“Duke”). Duke Medical is a Durable Medical Equipment provider of home medical equipment servicing consumers throughout the Houston and Galveston, Texas area.

 

Pursuant to the Equity Agreement, at the closing Duke will transfer to the Company all the membership interest of Duke Medical for an aggregate purchase price of $7,000,000, subject to certain adjustments as summarized herein. The purchase price will be paid in a combination of cash, promissory notes and shares of the Company’s common stock. On the closing date the Company will make a total cash payment to the Seller of $2,000,000.

 

Additionally, at closing, the Company will issue two additional promissory notes (the “Duke Medical Notes A and B”) to Duke in the aggregate principal amount of $2,000,000. Duke Medical Note A in the principal amount of $1,000,000 will bear interest at 5% per annum, with monthly payments of principal and interest, and will mature eighteen (18) months after the closing date. Duke Medical Note B in the principal amount of $1,000,000 will bear interest at 5% per annum, with annual payments of interest and principal payable annually over two years from the date of closing provided; however, that the principal balance of Duke Medical Note B (and the respective annual payment) shall be reduced if: (i) EBITDA for the fiscal year ended December 31, 2013 is less than $1,500,000; and/or (ii) the EBITDA for the fiscal year ended December 31, 2014 is less than $1,500,000. At Duke’s option, Duke Medical Note B can be paid in shares of common stock of the Buyer on terms acceptable to Duke and the Company.

 

Total consideration also includes $3,000,000 in the form of shares, with the number of shares to be issued to be determined at closing by dividing $3,000,000 by the average of the closing bid price for the Company’s common stock as quoted on the OTC Bulletin Board, the OTC Pink Sheets or other similar quotation system, as applicable, for the five (5) trading days immediately preceding the closing (the “Duke Medical Original Issuance Price”).

 

The Equity Purchase Agreement also requires the Company to enter at closing into employment agreements with Duke and his spouse for certain management services and; also contains a covenant of Duke and his spouse not to compete with the Company for a two year period.

  

The Equity Purchase Agreement further provides that the Company will engage its independent registered public accounting firm to conduct an audit of Duke Medical’s financial statements for the years ended December 31, 2011 and 2012. If, for any reason the audit cannot be concluded, the Company will not be required to pay any amounts due under the Duke Medical Notes A or B and such notes will be cancelled. The Company, however, has no right to receive a refund of the cash portion of the purchase price as tendered or to effect a cancellation of the Shares. In addition, if Duke Medical’s total asset value at December 31, 2012 as determined in accordance with the audited financial statements is less than the value set forth on the financial statements previously provided to the Company, the purchase price will be reduced by such amount on a dollar for dollar basis through a return of a number of Shares equal to such deficiency, and, if the deficiency is greater than the Duke Medical Original Issue Price, through a set off of the amount which will be due under Duke Medical Note A.

 

Share Issuances:

 

In August 12, 2013 the Company issued 6,000,000 shares of its common stock upon the conversion of $6,000 portion of Convertible Note due to CLSS originally at $220,000 and sold to six (6) third parties by the original holder, with the shares valued at current fair market totaling $11,940,000.

 

Management has evaluated the subsequent events through August 19, 2013, the date at which the condensed consolidated financial statements were available for issue.

XML 36 R20.xml IDEA: DERIVATIVE LIABILITIES (Details Narrative) 2.4.0.80020 - Disclosure - DERIVATIVE LIABILITIES (Details Narrative)truefalsefalse1false USDfalsefalse$AsOf2013-06-30http://www.sec.gov/CIK0001501972instant2013-06-30T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$AsOf2012-12-31http://www.sec.gov/CIK0001501972instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1simh_DerivativeLiabilitiesDetailsNarrativeAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2us-gaap_DerivativeAssetsLiabilitiesAtFairValueNetus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse18475601847560USD$falsetruefalse2truefalsefalse4069740697USD$falsetruefalsexbrli:monetaryItemTypemonetaryFair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 107 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 133 -Paragraph 4, 17 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2falseDERIVATIVE LIABILITIES (Details Narrative) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://sanomedics.com/role/DerivativeLiabilitiesDetailsNarrative22 XML 37 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Statements of Cash Flows (USD $)
6 Months Ended
Jun. 30, 2013
Jun. 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (2,569,979) $ (1,036,821)
Adjustments to reconcile net income (loss) to net cash used in operating activities    
Depreciation and amortization 3,798 2,122
Stock compensation 255,738 369,751
Amortization of debt discount on convertible notes 337   
Derivative expense 2,830,798   
Unrealized gain on fair value of derivative liabilities (1,047,628)   
Changes in operating assets and liabilities    
Accounts receivable (41,259) (4,600)
Inventory (147) 29,867
Deposit on planned acquisition (400,000)   
Prepaid expense (10,810) 1,926
Deposits (7,999)   
Bank overdraft    (4,522)
Accrued salaries payable 69,392 131,539
Accounts payable and other liabilities 50,950 (34,240)
Accrued interest payable 66,856 108,935
Due to related parties 60,859 20,547
Net Cash Used In Operating Activities (685,094) (415,496)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of fixed assets    (45)
Net Cash Used In Investing Activities    (45)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from notes - related party 581,492 47,000
Issuance of stock subscriptions payable    133,500
Sale of common stock    238,000
Proceeds from convertible notes payable 150,000   
Net Cash Provided By Financing Activities 731,492 418,500
Net increase in cash 46,398 2,959
Cash - beginning of period 26,084   
Cash - end of period 72,482 2,959
Supplemental Disclosure of Cash Flow Information    
Cash paid during the period for: Income taxes      
Cash paid during the period for: Interest      
Non-cash Financing transactions:    
Common stock issued to consultants for services 96,343   
Common stock issued for conversion of debt, net of derivative 78,197   
Accrued salaries payable converted to convertible promissory note - officer $ 703,339   
XML 38 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8
Consolidated Balance Sheets (Unaudited) (USD $)
Jun. 30, 2013
Dec. 31, 2012
Current Assets    
Cash $ 72,482 $ 26,084
Accounts receivable 49,376 8,117
Inventory 2,318 2,171
Deposit on planned acquisition 400,000   
Prepaid expense 10,810   
Total Current Assets 534,986 36,372
Fixed assets, net 15,741 17,049
Patents, net 34,306 36,796
Deposit 7,999   
Total Other Assets 42,305 36,796
Total Assets 593,032 90,217
Current Liabilities    
Accrued salaries payable 656,569 1,290,516
Accounts payable and other liabilities 314,786 243,836
Accrued interest payable 283,857 217,001
Convertible note payable, net 68,385 4,688
Derivative liabilities 1,847,560 40,697
Due to related parties 126,597 65,738
Notes payable - related parties, current portion 858,132 1,379,427
Total Current Liabilities 4,155,886 3,241,903
Notes payable - related parties 1,102,787   
Convertible note payable, net 31,250 12,500
Total Liabilities 5,289,923 3,254,403
Commitments and Contingencies      
Stockholders' Deficit    
Preferred stock, $0.001 par value: 1,000 shares authorized, issued and outstanding as of June 30, 2013 and December 31, 2012, respectively 1 1
Common stock, $0.001 par value: 250,000,000 shares authorized, 20,508,609 and 20,403,586 issued and outstanding as of June 30, 2013 and December 31,2012, respectively. 20,509 20,404
Additional paid in capital 6,785,860 5,748,691
Stock subscription receivable (20,000) (20,000)
Accumulated deficit (11,483,261) (8,913,282)
Total Stockholders' Deficit (4,696,891) (3,164,186)
Total Liabilities and Stockholders' Deficit $ 593,032 $ 90,217
XML 39 R7.xml IDEA: LIQUIDITY AND GOING CONCERN 2.4.0.80007 - Disclosure - LIQUIDITY AND GOING CONCERNtruefalsefalse1false falsefalseFrom2013-01-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-01-01T00:00:002013-06-30T00:00:001true 1simh_NotesToFinancialStatementsAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2us-gaap_LiquidityDisclosureTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The condensed consolidated financial statements have been prepared on a going concern basis, and do not reflect any adjustments related to the uncertainty surrounding our recurring losses or accumulated deficit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently has limited revenue and is experiencing recurring losses. These factors raise substantial doubt about its ability to continue as a going concern. Management has financed the Company's operations principally through loans from an affiliate of the Company&#146;s former CEO, who is also one of the principal shareholders. Through June 30, 2013, the Company obtained its liquidity principally from approximately $582,000 of cash advances from an affiliate of the former Chairman and CEO and the Company's principal shareholder. The Company may need to continue borrowings from an affiliate of the former Chairman and CEO and the Company's principal shareholder and will also need to raise additional capital. However, management cannot provide any assurances that the Company will be successful in completing this financing and accomplishing any of its plans.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ability of the Company to continue as a going concern is dependent upon continued financial commitments from related parties and eventually secure other sources of financing in addition to those funds provided by its affiliate and attain profitable operations. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.</p>falsefalsefalsenonnum:textBlockItemTypenaDisclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations.No definition available.false0falseLIQUIDITY AND GOING CONCERNUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://sanomedics.com/role/LiquidityAndGoingConcern12 XML 40 R17.xml IDEA: NOTES PAYABLE -RELATED PARTY (Details) 2.4.0.80017 - Disclosure - NOTES PAYABLE -RELATED PARTY (Details)truefalsefalse1false USDfalsefalse$AsOf2013-06-30http://www.sec.gov/CIK0001501972instant2013-06-30T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$AsOf2012-12-31http://www.sec.gov/CIK0001501972instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1false 4us-gaap_NotesPayableRelatedPartiesNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse11027871102787USD$falsetruefalse2truefalsefalse11027871102787USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 2 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.23) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 23 -Article 5 false22false 4simh_OtherAdvancesFromClssHoldingsIncLlcsimh_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse858132858132USD$falsefalsefalse2truefalsefalse276640276640USD$falsefalsefalsexbrli:monetaryItemTypemonetaryCustom Element.No definition available.false23false 4us-gaap_NotesPayableRelatedPartiesClassifiedCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse19609191960919USD$falsefalsefalse2truefalsefalse13794271379427USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 2 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)(5)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false24false 4simh_LessCurrentPortionsimh_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse858132858132USD$falsefalsefalse2truefalsefalse13794271379427USD$falsefalsefalsexbrli:monetaryItemTypemonetaryCustom ElementNo definition available.false25false 4us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse11027871102787USD$falsefalsefalse2falsefalsefalse00&nbsp;&nbsp;USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount for notes payable (written promise to pay), due to related parties.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 2 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.17) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 17 -Article 7 false26false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3false USDtruefalse$AsOf2013-06-30_custom_SecuredConvertiblePromissoryNote30Septemberl2010Memberhttp://www.sec.gov/CIK0001501972instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseSecured Convertible Promissory Note September 30, 2010 [Member]us-gaap_DebtInstrumentAxisxbrldihttp://xbrl.org/2006/xbrldisimh_SecuredConvertiblePromissoryNote30Septemberl2010Memberus-gaap_DebtInstrumentAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse07false 4us-gaap_NotesPayableRelatedPartiesNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse181000181000USD$falsefalsefalse2truefalsefalse181000181000USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 2 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.23) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 23 -Article 5 false28false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse5false USDtruefalse$AsOf2013-06-30_custom_SecuredConvertiblePromissoryNote12March2011Memberhttp://www.sec.gov/CIK0001501972instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseSecured Convertible Promissory Note March 12, 2011 [Member]us-gaap_DebtInstrumentAxisxbrldihttp://xbrl.org/2006/xbrldisimh_SecuredConvertiblePromissoryNote12March2011Memberus-gaap_DebtInstrumentAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse09false 4us-gaap_NotesPayableRelatedPartiesNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse367000367000USD$falsefalsefalse2truefalsefalse367000367000USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 2 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.23) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 23 -Article 5 false210false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse7false USDtruefalse$AsOf2013-06-30_custom_SecuredConvertiblePromissoryNote30September2011Memberhttp://www.sec.gov/CIK0001501972instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseSecured Convertible Promissory Note September 30, 2011 [Member]us-gaap_DebtInstrumentAxisxbrldihttp://xbrl.org/2006/xbrldisimh_SecuredConvertiblePromissoryNote30September2011Memberus-gaap_DebtInstrumentAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse011false 4us-gaap_NotesPayableRelatedPartiesNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse220000220000USD$falsefalsefalse2truefalsefalse220000220000USD$falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 2 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.23) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 23 -Article 5 false212false 0truefalsetruefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse9false USDtruefalse$AsOf2013-06-30_custom_SecuredConvertiblePromissoryNoteOne12March2011Memberhttp://www.sec.gov/CIK0001501972instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseSecured Convertible Promissory Note One March 12, 2011 [Member]us-gaap_DebtInstrumentAxisxbrldihttp://xbrl.org/2006/xbrldisimh_SecuredConvertiblePromissoryNoteOne12March2011Memberus-gaap_DebtInstrumentAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$nanafalse013false 4us-gaap_NotesPayableRelatedPartiesNoncurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse334787334787USD$falsetruefalse2truefalsefalse334787334787USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 2 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.23) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 23 -Article 5 false2falseNOTES PAYABLE -RELATED PARTY (Details) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseNoteshttp://sanomedics.com/role/NotesPayable-RelatedPartyDetails213 XML 41 R16.xml IDEA: LIQUIDITY AND GOING CONCERN (Details Narrative) 2.4.0.80016 - Disclosure - LIQUIDITY AND GOING CONCERN (Details Narrative)truefalsefalse1false USDfalsefalse$AsOf2013-06-30http://www.sec.gov/CIK0001501972instant2013-06-30T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1simh_LiquidityAndGoingConcernDetailsNarrativeAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2us-gaap_DueToOfficersOrStockholdersCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse582000582000USD$falsetruefalsexbrli:monetaryItemTypemonetaryAmounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 57 -Paragraph 2 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 12 -Subparagraph a(1) -Article 6 false2falseLIQUIDITY AND GOING CONCERN (Details Narrative) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://sanomedics.com/role/LiquidityAndGoingConcernDetailsNarrative12 XML 42 R18.xml IDEA: NOTES PAYABLE -RELATED PARTY (Details Narrative) 2.4.0.80018 - Disclosure - NOTES PAYABLE -RELATED PARTY (Details Narrative)truefalsefalse1false USDfalsefalse$AsOf2013-06-30http://www.sec.gov/CIK0001501972instant2013-06-30T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1simh_NotesPayableRelatedPartyDetailsNarrativeAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2simh_DebtInstrumentAccruedInterestsimh_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse238868238868USD$falsetruefalsexbrli:monetaryItemTypemonetaryCustom Element.No definition available.false2falseNOTES PAYABLE -RELATED PARTY (Details Narrative) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseNoteshttp://sanomedics.com/role/NotesPayable-RelatedPartyDetailsNarrative12 XML 43 R3.xml IDEA: Consolidated Balance Sheets (Unaudited) (Parenthetical) 2.4.0.80003 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)truefalsefalse1false USDfalsefalse$AsOf2013-06-30http://www.sec.gov/CIK0001501972instant2013-06-30T00:00:000001-01-01T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2false USDfalsefalse$AsOf2012-12-31http://www.sec.gov/CIK0001501972instant2012-12-31T00:00:000001-01-01T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USD_per_ShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$1true 2us-gaap_StockholdersEquityAbstractus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 3us-gaap_PreferredStockParOrStatedValuePerShareus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse0.0010.001USD$falsetruefalse2truefalsefalse0.0010.001USD$falsetruefalsenum:perShareItemTypedecimalFace amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false33false 3us-gaap_PreferredStockSharesAuthorizedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse10001000falsefalsefalse2truefalsefalse10001000falsefalsefalsexbrli:sharesItemTypesharesThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 2, 3, 4, 5, 6, 7, 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false14false 3us-gaap_PreferredStockSharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse10001000falsefalsefalse2truefalsefalse10001000falsefalsefalsexbrli:sharesItemTypesharesTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false15false 3us-gaap_PreferredStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse10001000falsefalsefalse2truefalsefalse10001000falsefalsefalsexbrli:sharesItemTypesharesAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false16false 3us-gaap_CommonStockParOrStatedValuePerShareus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse0.0010.001USD$falsetruefalse2truefalsefalse0.0010.001USD$falsetruefalsenum:perShareItemTypedecimalFace amount or stated value of common stock per share; generally not indicative of the fair market value per share.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false37false 3us-gaap_CommonStockSharesAuthorizedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse250000000250000000falsefalsefalse2truefalsefalse250000000250000000falsefalsefalsexbrli:sharesItemTypesharesThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false18false 3us-gaap_CommonStockSharesIssuedus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse2050860920508609falsefalsefalse2truefalsefalse2040358620403586falsefalsefalsexbrli:sharesItemTypesharesTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false19false 3us-gaap_CommonStockSharesOutstandingus-gaap_truenainstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse2050860920508609falsefalsefalse2truefalsefalse2040358620403586falsefalsefalsexbrli:sharesItemTypesharesNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5 false1falseConsolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)UnKnownNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://sanomedics.com/role/BalanceSheetsParenthetical29 XML 44 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8
PENDING ACQUISITION
6 Months Ended
Jun. 30, 2013
Notes to Financial Statements  
NOTE 8 - PENDING ACQUISITION

Prime Time Medical:

 

On April 26, 2013, the Company entered into a Stock Purchase Agreement (the “Stock Purchase Agreement ”) with Prime Time Medical, Inc., a Florida corporation (“Prime Time”) and Mark R. Miklos, the sole equity holder of Prime Time (“Miklos”). Prime Time is a Durable Medical Equipment provider of home medical equipment servicing consumers throughout West Central Florida.

 

Pursuant to the Stock Purchase Agreement, at the closing Miklos will transfer to the Company all the outstanding shares of capital stock of Prime Time for an aggregate purchase price of up to $3,100,000, subject to certain adjustments as summarized herein. The purchase price will be paid in a combination of cash, promissory notes and shares of the Company’s common stock

 

On the closing date, the Company will make a total cash payment to Miklos as follows: (a) if the closing occurs on or prior to May 26, 2013, the Company shall pay $950,000 at closing, (b) if the closing occurs after May 26, 2013 but on or prior to June 26, 2013 the Company shall pay to Seller $1,050,000 at closing, and (c) if the closing occurs after June 26, 2013, the Company shall pay to Seller $1,150,000 at closing. The Purchase Agreement requires total deposits of $400,000 to be paid towards the purchase price, to be paid by June 26, 2013. As of June 30, 2013 the Company has paid $300,000 and recorded an accrual for $100,000. Subsequently the company paid an additional $50,000, which has resulted in the seller granting the Company additional time to close.

 

Additionally, at closing, the Company will issue two additional promissory notes (the “Prime Time Notes A and B”) to Miklos in the aggregate principal amount of $1,000,000.  Prime Time Note A in the principal amount of $500,000 will bear interest at 5% per annum, with monthly payments of principal and interest, and will mature three years after the closing date.  Prime Time Note B in the principal amount of $500,000 will bear interest at 5% per annum, with annual payments of interest and principal payable annually over two years from the date of closing provided; however, that the principal balance of Prime Time Note B (and the respective annual payment) shall be reduced if: (i) the earnings before income taxes, depreciation and amortization (“EBITDA”) for the fiscal year ended December 31, 2013 is less than $975,000; and/or (ii) the EBITDA for the fiscal year ended December 31, 2014 is less than $975,000. At Miklos’ option, Prime Time Note B can be paid in shares of common stock of the Company on terms acceptable to Miklos and the Company.

 

Total consideration also includes $750,000 in the form of shares of restricted common stock of the Company (the “Shares”), with the number of Shares to be issued to be determined at closing by dividing $750,000 by the average of the highest bid and lowest asked prices for the Company’s common stock as quoted on the OTC Bulletin Board, the OTC Pink Sheets or other similar quotation system, as applicable, at the end of the trading day immediately preceding the closing (the “Original Issuance Price”). If as of the first anniversary of the closing Miklos has not received at least $1,500,000 of the purchase price in the form of cash (including from the payment of principal on Prime Time Notes A and B and the sale of Shares in the public market), then, following such first anniversary, Miklos may put, and Company shall promptly purchase from Miklos in cash, such number of Shares equal to the difference between such cash payments and $1,500,000 divided by the Original Issuance Price.

 

The Purchase Agreement also requires the Company to enter at closing into an employment agreement with the Seller for certain management services and; also contains a covenant of the Seller not to compete with the Company for a two year period.

 

The Purchase Agreement further provides that the Company will engage its independent registered public accounting firm to prepare an audit of Prime Time’s financial statements for the years ended December 31, 2011 and 2012. If, for any reason the audit cannot be concluded, the Company will not be required to pay any amounts due under Notes A or B and such notes will be cancelled. The Company, however, has no right to receive a refund of the cash portion of the purchase price as tendered or to effect a cancellation of the Shares. In addition, if Prime Time’s total asset value at December 31, 2012 as determined in accordance with the audited financial statements is less than the value set forth on the financial statements previously provided to the Company, the purchase price will be reduced by such amount on a dollar for dollar basis through a return of a number of Shares equal to such deficiency, and, if the deficiency is greater than the Original Issue Price, through a set off of the amount which will be due under Note A.

XML 45 R21.xml IDEA: STOCKHOLDERS' DEFICIT (Details Narrative) 2.4.0.80021 - Disclosure - STOCKHOLDERS' DEFICIT (Details Narrative)truefalsefalse1false USDfalsefalse$From2013-04-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-04-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1simh_StockholdersDeficitDetailsNarrativeAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGrossus-gaap_truecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse3884238842USD$falsetruefalsexbrli:monetaryItemTypemonetaryGross value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.No definition available.false2falseSTOCKHOLDERS' DEFICIT (Details Narrative) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://sanomedics.com/role/StockholdersDeficitDetailsNarrative12 XML 46 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
LIQUIDITY AND GOING CONCERN (Details Narrative) (USD $)
Jun. 30, 2013
Liquidity And Going Concern Details Narrative  
Due to Officers or Stockholders $ 582,000
XML 47 R22.xml IDEA: PENDING ACQUISITION (Details Narrative) 2.4.0.80022 - Disclosure - PENDING ACQUISITION (Details Narrative)truefalsefalse1false USDfalsefalse$AsOf2013-06-30http://www.sec.gov/CIK0001501972instant2013-06-30T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 1simh_PendingAcquisitionDetailsNarrativeAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2us-gaap_BusinessAcquisitionPurchasePriceAllocationCurrentAssetsInventoryus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse300000300000USD$falsetruefalsexbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to inventory, including finished goods, work-in-process, and raw materials.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph e -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 37 -Subparagraph c -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false23false 2us-gaap_BusinessAcquisitionPurchasePriceAllocationUnfavorableContractAccrualus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse100000100000falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of acquisition cost of a business combination allocated to unfavorable contracts assumed from the acquired entity.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 37 -Subparagraph k -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Emerging Issues Task Force (EITF) -Number 04-1 -Paragraph 4, 8 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false24false 2simh_PurchasePricePaidAdditionalsimh_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalse1truefalsefalse5000050000USD$falsetruefalsexbrli:monetaryItemTypemonetaryCustom ElementNo definition available.false2falsePENDING ACQUISITION (Details Narrative) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://sanomedics.com/role/PendingAcquisitionDetailsNarrative14 ZIP 48 0001477932-13-003954-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-13-003954-xbrl.zip M4$L#!!0````(`#0P%$-SB'9=-#4```2F`0`1`!P`-ZK MN9TJR^:[2#O)EF,GL[[)Q%X[F=W]-`63D,4=BM""I&W=K[\&2$J@1$H@"3GQ M))FIQ"9>G@>-1J,;`,%7?WF:Q=H#IFE$DM<'QI%^H.$D(&&4W+\^^'P[.KL] MO[P\T/[RYC__0X,_K_YK--+>1S@.3[0+$HPNDPDYU3ZB&3[1?L()IB@C]%3[ M%<4Y>T+^\?;F`_Q:U'^B64=.J(U&$I7]BI.0T,\WE\O*IEDV/SD^?GQ\/$K( M`WHD]/?T*"!RU=V2G`9X65<:S::_&?J_G^YH?/0T`<87*(/GIFY8Q[IW;.J? M=./$=D\,7;+^#&5YNJQ??]++/T7Q5PPH.F%_:R#P)#UY2J/7!T*3'JTC0N\! M6#>.__'+A]M@BF=H%"5IAI(`'U2EXBCYO:F3JZ1VB^+#!!Z1W/7"8TD($4 M2F*<-I;A*0V%$I(D^:R95YC1XVPQQ\>0:02Y,(V"9;G=A>H%@`-[W,R.IS2P M"TB>9'31W"5E8E.QG%(P(FWERM2&@O@IF#878BD-!:+D`:=99BRWI;N6?E"9 M(39T3U)N(&[P1..C_F3*QP*K9U05.'I*PX,RF?4P3Y[',(2/JZH*LQ20),-/ MF1:%KP_>4S)C%3!^NI&1XF=WM,)?%L-)%F6+Y=/E\RAD*9,(4XVSQ#5-K21Q M?OGSP1LPD(:C&_[8?'6\7G@%=]R(5Z+-0&^,-D6DT'V9M6`)429HE1( MY@C^A\'R8H54-F"O0GJ9H[2N2>)P4RNDTJR9@EDS7Z3`:F;-[&/6S&%GQC^Q`'CL> MNSEG=*"X3K.I5@'T`B?@8">[8'>+?AVWJ>(JO28%"9G.\P91UJFQ+/)]UAR( M7()N0ONR&QCS[+PN#J\Q#2`!W6.MU-P;=HI.YA"#QO!X;LY>"W$0S5"ANJ1[K\Z[LYC7RUH\J%V-\'[\DV0-X"?=B4:S]E<3LE8'T$)X'KX[;@#:)G`-#BN++ M),1//^.%-!-Q+FRM382[(`&7TZ?%7+Z]AC[Z6U&_6+RIVFL^';XK/`KI^D7? MK[6V)KCW41J@^)\8T??P).T$6(=:JZD=K.#4#>YO9A.84%.#0I#9C"2W&0E^ MYW-L>I5GS`-AZM4RKO@)VM70*=V,]<%CNH[NN0X_<$RJO MJ;?``0S$%O(11>C>VG,"30;%_77*A!K/N?G M\(7^[ZJ\HVKE9UMMFU+\.X[CGQ/RF-S"/$X2'%ZF:0[RD87]2$3!M=2V"?LK MB7,PAK00M;P*U^'6:FE0WT(.R\XN7@R21OLG\[]VU;8^,0GKJ1](@3!JF.,L#!EF_$Q'UU?3S0X4!:0J*6PC93%6STE*T@O\"L0G MZ^UM4K5=S_L"'2WIU'T%2M#1>=MDW)]MY=>]>YKC),7,Z9.U)ML(.;9EC5>D M&E!Z$FDZ8B\I&74DFA85MRJ4[OG>GJ2QL>JF3AKU".!S@F9LFO@_'%[`-,Q> MSU-JT-RZ0=L)KIAMUR%GF9YA/C?=H9;-ML;.L\MXL'5CI(>POJ9X@L'3";DG M?HWH%2U"6/XZ-80+W#F7]F.$!;J&")HM&G<#5D>WT18]+]TBSCG+LRFAK$_D MI-H24QFZV._;@8;3VI3>,]'B,<6^)56`#*.C4$+R='8$Z`I%U!"=#R"F4%A; MB`E+#,]HV"10%1$=:-*&$55JS)A[P_\TLMME-SJRDE8^Q:P4F#)3MW7+\=PM MA)J-1PRDUL`,W1Q[0J`L M`Z:*H(SXOBC!@2^&;FV75Y]UOX#VD MG"=K[-NF5+]N8"JF*^5*^>`>&_X@NKPWUMY_"0(*\4>UG-^7G6EYGNN5_;T5 MH8/H"O)G2=C+4WY*HY,DBE\?``_Q5CEUP(H]X";86L]]P&F5Z9JM69-DL.ZW MU-L#MK-5:$=M7JD7#/I;G&`(P2(4%P_9ZPOO,N.4Z;3L&.JRN@RA<1BF6@BYS"G%B<0./9^=+'6Y0R?V;&=EKYD<:?*$G; M3NUTVUGV/%O8A>S)I&8MKG/PK"#;-8T"?(VB\"P,H_(<9M]%F,)AWE7]NES? MYFF4@)$Y"_Z=1RG/5"M]%L'`3!OK"@N5EQ/VB9IMJFI3LR MT*5C-">@``J# MK+;%R!QFN\5UC+B']0Z&XIQ-@P.:9XQU6_#'MT$,I2,U(3ECV^A'1]$HM,8; M@[YE`"H9>XYE^^)&QNXA?TWQ'*:,\LQ2]_;N"BFZ@4AUJNX9^II]:038/`%6 MSAX#%!PF"D&AQ!J[HLF%D(8GAP81)3NGD][@`(/+!1XL9!JHO9Y1FQ6W(`QE M(S6M^-;8[4>'[9M%&1OH*8QZ<.C9R6R[YN=X8::7M,V_)9&MJB)'+B4KAJ.XXEV>#M`,.HR*T>N$XMA)7GLHP@U:E&:SPMT4L=Z0R,FG<3$I8LQ%6T MH1)J>[V@`6,X(QDAN9[E.7TI5>NL:H0#+D#M0%1S[?TY2#D&3!P-;P-LYU#- MF64NF*6*X*Q8C58WP$S;\JR&N5H6=Q^\Y5Y5LL>>6MXLXRV*$1TN5H MTVNHOC\)J7'HP']^5P[BNE\2BB>$6`B6-2XK]5BXV06C@E:?Q9ZNO-0)"-)= MVQ!U6A6ZC!Q&MNN[GF]T0;_!&8H2'+Y#-&%[H:!@^2SGGL(%7Y'O/7Y&P,0R M/:%?=F.I82KT*BW(1=6F;=4/X2& MU&S7C<;2-BV7P=FB^&5RCN91UKSD+B,,9VQ[KJC,+?4/H"%E@<>>XXGNHB0- MX?`HW[SHKQ.V;C>>2>75]H&5TP&GY2AL(VS]S/^@!K>^SC,$6"HPZ`2LT/W? M>@Q$XKC'0!^CVA+O@`[^!TYO\`-.-C

^]X&_I8T+@UB!X,NNY36XYN>BH) M=-T*=2U?7#Y7(H%.+]>.#5T>_YRDV=7D)T+"]!8\#!4Z8%F.;XI&IX;0@T!G M%0`/2BF!KBH`L:YI*)9`)Q4P3-N5)\#WWJ\IF41*;(`'4[Y@!H7:.P)W[GJG7CR=+!)$UI[7N;LN\)Q"+3R-&:_BZ@YE M.@2A8.T&RU:P@;RZZI)IF.9S\.KL,'N^_TSRZN9'ZZ(;W8'7U9Q=5QPE]Z45 ME+X:;VM@Y[J>+:PB;8#T8M%5AWS3,\4`4PV+SE;(<@UWO`=9=-(/!SPV,>B0 M9W&9!&2&/[0?O^ZD&2-W[%M.DSA6.#VI=%6/D6^./?&E!W54NNK(R/1\T]Z7 M5+J&:J;I-VE*.Q71OEQ-WD<)2@(HP()YMB-6W3*E1('6[LF3A59)64+1=CF% M`R4VY"Z]+R2QH6[TZM3,3RA*F!9>):MGJA:%=7OLFC6':`>J$IH*%*JO>+HY M/U],/$.U9^WN1C4!O&$(D\<:0@\"7>4?\=7]^/#R'0J7[1)+T+9X0BHM\G]`33M\]9101&L)42A>7&9[Q MVQ2@)"5QS/$:WE#OJYZFX_K^N#98]D;X"\NFQQ"Q7,\TO@79=(],#$NW]?&W M()ONML)CIW6^H&B@BM(<%2^T]S45N]TG:30%OFRWMNU29[5M&^J(@HNK>$%E MP[#7(#KC#S>>P_"'&ZC![1]F!+;"5V<]JZM4WZ(T"GCT'.<9[G>H9D=J!KH#L3NW93E;LQOV3W:EJ.R2K/[-DM^OE#LG:OL[4K?=H>U;3J>;_E?;[.V M#X_VWC)T0S>_WF9M'TC/W%OB1AW\'.-GW^9M0U7%5-W&[RZFJ_<']G70HAFA M.W[?@Q7;\9L7ZMD56-7:_#7%LRB?J3DZV[H)TX"HA.*`R((+[G-",8K9I>QL M[9DDRPNJ&(.&5W+5K`I62^:]*"CGKR8Z`Q[L^T?%OY?)YET-2D1G&Z937Z_: MB:N*:^<@R';%`W-JJ%;W@2A317N\C:(`-YA;9Z/O>VY_+W.JD167%? MU`ZD`804#,=K2@*,0[[B=(/G:,%O*+F:O$7)[U?@FX0437I+8W_@W4>8(_H% M"S]X;UUG;+=NTGZ]U:]=+*#I,X;I>?7MZ-ZPJJGVVTBU'-5?)BW;ZBE?W MMKM'\K?P#*7>>;K7G>V^B#QU=BL82JA?L26C#"/3P_G:J7P/T=G=U:5T6RK[A[!FVW^JE MUO&&3C:LY&C_0/5S%AL!VW[VTBO?P9$'K MBWTHAKS"717[D(042.<9V/*$.U?6$;;I9NN7V?L>N77T5L7<]AGV+IP4A-DM M1F=Y#'K_?L;8JAN788SVW[[.!LJHOW6JMGV\*GZU_[JWJ>250G]0N@`Q#[M@"`(7N\YJ)Y8R@E(#S;3% M6\2>EZ#1\W+B_CW61XTZRT,X\<9NL=KW,;5V%"4;(-52P!X;LAUBZ%:8,-<7 MWS[Y1,"(IGF<0=R1OB?T%M.'*%"S4N>[EFV5KH8TL#JZRF4%>.?+CP85NY

\_PQVU2VTUA'TT8*LER)^0J8>%M@D/AZS!J-@QUX2+!+6!#2"FP M']7'<2[P,KH`>\H.BH!)OH9A#_:4.S&?`/MMW"&L>/-#G)W.M31;Q/CUP00* MG6B&/L^T3]$,!L='_*C=D!E*#HL'AQJ,FVARJLT0O8^2$TT_U1C,",71/?SZ MKQSBZ"L_SM/DYR>DJ02-4RZ982&:'(5"R M6&7Y49L0.L,T7F@_492$VL<(W2.*M%\B=O"-4V./A3M`M'-2M:"HQ[)/:V67 M3W_4'J$QA$8@,A0#1`2S#IT3RF)H^(632Z$'L48FVF6(IH0]-7S'T5A]%(]" M,HN"*"Z%M%[D`L+Q1T3AYT0[F],HUMQ#S=1U_TC[!/G*UAY"(4KR^ZG&]A93 M"%6C,.);-8D"U3R#0'"?/ZYCC3II`3^AK%V50+H/P1 M4\7C.5,=7FWQU][4L^Q[5S]]7ES6(2@(BBYA7X3/$Y2'47GT+&3[O^&*&Y,: MB:.0:0HG-BF"&1A&O/?Y8J`V16!^[S!.0.IXSON"#2!`H2%;G=`>(Q`R*C:` M&&;9.3&TY;ZXY0AZ"=+95WJ7&ODYX:QN&4[*U.P,NB\*T'(PL$PT9Y446GK/ MKJ+EP1UDWJR!?W.V6.!C^=\]!5.4W'/U9%^>9>:3*4K$C$4TTU8M!06#P*N@$?'BL+`84[S00@)ZF;&!%><$)(EA&LQALD_1;10 M3J2Q#J%X"N)G4]EJ1=`K$4="-!][S#_@<$-`>[PFJ9DD<8<92-391QWD`7V@]0*&1Z4_3PGYDB M1'RQDO%)6*MBH,"^@+FT3ZO\/PHJ,4,@D,=I%(`&@(E8;_@$151KT*J:#`H[ M4K:8%RRD6_34G(>(!0>&`!U1H43\D M!S$L,*+?D$E868%-_5^-=$XDG9(\#IGD(!3GHQ64XU]Y$G!MY4,]6UG]:HYS M3U/M+$ERJ.\&'!B:L61FA%J^"R,D)L M?!5CB\T#.(/9,2/WF/VR(O7+-'!OLVE:UO:_>8(U2^>U M6%HW)8;J*SM4:*Y`5E#@53C'^N$Y5S6 MHCWK2MTPA3%MT.X),WE01P`>I':'N%IPEZ2P^.`\QF`]X-&B9C!IL4/!3$S& MAQ>49YJ=+<#SH>`&\;/6&OB):U84Q,DNT&&V<76[.KA%_'KU;\@@E>9#*[^Q M#$-@"DYL',VX2:#%I;NL)PH?,.5F')Q)OM*ZDJE6R)./S!0&"`HR`MXA11'\ MQGQ0%I`S?0A)?@?=>$?RC/NGQ6&4!>O`H%BMQ2PD6-.((]&B%'J4EDI6.*15 M._B6GY=M;6#5G"A[!#!6F&-JF5:[>2I*-+:K%&J!E"["? MJZ!NV8=W!$;?(XO_]L:$YWN,P!2S[JC1*/0."5_;+>[&/X*HM'3$5GX:)";, MQLR+#87"QJ1@/@I!]*FMK4L_XHJ0ZI(E?"SY#V9GBI" MDFZF\H;4(SWS6;8%:"(DCR1#Z%\_9[FK)-LR-D3$='7E!2+IWGONV=<9"@X0 M!BR<;ZD*0?"7XB:2&(IXC%MEZ]0.K&AZX`!S$2J5D4 M4Y-E*-:+U-568=DF*DE(0M];+$E"G-5F060#'R`+NBEN;@,GKE-UUBDJED_- MC,>:R04[JC4*[Q8%(_<*E&;HS\(XSA(Z^J[_ MQ"Q%0"1_>^._V?0Y>`$!8@+G)(_^%3*$U#-3_(N4=+3R5%T(OJ-^J-]0DMYG MP>)O;_B_&S?ULL$D;1L'[)H&H**_9COC5WMA"BH#2/43WCH<(0Z`'WB=`1`@ ML4%;J#P6ZLA$?F/$?#8@^L^'LDWA\1BX-7ZGA`&_9D_[!&B#^R9Q[1CY4^B; MS+7Z'L>DXK]O2$6O]_.*\$\/T`_.%'C>-?E^3F"1-'OO_-O9V>?/7[ZLDX=" MB1N-WJXQFAK0#(4_0'D_TY-JG6^@R$9YGH+:C23EG#AG7R\OC0CIUZ]GKL.N MLTL,SK!:P+Z";H=?"JCN*F>_)S:J`KU^\A:]\J#S)\M;^`![:L#,88(%0^5B M5J3X+?:<]HY/WS65>#98O+=;"[;2FPU`=_2XO4U*-Y:AL=-X46_LD1-E-T5@ M;V`Z/`#OB<3O;Z(BW$78[4JX?^+\$,?SB=*\/1*MTYQJ]\ZD:Y34[6Z_-QSM M0%[[/D][SOWT@NV7":R=<+_RM2UD5ONPP/>[!XG]F\Y]<#Q_U!D<%-?O]=W1 M>'1P>+_IW.WA^FLP_N3BZBJ:88R,D9S,*_'XVZ/;?7FSC'']\Y?V'&*,8C:,G!GJFAJ<=L:[U\.Q?<=@AVTA*2^LV` M]RSRJ'TT".(7*\T]U^OZ!RG/-Y_\E7.\<"QH.>>@YDVE MK*XZ>P130$),0J&,N.F#$V#"B67([-^@>)%:P'@P=KV>[[2$F;U(&/JCH3OL M=U?#\$#98B.1,AEVW8DW:0G^/>?)>Z.)V_=_N7G[7R>DY*V='/20]^QT?@8U%('#Y9&'OS MTKM=?+NLX]\>X%NY\?Z@G&_]J[H_XM^QR"(7H:V9X>@W+$(NX0RFJ:CNQV)( M8##("3*>)8!&I%&YA97CHMPZR/-0IP'*"@(J=:"OJ`5=1Y3.<,$.%6=Q5764 M4)D!=A_ADAY58&U]LL#*Y>BG.@;5CBZR:$8U1$?=SJ!+,0?Z1(<-XRC'*BW< M;WJ?\#'L8J(OJIZ+RKFH>`AKNG25$>W%K#2R]_5\I3KBEQ$5O,!#G4&4-,2L M]M0Z%.FB0>)=?[SXN0M70.^&!HH-GN:<:Y?,OPN,<#TXD[H*/R*.;`Z M"T5Q:YC=1@F^&`:S&_DVD:\31WE1(G1!W;!HA&U]`+=S;*6`UL@(=*LWQN[X^&8"Y]D MLY2:S=^'HCQ['L81_)LN\K5@:K2)$.7:^H!T*.S)0O51U-^(7KI+,)`I_?QU?`G\%$&+VP""Z$*JG!E%0IV!`@3BGK%VZ#`SA>R ML,U\2H0^.;8_Z.PBP?;#9UY92@.6\K$%+,6*OE>9"I8;8C.!B$HBB23,:EGL M[%4KP\2CGZ(LQ%)M@]4(4E34F^.@!ZS.+`*<.ZM#]"3#`R=.D2B`/U492I#+ MPGVD/-(U2H<6-@U0-YVW8WL4D460ZSK*-[RXXG8>J8M48+6='O(XZA;MR3:6 M2%;GK_&0K/8UB-#\U>]SYPX;?Q5OY5+?"OI@1X^CT0`SR5A<5)Z@JE6IZ2)& MWU#%JF+$2P.=E**P32.YM@K0GV81:NUH1HT MJN"-5,-7*;#G"6T"@43UR=7B\R7P[:P(?H1F=?G]382%NS=4'CTM&"RX9]?` M>%P#SDH=.$A24DVP2?"\4ARBA6"JX^G5%8L^L7'9K*6.'CK.*9%/J=5*HENY M2"DHD*'*-&XQ&8AX$6WB")[W`4SXC2-X:]#MJM2A91+PP+APKM*(:/FC?L\= MR9>&XB6X$FQ!!-I$_(PZ_"^U!($$%=R'M31(A$`Z&H,[,!MX?5N"VH(]AT^5 M4H0076-3RBYYV'X/69G9>T\T'-/BB:^:[JLWPCMB,L?WN.D7=RM"/0S3R5+- M3Y22/0V#S$Y#&Z\F7T!V1<'X47$.;D+#@M8S,!9_0]OPQN*W0N21+,1MPSX\ M?UPO-4R=7K(%ZM).7*$B1\+_PYY-]/F^_U8GQ;'2RU?#$T7E.G%ZCT?F?D?( M_I%$IW!2^J#:CK7V?"EU6,`PI\@":H\S#QZHQP:#R-@:,F"OTQNJ!C#\D\&Q M]DCMSI%STCUADNV[P_&XCLQI%U;&(&,.O];SW3$N=9B4OD95K"'S!_?[6X^ MP$8$*=&RLR"C86L![IX^J:Q8-K85=AJ`N3C_9$)%]F&+J'<(-PB=!CDS(D$G MJ-)SEQ#:%/$PX-,DKP7ZSWQ>`\ MN2#?01UT-`M77T=673T8=6NI'`U4+]&$A#4SSJ@AE;T7&5'Y?M%C4 MH&3I%N!MG=#"ZD,@EK/K4&II'DB,8+&((^TEL1`8E@35S[BU6N],8F%(1;?= M).6$$F]+.E)ET0(4+38-BC8!6B\3I:`#C90-V"._,QJ@5!H!:I3$(,@RA@>_ M*QB//]@HY0`XW)*S("8LE6F#5O34;D)#92IC$[\,U&FZ=>PQ%RR+&^`&4DY- MEP6V@&;/DP:?!:.!8"+BGV47PT6:YY&HNE?26!/9!Z81V;(J"Z^Q=2^3%"GV M.8IFB1XUK!RJ5MS7C^P.T-N4WT M45PO!"*6U]/NWP,[3.?%M M6KT"RJ-!W^WU1@PVU"V1(9=7+RL$@3FWWMB,<3`)?]U@E-9?!;::QVOC/GOI#!;C4]I(^N:GI:OL;:AUPJ?4M7U)*<"Y*?)7(T=;Y,/ MRFQ6&&##V7\)==',>G@PZ8,@B!=^DG(=U":3EYRL5MX_1G6?5NO(X:= MR^;9R$G&WN#$8\J>AQSFD7T,I>_'%`$+J_-V-6R"5B2<'5VO:'_-Y]355%W3 MBPA=/ATF4!?L.QIY0_HH,,%P81*ZA!F;F1INQ,OT_1"O(#Y]Y+L3;^!ZX['H MCBY83SW\G5A/WV5]L^Z2:+$LI'W.I5>2=@:)SNA\+<($UZ!^HN%C(C-64=:^`U^K M50+K?32V0NBYX_[('0R%;Z7?=8>344GJTY9089S+Z62DKKA=>'/HCX46SE"P MMDLV4OV6IV%QCQVBF4O+Q91R$MEPY*Z=$0UX(K1.0'.%K7`."Y-`0K"B7=3` M*U\A`M?+MLJ@+=UT%(=@I32!`=LDAWD[HS-?`=H9H;"*'@__: M^C?;_(1%47*7QG=Z",M=`)@'UE8YZ1,H%]*]+S6S`!>6]794B()K$!-O\R/J'9Y&,@AX,-3GVYOJ;Z*-L,($+!GHW:6RB<:IS/#$4++K%!B0OT:D.'/ M(,]!FB_SL$"\0G8%I@GZP&9Q$-VB%,>Y.\A*A"QV!!((Y"Q`9(3D0T-T`8UD%:\5#I)&.#D)M1,ED(%AA/2/;"6-..` M?H(-P!,.E)#N`X!7_A3ZQ0S.RH,U\A2['C\X."'ZE@P"TK7@NT@8'8V/BECO M0]ERF2>:,)TO"V0=.FI*DV"*@OL74,PU,$>^,,VR38OR"9U'&R`8_ MPH05.,QSM&(P>KO8?A^1U MP)ZV0Y2!$(\K7&Y\2\)]C5ZAP&3J1I1ZP+%&>]2,Y6VQ$OUZAR,]R;KPQ\UO MVQ^XX\E@S6T'SF(YC:,9>VK(ZW$5@782H%`KBEA)(AIS5XL'=G*-B0 M%YP->(`YK'U_'1Y8UM:!H4$EB<)`#!YCE7!`2'O,?VG6B:ML5#4-1R6&Z#C0 MTZ5^D,GF/N284WA"47]&1^E-9A),,,;)*K:I=J\8V5D2MF2??0HH<&^.#6ZFP?LO0$8#O.W^B11;$[P^0XGBL MKC]LF$/%#*I&7I62J58^5\FPJEX#3Q]V07!\B=,,<-:9&3X)0_#1JQR&Q;\8 M7T::`5[RP_FKX_P9_0!LY9,!#5#B(1K>NDK`V(+Q=7[/^&K'?)#JYSXM,[(' MQ<8=I)&%&MDF"^5C0HL3I$ICA'-IM^*\N/_!L.T9/)C!6P(8 M!R(2OY6"U*L0"JL(+[K.\735*@&EXYD?=S!SJ[0X&S+R@$:FO!2` M&L=A1G&PFHT@SAW/UF_&6JSFJ`[E.\J51&JVZU568X*I$3P9B=H(I5,QM%HF9]T$VYZ)0F_Q<6:29.<.7RVD.1^'"5)'N3A^E#P:).012Y.O*0,T-E:>A.T`/0\_Y MYDB[EFJH8I'Z2R)XPBXC@/2A6&:G"@18;VLBM0DH9`*LA%/R*[KM#-A5>'!) M5S)$"R?2G!(Z?#05&LU'I)ZOI4_)SI<"X(BF4##BU-C9I55AT75^`Y&V+D5/ MD%D5*':K;U+KR#-FX>R4JOU"64G:'X#^S-0WM\]DQ&?K9(_+8\H:\X_@.XH`C'* MS-1+3(.8\C1M#44<_5C.E362"NS=OY.N%E8H0-E?8C?%Z`ID5/1.AJ`2FFHK M$K]%XD$1_$1*`C8*;"O2P2LKF=#0IC]_//_^Z=1$:7L&N@)):0ZZ\BP[%/G* M:;YG`@*/RR0I1?`/^-)Q)/;+"S68L"Z_W)=?EJ:\_CHE2MMVP/"#*J.M`EQ$ MV:1>ML+56ZJUQ40Y*LD`GA\NN#I6B%6I.MCC@0\Y&XDU++N@@MJ9R"8.1R.6 M>:9/!!M,(-3U?2"Q8D2:/".KKZ9LU'+?%HW#KNX#`?QARJ8>/R5T"0X%R/N< M6BEU6IJ@"C&/@-RYW%PH-:(4I50$=Q-=WR"KF4;L&A+5`$'^(U2%Z11N9_6/(6"C1Q.+\I2NYD)5(YSF: MBS/L[0\@L*SV\RO+N*4C5>C,8QD<\+00P8C71C&7'D5E(0;^\![0(!**6+J#!&CYCGNBK.=F$^(I)^B6MA-!JNB!GA:U] M6JV=ZI)ZI'0B!=BH(RDK9AX1/I5L``]WA=_M020QL6RDY4'M0@2:4GD`)\I6 M[3-'/"*(@@))Z%.0-,$F`=?=<_6H9+JP+/-<9FK)ZW&3UA5R!;Y64#%A*.O[14I5(+=BE?$PW\4V M&\H@==$-4W];.ETAP(9W(I`%&%23-YV;FDQ4K1E3M[,JMPJV6G*`?49.[;D[0SN M\7DE$_3<"#@AUA'Y8^5PWW_#4(`PWWXW+I@'VVH_%W37+!V M_"QA/MSL/X"3%<*'\O<@O@OQ)U<`"#C*D\;]+,6F?9AT3QJ7CXST5=P! MU".R[&FMZE)K`UZ&7D\=#+0;^B#X;O.0@5,7+I`\96W(P,+-=4$#>G!CR*!T M3Q;JTWX:1`A4M&'K&('3(#[`)%.*$82H5&/AW+$W?B>S45<$"YP*R&IB`QO. MHTH_GC8ZX*R/#)A"IWETH.[X#>(#SJK8`.UB:U][V8NOG#H[^/%I)V5??OG[ MY,DW13W:.]*17P>;K5SY'YL%C^N`!#(MS-02L;(-1] MN'6>VNV1H95H47;=VGGE->Y;YU&N6\P(7Z*[T'#=6MI>G?.6XS(K'+@K)/W^ MG;M4G;?XA5HM>1=O+FVAH4?7>3)O+GL#2Q[=59?()MH3^7/+B+') MI^OLWY^KDS`;^W2=_?MSV3)HY--=+4=W=>YJGFWILJ<'8G?K(BJ\,:69Y`=7 MU7&NIWSX-2EU7IH`)^Z;2IL?L8VHT9CP:#.C')%U1<5*(:& M%,F6L3$-%SCR?9WWFJ>QRI#!CG''0[0`9===:I##VKAJ.\O>7"/[1FQ?U\+* M3D]4D,6I$,9`!\]S)_UG]DFU+H;\IU8+4:11]ZU`5H#F*LC#??FE/L*,2:*7 M5>M.;HI`!,$W+SWCZ37`7@'V#^(-LFA"UOBYM50BJ$JN:W8!(B,.+J\L; M0-3O(."PT]^.(2L%W(4>K=+N\3$\F&Z7^;!UPUUF9*XT'THY2Q$0R=_>^&\V M?2[>/"H&GYGB7V2>/:T\51>R_6#"?9RQO6`RE;X&H(JW']ZY;D)1^V"ZW6S4 MQT(=F`[?&[SSUS-1&>]HG0!ODHM?[>47XIP?HEA.K2Q/[1J.WZRW:331S*6:!F<97>=#)"9M@_P"KB?LV M4O8-*^.7X:(0:@'G"74[HE4^-42S)PU-K'@GFG<4TA0$"U;@Q:Q(\5LBVH94NW%H!_+:]WG:<^ZG%VR_3&#M MA/N5KVTAL]J'!<*K>G#8O^G;SMT>KK\&XT]$ MUSZ)Y-90QUUXN^A,RWQ]H,9\6:.]Y&COXX_OG+]"T2:*EASLF1J:>LRVULNW M<\%MAV`G+2&IWPQXSR*/VL?16N`&>LJ3M(?;4G[MBY7FGNMU_8.4YYM/_LHY M7C@6M)QS\.3.8'Y'J5-<@U)GC]`T$,S12T2^76`6H/%X[;T;%"]2"Q@/QJ[7 M\YV6,+,7"4-_-'2'_>YJ&!XH6VPD4B;#KCOQ)BW!O^<\>6\T/VP>] M5W'Z+.Z^KV&>OW?.Y-!1SI1]E8E*)K:$);U($+:&NS78JY77_X"/QYNH2-/%D8>_/2NUU\NZSCWQ[@6[GQ_N#^K>I7^H^X40*YD>.^(77= M'KD2!TD2SHUN1Y^XO[F5X'Z:7UQA*N4)_+_GO7&62<3_\,_+3V^3B+;H,XQZSW_^AW\7^R^]2JKY?S^3^*(:W&D[*6 MDFJG3F,`#=7,_3.Y"NY2ZMN#XQ>S8%:6?Q!#S\^0;]G2,YGO$+Z\[]@QRV;3D/K;8`)NL+9YX$W^X M_1:)9PD*O@SB(`,U1F@W9W*.WO?4N%0=\23/V!Z`.^KV>KV)8)^/W\H3GNAQ ME/WO?_R<9G'T'O^$'_\?4$L#!!0````(`#0P%$,>ND'#"`T``,*:```5`!P` M&UL550)``.$/A-2A#X34G5X"P`!!"4.```$ M.0$``.U=2W/;.!*^;]7^!Z[GL)F#+,E.,HDGV2D]:`]K%4DCR:[)7E(T"=FH M4(0"4'[,K]\&1/NS#.3]^Y M1J.A,-D-\EU"KR?6=K+[(%A>-)N/CX^G/GFP'PG]SDX=HC;=E*RH@[9S,;RX M_]9N_7BZI=[ITQPX[ML!O'[6:I\W6Q^:9ZU9JWWQ]OU%NZ4X?V`'*[:=O_74 MBOZMR3]YV/]^P7_/S?#=S=#4R%#?OTB;DG&^6'&J3$0Q,T-_C_8!O;IS+; M)POD8H=;Q*+)WVX"1*L%\KD=PT\?/>(SXF$7#-#MVA[7\/0>H8#)F)02EL7ASN1C MFX)*[E&`'=N3L2BGK$*+8*8!XO`Q,B=+'I,`-K;R[96+X>TB>E6HJ8X/ELDP&\W'%#'N4"K>ISY#63P/\(\5!FT\ MP^.N"*1"4)^#J)13&5U9_`U)@,!_GNU;#S4FR..H@CL%SS(&I82E6>YH>&-. M9E9W8`Y',W,Z[GSMP.\3<]"9F?UQ9S+[*C59]2G*XKJ/*'X`BWI``VS?8@\' M&$GCKI"HO$BP6.`@=%JP+3"K`*P+"C4%_A1(R^)R&A#G^SWQ7"CP^FB.'1S( MN!.0E,75&&I'$+GC@',RK!)Q\BE*T]3JEJ$?*P#%?.#(2-64,[[RB#+CKTC9 M4R2O.C[W46!CCPUM2D.'W#=>Y\U3N;:C!^^M[@3]H?A55GCAB4JLI&"1&V!X M;IR'HOP7G*;2O%24]T*35)@1BO)=8(KJ,D91IM5G$/$,"R-GY84E[@#^WJ%` M3P$\XZ5>YXR_>@$,+_-96JU6VV@8&XKXKT!MF"&Y8<7I*V1L1QN'6%D&/3!L,*F[<,LK7Q!%\J2`,8/J4,<@ M%*+!YY-VJ[5YDDV='4-*;RM%(YILM5@;;0.P7VSHYY0L1!J/M$OV$2:.#'!Q M8CPB?'X^M!9`5O_K8+*[G"8+ MJTP<=%/VF/*SN^"9A]H`ZG=>NR_YBE%868FIZG<$(3`J(JOA5%<)*2I0CL/L M8MMNTCR9-;;>I2)=(7=J>S9583]O?/WA*Q^$]!I1(+)VQK59TD8[TN#B:\]8 M2U'$](K/5'_L*X+J7FK2#F_+#Q!%+(@$D:*:-[[^\*Z,G5AD[1#*.2N2(B6C MJW_C0!DQ-15HAUQ_A68D=CJI$C5%-/7O.B@C)A==.[0*.=:E?0Y4!P1`+&4.2#^W0S11=SGEX M.Q0O.2$MQW?Y_MU?!MO=N;]^6`-[*J?(-X*^%8DX/8- M9I"Y,=K.ITES^Q4EC(TIF8O2PLZ@.A=XMH?8!#T@?X6$C2"I@?6'O`Q%)WT_ M6SKM4E./L&`TOR+$95.(5*(546)@_6%9CD*.=/K5>5$H\>^BIE_!;G#&T!H9 M7]\ZXT%:[+@+[&,6K#]N%3$G"$,RPOJ]/!>4A)4IZD`[WY\@AH`=_I&:/D0J MCX0=:E+D)&3UQP55W)3DUPZU/EI2Y.#-]1R=!:%!=%N'Z)1/0%3_YHDJ8@JR M:X?7]!XJWZ[-D-LC"RZ=!*J\\?7OLZBB))98.X"V8ED^+"'0`(H*A>P;'ZQ1 MJDK+D$Q6&463ILMN=:'R+5.[2F](?+(KES3A"D@TZ(B4LI\:6+^[2$'(:864 MUP8U6U<\(X[FE]BW?2>\9X6%MQ'U,5OWXPJ.6)1GJ#]`%(6QJ';TP_>ER>G* MQCZ/B"/_Y37A-HH":?V%8%%$E?6A7=711[>!Y<-2,;SG(]:(HQQ7U6>HOW0L MCFLQ[>CGJ2\URR4H8WT-W`JD?]DT[J(YH6@];F8_(68^!=0&,"`NT6<+U,EX MGPY0@J:]4'%KV46IML*'UI^V#Z#3O,(RHP35M&H^O)+DSJU;\(7$H++82PRK MWP$R^4[5JM7CKQN>6UDBP^LB'PD/P7()ZO=?=8QSY95DPT.?+^]Q&?+V./:= M^G$LOQ;*N.3SU7@$RR\V`C[&E#Q@T%'W^9HAU_*W>:3C0&&Z[HS/\$QA*'K5 MO'\'VWT4.EF0*GXY(BIJ0?N;E7QY?!F=VI,T0*O%OGNIT"JP89`%;ZGK+3J'>_: MI\CV\%_(Y1M3Q+^T,0V;\3E?@@OL$WY9?)KZ.WK+=]M]E:F=5T/J!TD8ZJ/U M_Y:?OAI3N&A1H*[_T]65^'81U1T![IL[.(4?_)60U?_A[`,AG:&L@]W(-_+3 M-T3F!&LAA1I8'XX&+*G`VKKBS@%")(+0"7,(U!#]>#2(RN35%%"0WD'(#7<[ M)VAI/X<;0J-YU_:_CQX0=:D]%^&K2J^\(7%D>!?3GW;P9]8%\9OD"M93NZ2* MH!_=-I2RUHX#[ZP[YK8*4KICY973*MK)T>UFE:+M(["AQ%UWDBO_5:@5+>)X M]L\*27\TP.]S]URQ610-X>@VV_;1Y1$8Q.Z7+Q0Q@B2E(O#'LQ6G++G2*?3? M/7<<_:/;ARNA,Z_VWI\LK?`])K:KE<*G\9ESU+DTCA9S,Q+NS%"4>RV]8'E< M8`YMS^P%X"97PX55IE^8RU'"MM^]Y!X4Y7FUV22*?P_JK?@K*`14VEI[0:"% M^T'9JJI^]]UB;,7O$AG-4_[FY*1*E-HVG^R)G;+@Y<>LO,X3VP-.8E?1 MY76>I,=IVWGR"G!RU:%=?13W?[6K\E$5 MT=2?^N02I1LORU@,:?JAC[+4(2J4-?VZJK)$+QH2M+K";43O;#_J?(-%2M=F MF(WF8UB/\V\@WSF0W[;6O^??,XZ9XQ&VH@C^&$VN.D/K?YV9-1H:G6'?Z':F MUM0871KCB3DUA[/PG4JO;AM@6%ZY.'@&(:Y(^-E_)+D?6']<6WUK M]C5D_6ID#:^,WFC8,R?5LAQ/`(UXP9SF^4.2Y^%H9DZ-<>=KISLPC<;$''1F M9A]>F,R^5GM%WFAX8TYF%CPVY"%B(6(@>GZ2_8])]F.S[(I2*>_BEK\-M^U6 MDMN^.;%NP(1O3+"53M<:6#/+G%9\$^%B@8-P0X%_;WD83NX01)DLAMMI]7[Y M8LV^@.--0YL&=<_`JLUAKVJ^XS=7)B]7W?)[EN1W.AOU_OO[:`"*GOX;U'UI M]:Q9I7R.87@8L=-]1ULVSY-LCLUAGP>'3@\"QM2J/*;QA1CZL>)72_$VM@SD MWZ8T>=V=FG]<`_*&>"S?@K&?R^*Q+'C#?K::J]\S,O&]IT M?2=;6IA4&A0D$N---)^QG;!:L7*AB?A(BY/*BV)LHGGJE4*`3J&4>7!XBH]N$R9Z54JT9EBNCVX.!FI3"Y,*A5GIK:#RY).=W)14EDZ(_WE"Q*M M8_B/6UA1P2O_!U!+`P04````"``T,!1#TX(J)MX(``"K4```%0`<`'-I;6@M M,C`Q,S`V,S!?9&5F+GAM;%54"0`#A#X34H0^$U)U>`L``00E#@``!#D!``#= M7%USXD86?4_5_H=>\I#)@XP$]FQ,QIN20794P4`0=F7VQ26DQG2-4'O4DHWS MZW-;EF2!OK$$>/W`@.A[=RUV\_/SRHZ!(U^,K);WDOA]/7>LD_4"$`]T M%ZYW1*G;%G]I=\29*/5./_L,(Y#` M9KTU(Q>M&*OG[@EU'N#>HM3^ZV:H&4N\T@5BFVW2%36+PY%FU^==M M4--;89NG/+P2]X6`M,[*APL4?']+!R\N6CQQ!)XEXN>NR&_Z8QE;]^41^[:/ M%H2DO3/./K49M8@)N6I>ZA:/L+;$V&5%(`L-ZT*XX7RB.Q"2)7:)H5M%$(LM MFX@BI*F+N7R,+N@C'[Y`-N;9NF<2^+I*7$NZ:IJ%H;/EPJ+/[R>1[:DN#F/G M0;?)WWZD9!LRDQ$V7DPR"-5T)?"5,ZT*IN=3XMJ26"6O!`5X0@[A%Z'),ZD(U@64F4)8- MZ)R,E!EQLBUJBY0W9_B[!Z(H3UR9PC!EM&]\1)GQ*X7P2IHW/3X/L*L3BXUT MQ_$[Y*[C=9:?QJ,=W'CG<&_9[PMOZ8!7=E3C2@KVPRZ!^\8Q5,5?T4VC\U)5 M[)6<-#@C5,5=P45S,T95T.4]Y&'6'2.$G=8X#B%C-QUNZODV^LQ'M@07CN'- ML6`26!0P?W(+;A2/2^2%V&X;FK:#-NU4!\WCCFXFF'2EDXJ@D]9[0.S?25CA MU1P[%>%NFC:/5;>L:@A]@^9QV=25JT(+;?::DWBA>Y:[QTU18(M>C=&GV[#@\7.3Z$M4O"+XW=W@HT\;?ANELTLM+.)WFL=B^!VMN%JLW'_C]_'0PBS]A,$^TKM MJ[,F8>;4ZR*4W6V4$V4TX,."W(>A0E.;'LPR*W@1PM-$'&\O->7/6Y`=*7=< M_(,,75LEO`CN694!#'UZ==/H'%ZYG!=Q24Q^.?,'^A3X0Y'#1EF5+O9%;!*S M8;XR@9^?P[/UD(1%C0WD%C_-+9>% M5WB1I".(4G":_V-P^3Y:)$&XL`IO(U:6/L>6?^_[H'%:V_810/<3O`3LH-TV MY+>4D9T0?+!1++D;?]V=]@R87"#)%,N_&^QP\0-_$R);.'15&,\@=C2703S` M`*2%J`/SQ$5+$M^P0`IB\Z+E.EX*Y3VJ-,!S5[49X.`$Y#7)2;"TMK6JE5I! M*U)G,^BT$'&F.D>D`_]=U2"HQY53(VY1JR;)`F&&(#FQSA,E234I34?\/]'F M7DIA4I<\8:ELQ^'NW?KYY+(D[.XJ8?((P?_]HH8-F,+-V+G3!`@1QJCSPA<& M75'#CZY?)K;`6KP)*L8)Q;BWW9S=UZ[E9G&[E$XIW8?60:SN47)'&:7.#=Q] M"8;2NQ1,^&F@)^Y=O712F3,)M8YERX9QG'=FV= M,,W5?=K$\,%$S.25.1D>=JT9WSC']LT$LQ&U@:H36R8DUS9EK.^E`PVOI?=L MY5GL:28"^$^K$Z^%;?2K9\(B#G@KR.<<-E M4/4WKA&K\F?"J92.I?"52-ZBNM?P*,XA-C$5'$:D-CZ:$XD"/7+K=!_P;*+O M8/\W.?SQY/R3B63+@YU+Y$6=%H`^UJ,)O[!\16Q8GQ/=>OOA%D>>61&(XE'& M^C!'%ID*;'>D\@$XPL.+IM4[YD.-&A7>Z_'&V.Z-=Y9)&JO.M>T$GA;>@^I_3##SBJ^ M!,]9&.0;WI\?0_6Y:"%7AD26<(>>?.(\51B['\Z/0W-OD^EWIY-9M"TX\H8Q:-XRQ8;V*/#2^7 MV/9_S*Q;KQ?Y&NP*5E">4[J#EO/V$36NP*SNHA*^WSIIM>?.PVIBI^1#&_NNCE9Y&CWBDGB@(_4)B7U3J?",>L0D M\:Q'RE,4V3R"Q.,O_/]V@RO_`%!+`P04````"``T,!1#2^?S22LL``"E80(` M%0`<`'-I;6@M,C`Q,S`V,S!?;&%B+GAM;%54"0`#A#X34H0^$U)U>`L``00E M#@``!#D!``#=76USX[B1_GY5]Q]P5397MD>V=V9U)Z>"R=I9E- M;BNU19.0S5N*U)*4Q\ZO/P!\$4F\$*0DH'7YD-V5NYL/@`>-QEOCCW]^607H M&<>)'X5_>G-^-GB#<.A&GA\^_NG-E_GI<#Z:3-Z@)'5"SPFB$/_I31B]^?-_ M_NN_(/*_/_[;Z2FZ\7'@?437D7LZ"9?1']"=L\(?T2<#'MQ># MQ>#\X_?O/YX/-.VG3KI)2ON#ET'^OTS]CX$?_OJ1_M^#DV!$FB!,/KXD_I_> M5$KU[?(LBA_)MP?G;__V^7;N/N&5<^J'M"E<_*;0HE9$>N6S&HRC`-_C)6+%_)B^K@D[25NN`PJ*_?84XZ483!#';ZG^VQ`_ MDL;VZ(<^T`^=OZ!$64>H$OV%`Z.?8KYW=QV:3UR:W8#ZBRCN%XC="@ZI>/.X/WE M@)67#4[#Y=(/?()^NKR)XA6.1T\^7HY?L+M)_6?RZ])W!40"S06P^'IE_F;_RQ-H.D29480LX)* M,RBW@W[.+/WCCV^W2/IP,B\M*^G221Y8<3?)Z:/CK$FQSR_>XB!-BE\H>R]. M!^?YB/WO^<^_W..`.6GBG5\7L1,FCDM#A>3JM?J7X8N?-*JNCP$3#.Y?,$KA M[MK6.=P;)T;_#ZO[.2WOWK\L8[?XB>+7N7Q4`PP,1*J[[9S(P:#`CP4Z8 M)DH:-&1,TD`(KTJ#F@`8&HA0-6F0RP"++&_(V)3B6_\9>Y,P)7AIY#Q,$IR2 M:>=GYW^C>!0X2:(8,#I9,,FE'D6K,JV#.A@>=L?<9&EFX9290%L;*#."KEX1 M,X.8'5`#G/[*K9:&2:9JKLYJB(-A8O<5V.-8;1U%JU44SM/(_57-+5[.**-D M,&L\:@K!88\$&<<9)H>8(`Q^T!,*>$4&^O%O&S]])0#744C'?=6*C5K'Z,J- M#OS:"HY*`0R?=%`VN96)HJTLJ-'N&B]QS)935VL<)NQTR#".Z;23EO,G/WV: MA)[_['L;)QB_N,&&+GG.GYP87SD)W4IX7;$*"+U9E*0Q3OV8:5[A$"]]&B\L M_#0@GGMK1D%A>W!,]@[;E5[M>+:P@.G3EBN@Z2X*..@J"C<)GA%S"J*EFAK][![=8MOT6B3I-$*Q^*)OU3*V`Z:'&*Y&<:+6*>B M&E>3(400N84DL+`VFQL6X!2.7B1H=IU0!K2^6-B4LLZ55FC\LB&;9V\)Y$E:SN8EU$T) M8^TLAE8VV*J?8C30 M5S@)N\+-51J4]CU#*:)2:RM=_#CC^3L,TC-26,>20Q MM-(CU?]LG19R3,V6+X2T/!*<@Q\71JOX&<%)SH!8K^QNV^SP M*EL(3[+C?N@P:OR"8]=/\"SV73PX&[Q;1.=G[P9R']:B8,RE:0$O/9Q2&H;# MTX'(K>_F.FA-E1#50FF$_H,J`HO2MHM6U<4N]FLRW*1/4>S_$WM?0@_';"MD MNJ9_I^M-R=5KK6[:3G\=Y$MFCYX>K*KJ!U?W_AGK/>GP99-V02:-X!V:^\FA M"\JIW(6.2[$)X59K6!,`03(2J28U2$8 M_%`@XY?O42:)+KX'>85L%&,6Q]';;HH)`"]F]-B:!&3MU%I#QCI56H#QEW37 M49RR6X>'WM-[?XU=QL$V)R$4-.@E%$`K;D(@9;WQ6Z$)'$4AB][OV5/TO*O] MXYRT3HY^\*'_Q6RQ'3"WL%7%U+YR+3("@X0[(.]SF;JTAGZD+!Y\`#;>T5NX MDS!)XPT]TZ4\NL@+FCU4*`-:/^[7E++.NE9H_![X0XJVDG835/RP]=B[^#RA M&3`N3U%(;8\GL&&=>CL"[^/ORD'[ASV[NY[\?3]8^]O0ZLG6RT$9+^S(69DE,,Q5%U6;OV(SQ\%B)?;= M@LW+@1E"ZY1-3>2N%HP1N%_12N)V4X=!V%Z8^Y,;3-E MG[)ZA6WGKMH._"YM(@)%Y/PSWX7KD1^UQN*V`[BV46@/.W!787YM); M%.8YVQ8/G5^P[()$\;Q_X"LP`B;FE190.]SE+,#@;%_8?8+<6@;*<]N/4;/;SWL9WNFY%^:6Z7DIU\R%/?X MT:?(PY2^L]0HM5S,!*7:0%(&R62L$Z8%&'>>-:/$5I8]>V6/%B/"U=@))J&' M7_Z*7Z6%X^3,$D,"L\Z,AA`@:HB12;B1"R,FC8BX#784?HSF.!<4J_YG4UP0 M@2HH4/T;B)87`)(.%E3&9BN7[Y?1(XN*LC3D3+>[$&:3`#4A4$P0(9-2(A,F M(83'SI':8,>0`/$HF)O`>124J_%W4VP0PBI84/LCB-87(>*>IBID$!6RT=:C M31Q3C'[B.L'?L1/+G8%!%"SAN23P31YD\H@I6G4,6K/R$ M@^"O8?0MG&,GB4+L39)DPZV\:,B;#2=;8-?#2HDP"!+I(.2R@B3%Q-1!5//T M5ZJ*"EV4*?_9'JF^1L$F3)WX]<8/<-P\U*N0,TLB"1I"@$@C1J8B2ZF! MF(I%AN3.,+MG0U-^LD>CY=,OB;CA.:P2=&,J*Y0%Q!XE0"F)?I>@4B-_Z1OE MEBRRB;%Y1,;1QRB6KX`TI,QR1PBQ3IF:"""FB'!)5CZ8*"ID+;J7;6[Z+"?& M=)/2%]MI=F%YCU`J&78U&@5H.!R%!B`R:<"4K:I5WA$X09DRJFC;7'[)8OIL MQG]#?A.-9`I9T\LP4KC-I1A.$`23VM!)EV3RJ5>^,L-4[+.&3@3U.%.1M,,8 M#JJ8+Z480+8TL;5QA4W3]\Z4/;Q=,EW>^*$3NC[I`5'B*_:?NZE:>M:YUP,L=P2B4*4O$93*J-!&/Q?Z0.[S9@^0M="P*622<&*`56K5)<"0 M2`B+6X1F0I"HD$\-M1C!R9HGA@0NSX^&(#":B-')UJ,AL6;D)$\TJQ/Y!WW: MZ=D)V.LOZT3@JFRI_AT,.P2@^/3YNL'GY4"B;=1SOPJC.12UNGEC9$[MWX3!;A3!@&GVJ3`9T)@\4I M5^M4RR@WTBAU@EO=>9;L*4%J!$&<92!8-.RF=]_-.A/NKN7B7@[0-<,L_66]-,1XNQL@$]M+7I6]. M2F^&1M;S5T+*=I^UK4!B:Q]@$NW MJ7/ZLA$W8E.``)IGG(0I)M68YD564UXE!I@2*8%4Y7>-:2)V'*R`=J(N,:Q_^S0 MUR*UQUVUBMGWAMK!UU\>DLN#89H&2'X!M5"!-RY>;_`BNL>!DV)OYL0:]%(H M&"57*_`:M:32<(C5!I&CU0:C-$)QID*<5PR'5OK#H_4Q47,@A#SZZ0]Y3+*, MUT^;Y#E!;KZTP6['0SE3ICWVV1[Q],8YRZ-;ZZ*_]L!6/QP$;C6LVBV$CI5, M?.](HVK[)QTCMER7?@%E7JW=`DB'IPV[HR^$P>'*'.4V"A\7.%Y5"]\^'1)K M69ITJHH@F76*5(SRD`!YB!*LUCA;6AMF6,!3NX*D=5<*,I MS5SBIRMV*2ZDN?%I]B0J!6Z'7O(Q4',P*V8^3=3:G!%NIK.C`H MUOG`!I0C&MT.91S!,8S.!R\`'[28$5N8!(+9:1+5Y6NAI-EK`5*H]=L`G!@8 MYLBQ":X;99(HR;)A_J9Z']'YR6`P0$F6)R?( MI\E!O6S#<9L\"SD)S3'R7YL0%R\"73*9\DGMRW/VZ\4)B?:3-7;IHFRPUQ1O MNPVP>5(Q988`3LST4"H"V1P_JS)@N"D!)AHIHU#.RHMW`\I+&3 MO!]\8-PC__G]X/+DW8_O=V$M3]HS&*P=>AZ[?>H$,\?W)N'(6?LD?I6=/)!) M&SW[H89<.^(A%@7#:#4^;G>]E$;LHJ@$IZC8ZB28>D7Y"J;VK7`N.FM*$*S@,5@LB#-*G@ M)TC:,RG;4U.]*2FL53,I/O'B&>#9:-L%A_9E0XD:I"LI+2NR0AU8A--$V[IV M>[A;*-*0*\^V.8K")`I\C_K.*X>@=/'\"6-ZZI=NBCWAU'>=0/7:9V]3!D.U MG0I;">-ZV;$^ONX!O&!7JC2"&R"/\,Q2[&N MM58E5[:W!-A6(/FJH$S3.F=[P6U=.RR79R#2,DOS/RS7B+1JA%>R1T-9`>3T M:VH`I9T$9BO=N&4_N+1C[VAUH5RA8)MN=>!M5,ND0=.L!E&78MF:,5QZR=^D MT=:R333)JS2:*J`IU_XNC8QWT6'>I-G+]EC',$]+T](F6I<`3T,-#!GUL:IW MWX#%==S#3ZU!G5+#$NETPCF%.$22:09R=7(!C>*X8BE#.*FT57+)@S>)*%Q2 M*<,V(:$@Q6P='A'44[%*JY90#?3S@1U`:K%LCQ%:E[7D\L=DNIRN<>S0O6%9 MFM3^9NRN(>L54KU^K+9AG8X[`E>N&V\MH.D2;6W`<(ES)\#)/7[&X0;+DT5S M4D9W;<40:UNV=1'K?%+C:M(E%X"4]'D4)>ET^2F*O&0>!?)PJR%E=CP40JP/ M@341,+00X^*]2,*>"7RD:,IB=M@US(3RX3!>)0V MA%SR^$*^>.`$2#CR"8<$6#`,O:&W\D.?%H(>\L^;5I&?9!>$6I^2:T" MAF5Z.#G7E6FQTS].30\&Y^YQ@DF%T@5LM&#QC"QQ73H*]4;2BQ6#S0-G,02)L=.*E!%R;?PDE MP7!)"4]\V-^M",*@SS5>Q]CU&2+J@5JJ05TO!0A;39B@$E#@>0>_^!KAC02BCH`V;1^2X*HWHQ\E[0LG:@H6I9QEJ4P`QQNDC%#]/Y3`-]ESLL(*M5U7%ZNKSQ0R=T2?'H4BN]VW+M M)UD:=TF5Z*L;OO4*AKVYV)M"M4/5I@9XN-*IVQ*W(F`WJ,>HMKD^.'])@ M8QIN?Y/O)6OHV4G,WE(,<79VB1*805P7:9-U7\(8.P$]!X@>B2(B;G+I^/GY MT\QC%D:`!)5Z;M&J]]-P5W@9Q3B36S@O.!F_D%E4%'LD=HU?)RE>)31- M,]$D=1BPBLEZD;0K'O"+9KWBP:NN[F$/]CE8G>SP!>6RB..T[)[LB`IZ8%\H M?DSI-R#U5U+HW/%@L8<0O77%NR%C M-&00P:N%"54!6%Y+!*W5S\!@19'1J[C4=^4DOLL6HX)-*KVSU*IEDCF:1:AR MJ44%C,_1P]D^I)'1,[MU@D[1`[61G3;)K,`@XD_8?WPB:(;/9*1_Q'<;FCEU MNF3%KERPT>-G7V,F:;M;@:ML[F<)#,EW@M_D?F$,.9DU%#)S=/6'OW:%O$U, M_T'F:+2+^)$'MW^45W*FRY&3/-T$T;>V8\MJ%;-)#-O!U],9RN7!\%8#)']. M*U>A?*1*B&FAGPN]?\`@&QE!*+I9'#W['O:N7K\DV)N$Y3[^D.:PSAX8$TS1 MVG;$]V3<<'2ZQPIIA+5[L`RF4^RU.-SMHN'\+^CF=OK3'-W<3S^CZ6Q\/UQ, M[CZAX6@Q^3I93,9S50>",WVY@-1@`ERBD)*&DC#,' MN%:21:1)PQ9G=9A/F$)3'E-5Y'B9]. MPQGY;(B]H?O;QD]\V?*$4MQ8I*@!N@P*%;)0^*&)4["&135HI+?.=)"S58+J MC\@DF;X1VW:SI$W-KE<2%T+MF.HZ\"ZC:.$5O/+`7OP%=3FE,7'/^XE\^)-( M6[S-U(2LN-54B`*:`:CP29P8D%A^%D[&S ME!))5]GLLS1="E1_G49'$PSK.L%MDI`*H:B0@D%%X>PDWF!O[@1.IVB>T[,^ MH105HW4V656"$KEU!2R81U(IE.1BB!`7\F2RF/?.,IC#T&,)2LHE'OGB\YYL M6J=NU^+K+9)H&#P*RG\&;,$ONZEZ!,M^1>"3EU^>M4%/U?:ZBZPP M;S)76VJ]'C.<0O8OMN%L%=8MV] M+*)SX^R>"S6&)B$JS:$AL..IDO+3C8&DTY'Q/H8`=`.-@FI07V$%S!I&;^AM M]U$F=U_'\\9]E(\PV#W+5VH6$=OPB#$I/>F*Z2O=!DG)'&),?F6)YV4+/QT, M&%UYZURPVNJ;MC:TC83.R+DM!0+JB40Y],S2TG^ANUKL]`<,ONKWT9T[.53O MNYO7/8K@0HZ[-9`H58\ED"CSO1[B\FQGXP`HW[-"-+I#1\O0`Y-^Q6D+5FXF M=\.[D?[E65N[@^7D^Y6>(-?:EFJJV-L)%(.7[__5Y<$04P,D?V(A4\FR^;-[ M%NBTMC!RJ*-6]+UOTE_P=)F]T;QY2-S87[,^DB\]B@X&::D9.WK5H1#E$2P- M'2A1;$>\W&F]7).E=6&WS)*J\K[6BV47#)V`8*X\`RXJG$#(W`5#&<#M!<.F MA'57HX3%W2PDIUWT6(!XDZCRFJ<3^IQ!',46D2W.R;50#+Y=;C1?]#%U&<2=(1I M,B1]+(Y?"??9[5%9X[0J&KZ:G>4WG*=DXM767OK0N34&ZB=.T0-^]$.:N)3& M:-F'_W\VX:6%)AR'RGV!;L`E#8CI>3"=IC.8_W*S7@Z8MJ3!UM8UFQ>Q6I%J"3#U5,$%Y-[S<=*^BC6@6D"!*-C&N)=%$%7,P&%MY MHV#F^+)4Q9R4E?3\=8C"M/R9"!A&B7$)_1F[.<6G^B5T^8C@Y>G?GI)4<*8J M8N/^E)PMV[\#H@H'J@=/,ALP.%*X4/K2"?G7[39JZ`DF>UN/V3)*[F[6](1I M'Y70#/MVL0F&\WLJ"#<[B\)3EFYRNP!`Q,.$YIJ,PF3GPTZ2%??*BC!=^L?> M(AJ1SVV"U"'![4T4SW'\[+OB5$P=E(VMT'LPEE+4+:T560E/6/;>6LJP`_&77:AQ@N*69+XCDN?@R_MDL>\Q(XP@L*/X ME>Z>B.IJ%VO&V+Q[D4M2]S<%@]L[X]>]3EMLGY4^NMQ+6Y=FV;8:.B6T7Q*' M'1^(\&SC;Q'E40HI>_'PANQ\G;:6,0+K%Z$D:KL*#$)JX^3#3[HE2[A5JJ*M M+HRIV=4F\4.<)->X/(]"8F[Z>%$R7F070R:G7_T+ M6IUP=;=BG<([0^=8/5V,T3GQB=/[3\.[R?\,%Y/I'1K>7:.KX7PR1],;-+L? MS\=W"_87&#R_]7_;^)Z?OF[GCFV,5JN8Y*X.^"I+5?)@^*@!4LB\"\*\V\E_ M?YE<3Q9_9[3[-*7'@D?3N]'X?F>ZJ4;H/!2I'BF5D4A7R>SXK%.`^O"LTK!. MI4XPA62Z)&2B_S)'L^'?AU>W8W1Z/[X=+L;7Y(?[Q=]A.*\BF[R>WY)*FWUP M1`FYF1P>LJ-2XQ/2ZGM"*^*/OH[O%Q-*JAK%H'"JF,0G=)&UR"[>3JXV-;,L MTRM$G6YJ'4"\TP(J).`[0L#K\?WD*PG!OH[)>#F\FMP"NC-#5YW\[-4H>OJ# M'>][Q&2*5%W<;^-B5R-&=WMZ%;"VM]/)`AC6]H(MY/![YD0_?YXL/I.YQ)R% M>L2IT@OKX[L1&"JS1=BG*/!PG-`C3"E;BM)G<0=]LV_@=BQ6_4%<364PM.V* M6,C8'PACYXOIZ*]_F=X2[SO_'?'!-Y/19'&@2A*SFAE=,1I;BQB8@& MZ'(*HI"USAQ-@$*B_$B(,AO?76?76AES+G3U&<+G"\ MHK/W5@_6JF;4D6D6HN;/6G2LD[`C4.Y(=:Y&CQ_<[?.BH\2YE8O39`[S*:*O M5-%VB\-KG#I^D-PY<*]=ES%$/OF69H8FE81D&2_(6,FB2N M2R:A>QNXHF!22\U81-^A$&40KZ%CG4$=@3;9PS21DZMF27-&M_,Y*K1/Z)7* M$W1[.SJA1WT1ICE#B*R''EZ14ST(3"D(W?^-`B=)_*6//754W\D"#&\H+9J> M4^34K3.[/V;Q\EQQJ-U,UL);G!3SD5D4R]Z%%4F96^200MPN8W`BUFFAQL4M M11#!CR@71>M,UE+R$@61,WS#T.L;TX@L&,Y(H_$B2T_\RN7VTST_SM)Q-Z?+ M@F=W&]9W>+07/+L:@.%'>J+NM/^S]Q5/Z9/D#^DD)#@W=%J:W^DJ\AR("M^B M8/!9<@W@E8?)%=(P6*4#D;N#5X3@].T^I_%@&HRPNEXLU0*E4-+TZ6H)U.;) MZH:8=0:U8U/M_=U&X>,I(<"VJ-QPIHRGN^1MB8Y;5`P'RZK6T47*9RJH)SN&E>NXSKEB-+PG M@1);2O=FF%1AF#J/>H.*VH`]OZ!3,+FK4&F#X6=GR%R.[E*`#EGEJ[`D.B8_ MA%S2;HC\_1(Z*[J8\$_LT3/0]/EEK=H2ZMECJZ(8BY4UY0]>G8KK)RQ>G:`DK@3^":O MMQK5A$7+3"?)WMS8>EN:Q0@(ZXMA9?RRQB'-,BY]*THH:2.)I@"J*)=F10P, MX^38N*=ZBM$:9Z('6\PJ[G;>^LZ#'V1I#3NLM78T8'"QJT?!*HM?';2MLZLW M9'X&6MA`%2-@SY*6:(?L!=8*Y&%:7E.^P_*(45O?SEURS6*)+Y6W*%LG;5_$ M3HI`5&P-72H!\TJQUJOV?"?=G&=G=3-/8+6O5#;Y]'T=:WSKR=@ M_GSBU@+*34!UF)4TG= MUHS?'N]?9.XN>7=3T,X&[%8,(?WI>X*EM+$KYEU<;1=MBQ?0M1VMOBH,/]L9 M+[^4R0R@B@6H7K;(;UB!.B,5^42ZU2SV73P,V,?)S\5A'!;WT%3S(8'T*NFW MNYNUD>5RUTH0Y;SL:]-Z5]AS0;@^DMM`:VJ$/ MA7GGJE29AMDSVBNC7^^0VSW"'M):&&$2;B=`SHKN/1PJ6JF"I>_G##V/E8(C M1)D`-]XF<$#FEGN$S&%D.^N72#WPGQ=/E312O<#QZ M\O%R_(+=#8UX\DNVG_'J`<=<(W51_L6+7&.M1K[%MEP0+]RH&18L)I#&S#`SC`CHU28)HW3M(T_P:IO#A<\ MWL])%!S30V22Y4/B)(FI)^(MSR4NJ+,%6&W4%S[`'M)6E/H*<-_V%%HYKC95 M%>&XVS50['/T,W.T+YQ-7VW0G'W43+KJ)JC9VN?Y4ZFY\'H)RJIE\E73A#[#F(?0N<7)XA^R^K) ML-::"OL%_;*/ M@ZIM*3YXM;VO.Q2@ZK\=*+R&R(^23<,9`19BKW*3B&L(A2RLAF@'"J\AOH0Q M=@*:\.V3XX=16*;TF"Z%*6NXUNEJ`%:3]40/KQUIR@"ZQ3==2F\3(-*TN,>88# M,IPZL5^>R,W73W/7+5Y*Y5JLORE83;IS.619))+<8OGJG5O8I&]@5W/^5EYP M9(\&G*(HNR-@FB-%CHTLJ8SB$<.:`*!W&\2XN!9B4B?%FW26*CD['-E6T[P4 MH.I6@!._<@JCYC,4.F0B!O=4FU;+\)4EBH4A.:E`%6W M`ASWK.56U#:?)4MD@C_#K&J=.C[F7<)+ZY6N#5&X0RC6L43V:E;=,8FJ4V%" M0%X*$/45X%0YA'^',F$T3-/8?]BD+*HDL>3,@>%\AJ&GUSIM.H#:2ANJPG>Q M!R4S<4N-Q/+TDMG+TA>.R94_`ZIZ$:IF+3,9E`G9BN/7F.:8#1_SESN$8S`G M!*B>Y=BX(+Z01(6H[3J?A&ZTPK>2O-P",8CU+D`GK_E,&'U'Q7]O:P*5/=3% MUE2FRQL_=$*78!M%24J]9/'0EWB*I:D+J*$Z0^:F:14#]"F*T@1B-MCX<*WS MY-D!V[3Q_I"HZ1HB@%I(ADSZ=-*X_>FD`];U711&]^ MU2A]6JYDRZUM_3"[JQR%!-R&X,N=;Q0F5W@9Q3B36S@O.!F_I+$3Q1[IT/$K M>X^7%,REV8:C(&"5P2>0,_`Y0-0P44J^FU?&2$0;&6T_C+9?1@_LTP7_V,=/ M4.WSV2/+)ZB.`$TTGH4_(%.O\3K&KN_D.U`!IO]"AJ+J0".BG(X>(.YT@LN_ M6+95/D&E.AMLJP:.Y:@_I%4D(3#AVL5(\_V7P[IUE@2J2,LX"8=N%FJ)U_.Z MZ`'J+)W@"CPF4T+?%>J_1WZ("@OVK@7(2U>\>2%9]58J@&XV$4[-]JJH'O/) M:B"N3@>B8-21Z8#I.;,8TR<,E#,]M0[H_B.!JMF%)FXMS*MH# M5E4)=+/)L.H/550=%?J0&HZ-H?G)(A*^LK,0Y8I>R^[M3@:A-WCG]J]^M7\B7NNS1!GBGNCQXV01L9E`3,\0$TSI*YT?I&3,H^<"UBN)9]#7!D2% M'J"Y<_.Y">H#QNC-2W"[[E="]*Q-V\/.T`=HUFE ML*?NFR&MB`YR:4!-K0&2NRY(5,C8RI20("RW>=XWNY)ZO8D)7S*$+%'"_,F) M\14!YU6WF=B90%'+]30%J%EW+8$X`51F$&46G%4LMR9G) MO.30)&1QFB(<@G3L_O5;H"B9D@B@2!$"Y.T\)(Z,*E755X5+`2C\_/>G>=AZ M)#$+:/3QZ/3-R5&+1![U@^C^X]'MN.V,+WN]HQ9+W,AW0QJ1CT<1/?K[__[I MOUKPY^?_;K=;5P$)_0^M#O7:O6A*_]:Z<>?D0^N:1"1V$QK_K?79#5/^"?W7 MQ:@/_UU\W8?6^9L?_5:[C6#VF40^C6]'O16S69(\?#@^_O[]^YN(/KK?:?P; M>^-1'+LQ36./K'BQ8#[[>GKR[>DN#M\\34'BCIO`YV1_%N0_AT'TVP?^UYW+2`L@B-B')Q9\/"IH]?W\ M#8WOX;M/3H__]:D_]F9D[K:#B$/AD:,E%>=21G?Z_OW[X^RWRZ9;+3-U\^\X M/UZ*L^(,OPTD[0N2L.`#R\3K4\]-,D]2?DU+V(+_K[ULUN8?M4_/VN>G;YZ8 M?[0T?F;!F(9D1*8M_B_XQNI;F1O1.?$#CWO$_)C_^A@@2N+R?3C$?>&-H?^Y-WY"?_2/V-HD^<'DM$^A&"2X]IR7M*(T3#P MP0']"S?D%A[/"$F82D@E85,2KC$?NC&89$:2P'-#E8AJ2AU6!#=-"(>/T2E] MX'T2P,;2R$W]`'Y=Q:Y(5KJU\%PVFX;T^^Y*B#DUI<,@OG>CX/?,4DX$GLD" M-I@.8\)X0&&B#\^A*9G[P;B962JNB:DN^&)@3BY]F] M"TE[1$*.*H13\JP24$G8F.<.;CYW1Y/>1;][,YATQT/GBP,_C[I]9]+M#)W1 MY(O29?$LFI*Z0^+@$3SJD?0#]RX(@R0@RGY72M1<3S"?!TD6M.!;X%8)>!=, MU!#R(4B;DG*<4.^W&0U]F.!UR#3P@D0EG82D*:F&,'<$E1T/@I,%F!Y'3-&8 MI=([1KZE`$KWD2.C-).@O?8>9<(_48J')-?=/W=(X@8ANW'C.`O(NOVUB(]V M:^=?7-O<&_3[DA=M\,J,&IQ)P2(W">![BS)4E;\B&ZWC4E79*S'1.")4E;L" M"WTC1E6A\1QD,C\4YKA]^&"-A#PE\"4O$W8N^4B]-6%#GAB@LEQ'V-RP6:J"$>_-/7T\]DEP#/*?\1^X(F?MD],\4?%G^.CK M0H81N0_X5T<)3PZ52`Y-RUMN"EKT!R?V6C2&H`"TECS=V%OS@NW<2M[B^"%; M?+>]61"N'&@:TWE54^9FHPI%BM8%$?8.P24H$KMA#SS_Z1?R+,-@JRD2A%/[ M4!!H;0*&I1X38%MN_?462*.?V63T,AU-VGH(`SX%#7R>S)8;?:,ITOKG-EJ_ M5&L3,#@@C<\EN@K=^W+S;S1!FOVM368OU=*$N2_3F*MX%3#/#;\0-Y8ZOK@U M$H0?;0)!I;NY@?>?)`Q_B>CW:$Q<1B/B]QA+22P;@(4D2&3>V80,R@KFX/E, MPQ0L&#]?!2$LKV2P;#5%PO%7^^`0:&UP>KJ(WQ%YH#'/SBZVCZ6S5`$%$I2? M[`-%;@-SV&0^<@F=Z3V-I0N'C89()-[;AT2IQ@:#@\[G-,JR0.,9:,X&:9(= M1P$GD8:(E`Z]JK,/'XQ!3*X[%M.0Q3S\"CX3=&22YEAPK%IS*]4WCPF?&J(1 M*33&XF'E@D:/Q^79ETUIF359W96^=BS5CL[5D;RA&R1M)73MA;$K1]N MEZ27=>C2:!)\]W:KFCDDT@L*%O- MC>5ZY18N@T&@JAUH7+ILQ@^;P#_=;VGPZ(;9\9/DTHWC9YBF9.=BQ>@@R8TE MB5%`T#HJV02BXWD4ULEL1#P"`O,];Y+DVDHB2TIE++-<`S*,_G8@U8OXH2!8 MK8&`8F366QE+-M=`HDR_72TOV'P>PD0J(O[:QOT#'QX%.\Z2]L8RR54LK-#! M)B\?)#,2#V/RX`9^]^F!1(PH>R,9C;%\X($O$J0#BIS* M6"JZREP:H[@=D97U`-@U9VEC8QGI*H!(U-0UXL-Z&&9YY9Z>#8^%!N;2QB@C M;HJKU7#RB5'5:9"&9"[:9/9.=Y#C:5E;)\UK8M2T MY[5@4S@!#X-^\80YGP`DS^H1%L\!BZ^VE?8.&=^J=K*CYRQ(C4X(RVBP"&I; MR5>&08BBU5ECQ_/BE/AC-W3C%UFEJ<;2]EB\M*WL$0;?2C5*-+<&G2P=FM]Y M`D=(\9RPB&K+$-1!M):U[,"Z%R4$3)SDTBL1%;7'XJ8M"5`9 M-[GF=J`CN(6H1$E%AT5+6X:@,EHX2]B!6NG]2R5F*9G0 MPAUE%%H2&BQ6VO(@U;%26L`.I"IU@KOT?&?:W2M6E+BU2& M!-6A'62ZI.ALI?T!3&]O:.15B3T,'ZP/:$N=[+CPKFD4I&5J!STPOZ.,F`_[DGI6TKX;#^T^,B\[9LI>2]^-*/]5 M%L,2(BS(^TC&U(M?9$$TTUUPG7V)!G8BSO:1C:D#W*'L/PR7_40FL.*L9HO.C<*JV_&% MH<5BKBTA4SG4\!:QHUO<5K#*/`^/D,:3)CO/Z%[+LDLUU:U_L@B/L[8$RB[K M:JDU&D5]_]>Y$>\;K.YSG]>[S]WZ88UOO?O=PDE"+H[P6OK:=RMJ<=;F9E4/ MO)<5MY:R"3NB^2K6WJ#A(,X,X6?+H"&)LY(IV.6XF-[T3?$=%^@JP]@(YJ+8 MC9,F,QH'O[]TRRH0M^E,7QS?$3R1(>P%+:MW5Q&P)8WI*^.-@+5N`'N!DM?6 MDBA8I[B6/>L0I"GLP*V0VZL^OJ&(3=^,WB7=>1@CVU8--\RP)B4R?8=Z%\SL M'M"V!%6-9D("TU>B=\?(QG&L8H%(D6IU1C![]M]J%H4T6_(.^YSB*FGR5I8T M6?V"M>BT-5CQV[D<7I5TR8L0@^F+"'52)2I.)M,D;DC8B#R2*"72"A%;#:U+ MB.#PVDR&E.MO2W?(DL'TFE*?C6DH':8V&AI]Z:0Y=`0&L`.=ZY@R-HSI5+8= MM];(Z%,HS:%2HOBA[_'DND?W>44F3&$6,8G11U>:PUEI%$OB,'N=/G0BW_'G M092]5L5O)>522V)316@Z^:$&@%93R";81F!+D(&7TNS`^!O2K%B3$C0%F>E* M?54A0UG!#L"RQ'2!(S;Y;TYP#H*UD1_];'!E69;3X M>_$LNT34"=BBW(L86SP'XP43\=C0FBK6C73;SEQWR%W2B\`H:1X4RXNARS(R MRI4)GH/Q>HYUW:*JD5Z#6RR+G%R[0<0'MT'T\IDT8XX@-5XPLKXC(,UB1Y^/ MCN':H:HM!U07H5<;D4*#U)B,65`0LBZ^2C,<^N3[93EQ!39;W.U.0=F7>>D% MF=*8+-I-W"?"ND]@,4`,IBOQE!'1"Y<%7K:$#=-$=O1/26BNQF:SL",M9$>$_I,$]S.0RH&5IWM/ M;M+Y'8D'TTSPPCDY-,IU^9DKU]DL^+O9T^ICB)[+9M.0?I>=0OP1?PJ1O_?8 MNN+\['B(E\N3B5/I`=X2*K/C+1=H&-/'`""_>+YEQ.]%JRT%QTN"QT49QI)9 M)B(+WQ!_4V<=4?B)QO(&+6M'WZ]W=J9M@=\L$M6F;$8K`_TG98O:;+ST,"SV MO"![=_5%X`E%6@;Q"K26;S-]NU2K[^@$R`X7+)X)@9]#4OMXC)C:])U6K2B* MC]BHS&FR9*JL<);BZ-JJQ%2M(VOZ7EC>`\@"UQAS&9!^D< MN]]?2FKZV.D>>P&T(6T9`ZS;U]?W#/4^QX+:)P&:[--OHYBX(;]HS/>A:73E M!G%V5YQ[9LGS)((NOSH;T\=C]S4BU#6P'<$/Q@#Q&>F0Q;\%]?-BG>J5114> MID_G:ETO5#>FK4ZP?-%-6CE5J'49M>E+YC6P48$K-M+A3P:WM>W!`!;!MTEK MZ2O(S!WHU><%)7:Q<&F7O_H]B(:A&T7$=[QO:;!X%E=\R_K"C7X;0/?BQ^Y4AA^6WOC)W9WAK&8I.]`MG4<6 M'\2N.-->)S5^6E?//+O,/J]QA!:\I+TR(>J5LAW9FCN$JW^I5L&NK]&]-A[\ MEE[.P5&;.WRKRA'SP76($GU%C5TTUU>)D[H=SXJ46$S>Q8_0SS-=J$9CFWF(`FX-C) M,\_$\2>B>0'8K,*39'U;@0<6XWT?;L0`1FMK_5I25WCC-=$SX+UEW\<9JWM+ M=9T!-N8*$HL;OIJ'&C!#:V_^?F" MZ$2R&X+DA7K_`I1+VF$QU9;&U(>IT"KV]:PW-"&2""WI6=8IL"AJRR_NK4.YF`ETS*KQO[/LP83.^T8S5#WU6GYF`Q`'U-Y-N8K^2T6!]1EON4*O/ MJ*WU&OS!B7S^#\]W/,)(&"7,`9O&\3.8*CMY+7<-!#GZRMK!>@G:AK4=YB'S M0UALQLG_#[?Y>H9WG'VG&_?H.-P,C;A.-[(@`SE.'Q["+%OBALML22^:TGB^ MP%1=60++`.LZ-N6%*EK'CNELH>C:T`TDE6^V&F(ATO?6:T5["PJ,K2MN"RK+ M0Q=R2(JML'AH2]OLBL>VRG:`L=2%ER"$'U]V#2*_9"3AMUM#RM(84?5]=\Y8 MT/4]V+L3Z$V95E.BM9!46CQ_.J&\XE,:)BX,]5((7[VX@\Q6M])AKEB\HXI%%,,)BZVVU,Q>L,7;5!/*V MC,ZSA_E=\]SWEM?.84DP#QBC\3//-`K`WH4A%G-MJ14=F.]N82LJ``[B>S?* M2U*`.7BQ0C:8#@O?L1)W5?GO7:O=>C$2_&O]V)KW!35?C(J(*SG50480 MQA!6Q$IQ+[1=/&JR'2P_;0;+S6#2';>&SA?GHM]MM4?=OC/I=N"#T>3+ZXX6 MF:"Y,8NVE,7`2DXYW6%%`5(IB^(`.OG/W=&D!YZ;T9$ M@CU>Y->=_Q'4%1Y\XV_=;BJ>(:*#A7E@88)SB!6Q`O/8P6+RGA\-S?;![XG MH'!9U)QNCR:?/O4FGV"Y/\Z6(S"Z3&!!TKVY_"-X<)LK8O-7&FBJ\CG(P*IG M+"O"+$L4SV@(5F4=,@V\PEM.J_`ZVPRO\61P^^R-_DC MK#`/?[R8FY].2;(L;*6(JL#B((.ILHFLB*,AR1[8*:O1M@JC\\TP&G9O.CQ- MYES^>ML;]UY_8EH@Z+;Q5,M^*<5AN;U2'8N\G%_,(=]28-CE]21+9F)OMX:* MVXMQ]]=;F(FUNI_Y?.QU>WA3!_K6[8P9%L0DAQ4/:GTL"@AA#GC"/RF)CQ^K M9();/RS8_*7QF"E++F9?A8D;!+')V/%FQ$_YW;/QC,;)A,1SGA_"A)"2TG@D MH7';C":D4:P(*M$F9(.U\^MK*)KZS2`9%.R]4/.K[5BV&B<8;50 M1%QU-B93;KS@U&`*RTB8O`_BXE1>6:X+0VOL$;AZ2)1GX=`VLB(8A2-O"CY$IQ65O#N`B,*T>@('ZQ"IDUKT0Y3X$$A;*V!X1"F?B% MX<\:$&[<.>G0N1M(GV@44=@!B-BMI*`4%7E9&31:>81X,,3ZPN.]YR=C\@"^ M=$?B$*A//F4_"H:]NLQ,O\RK\K>UHB0[&4S3`7F54*=GG^`[9T!XNA.`)7Q, MOXS;)'9",QF"K>!+.T,GX&7ZU5I-H6<-A(.HL>`K9V7Z1=HF`909RXX;HX*5 M1T`8OXVC2E#@J$V/AN*%R&;IG@K&T!1^V?,&CO_(2[]EY:4N0\;^04.^%\9Z MD=1/1(C%0PT]6V)=1 ME^QO5;I'I'N#2Y''Q6YP56?3[).C:ZF=Q2->RYHG`HD5-$8WJ>J"LO[P*,(F M5FQ.%=8B1<75@82_?J0[BJ0J8&.H*A-KLL.*W:O2QA9L8=4#39HLMFL[:UVV MK8%E;M\5U&9/,=AWHVN4;7-LM#PV+;0ULV>&:NFF8E!QJ MY)(*TX0K_3'4=F`E\K:MH,&HI&F,715O6DL< M2137E;"+WG6(M\S1JXQ=VM9T+J>^M26JVY%P*,Q*^C2ZYX<\<2\;*`E-G7M5 MC)Y>5FY%R<+D!:Q:N`I+L""M M944\EA2)4$?C5DV6TJ(1NH,1(;HB%"MQ,%U:8E'RN9/&072_>&,IGMXL1J(-]JT),26D+ MW:&NEEL1Z5486%"7N2#G,(V]&7CE,`X\XH39E\/'RV,4V5##*XU'(-*S..)W MYVQR?*Z.OZ!V\ZZ&M6-1@]?F-IJZCS3.:\9G%LHKRC?A*C+N1D>*/?J+VL*: M$O9K\O`G?!S?SP0MQ3:SBHS"6.9I-[R4>M68:^>_X7_=`5OXY/\`4$L#!!0` M```(`#0P%$,W#Z]BR0H``,1>```1`!P`/6?_@Y>7[7W@%CKI M3B:9.01(VML$9X!D.OTR1]@B:-I(M"0GI'_]EGS#X`LV26]\EN0AQTA5I?JJ MI)+*E#C];3FWM0?,!6'TK-*L-2H:IB:S"+T_J]R,JNU11]OWQ\;%&V0-Z9/R;J)DLG[@1<[B)0UF" MS&=_-AO?EQ-NUY93T+B+)+0?-)JM>N-C_:`Q;C1/WA^=-!LYY4LD'1'*;RP; M_E\^]BLBS)"Y?G3X]?'#;AQ^L=6R2Q1]_7?TX:-_=Z=Z0I\*BW)/+F\?%QW>T-2&.4KC5]T:VZZIX@@4/)T$LR MZ`D5$E%SC=Z2(4.4^+#N=:Z1DD32(X^4!*06WJ`3V*S=LX1=/D6.#\[X[R"93@JV*)A&_QU+-=[%`)MXJ+U@VB%(&JPOBA]^BVA8+`LL' M&OYVJN;9B;+K&+37U`-$C33IJKL.J\]1FB)JP7\BGY0L/G?'J&C$.JMD4JA1 M00=W7`M/"26N^J`-:M>(P[(9E@2T-?S M0$9_N@M:N[E`>[^H@@]\C2GZXFK4I M[".""&-Z'<'H.28'7;I#CM06#P=WFPF'8_A@#"_;`_UK>ZP;`ZT]Z&KG[9$^ MTHP+[7K8&_4&8[=G3UW2)]\=`G/\">Q\R2"]A/EK8NX[(K4WW?P?-LW?UW^_ MT;OZ^,ZU_:6A#RZUCC'H](;[:O,!DQAV\"T=.[TZW^ M<=/J`V/<&VG7[;OV>;^G58>]?GORD(S?&PX0?0Y3O#3K[:_N19.:W&;,MS$47!C2)]&R>U)%NZX-- M6X_&1N?S)Z,/$WWT+YCN%WI''^^IC:\Q52_$VR8<4@19'1\3VM,MW-JT\'5O MT%5GE'8'SBTC?8_/AB-G(O!W!P#U'E2,\"?P9FNZ;=_'9N_-^:CW^PU$"JUW MJ^+%GEHV]8@W5BUBRSG0)TJW^V&1TZ#VSI.WKV\-TG*<+I:(V&*`.'=/)-D9 M48PZW3NQ!#4C0]+>^8*U4/*^^BEU.?@6VK)H`JITO\0RU^Q5XPM\RH3?6 M37[R=`<52G+?5D[TO>@#YI*`Z:-N2'947N)T-^5/@-]\E)T4)WLH'VFJ?PYR M)LUOSLE*YI)=DXM MX0\6(*5HD\JB'ZHHY[_B9M8U9XR69*E'/@,:JIJXZ>&G."JL2,KE/SU6!0*XM9&$E(FS^\W,5H0@.UDI@ MLX@>*R[OL;H2L),6@IB%=0AXU,.SQY<+7ER!@,E]2E?!K\-V$Q+WHD-[.H7D M'4EL3%5Q-N:=&<'3WA*;CDH@#.@V,;_"\PGF%5?ULTHQ'C01DB-3GE4D=V#/ MI,2VU2\X>5JXI"3F8M/>*C M]H(3&V9FHQC#MW<[/7(YO>V_IP@SUERTSW^[X5&`%$+O7P#BM8THQ=;:%_(+)DB( M*XM@J_+>-TXRZ)IXUYP!%)XH`5%$1DH;B'<)XF#TK5<-UGDI06EW]3./6'%M9NY&_&@9W92Q<:$I&L M[E$;T]65]UQ&V,9:0@/`].VP^0)3X8\3F=<;'064_9].YQO*,;+)#VQ=PJ;( MZ`4BW/T=)6.:YF`^LD[%4TF$@YFT;"2BC\7:VDMT39-[B`;IBSB M)*SG][,BW[G)"5+XI?-S))1U6;B7&\;L@E`8C0"Z\)RP>:S(0UFZ4T3T[L;: MW4&\E.=V))3E(=PU)9:!C)=(KV(UW#$HV21E`)%J;/<&9N+$RT%=NLF7]Y+D M)N#B?*6#GN8S'T)>%\?(2P?4@%R2MZT'%:O%!43]:*6-3LV^;8;?;>8BW3DQ M_\G[9Q\+T7%+#N4UX]'C>V)/66%LF6FI:[(X7^FFJCJPZ6!U[KTJ5:<9;.E4 M8HY%Y,U7-E%9_9IY7S/5JT6Y2NC3')<@8V_+BS&5#G2.ZX7Q=V(%6$H'>/O% MO4V\13C*!]?AY@SYI677B%AMRW(QJ-^`]?%EDKSZR^W3NE M`Q0````(`#0P%$-SB'9=-#4```2F`0`1`!@```````$```"D@0````!S:6UH M+3(P,3,P-C,P+GAM;%54!0`#A#X34G5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`#0P%$,>ND'#"`T``,*:```5`!@```````$```"D@7\U``!S:6UH+3(P M,3,P-C,P7V-A;"YX;6Q55`4``X0^$U)U>`L``00E#@``!#D!``!02P$"'@,4 M````"``T,!1#TX(J)MX(``"K4```%0`8```````!````I('60@``&UL550%``.$/A-2=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`-#`40TOG\TDK+```I6$"`!4`&````````0```*2!`TP``'-I;6@M M,C`Q,S`V,S!?;&%B+GAM;%54!0`#A#X34G5X"P`!!"4.```$.0$``%!+`0(> M`Q0````(`#0P%$,9CB?*?Q<``+I/`0`5`!@```````$```"D@7UX``!S:6UH M+3(P,3,P-C,P7W!R92YX;6Q55`4``X0^$U)U>`L``00E#@``!#D!``!02P$" M'@,4````"``T,!1#-P^O8LD*``#$7@``$0`8```````!````I(%+D````L``00E#@``!#D!``!02P4&```` /``8`!@`:`@``7YL````` ` end XML 49 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCKHOLDERS' DEFICIT
6 Months Ended
Jun. 30, 2013
Notes to Financial Statements  
NOTE 7 - STOCKHOLDERS' DEFICIT

Common stock

 

On February 9, 2013, the Company issued a total of 50,000 shares of common stock to two consultant for services valued at $1.15 per share. As a result, the Company recorded stock compensation in the amount of $57,500 for the three months ended March 31, 2013.

 

On June 28, 2013, the Company issued a total of 25,895 shares of common stock to a public relations firm as settlement of its services valued at $1.50 per share. As a result, the Company recorded stock compensation in the amount of $38,842 for the three months ended June 30, 2013.

 

On June 11, 2013 and June 28, 2013, in connection with a Securities Purchase Agreement and convertible promissory note (“Note”) in the principal amount of $37,500, the Company converted the Note into a total of 29,128 shares of the Company’s common stock at a conversion price of $1.36  per share.

 

Stock Options

 

On March 7, 2013, the Company granted to its Chief Technology Officer 150,000 seven-year stock options with an exercise price of $0.50 per share. The Company determined that the fair value of the options was approximately $159,000 using the Black Scholes method and recorded as stock compensation in the accompanying condensed consolidated financial statements.

XML 50 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
LIQUIDITY AND GOING CONCERN
6 Months Ended
Jun. 30, 2013
Notes to Financial Statements  
NOTE 2 - LIQUIDITY AND GOING CONCERN

The condensed consolidated financial statements have been prepared on a going concern basis, and do not reflect any adjustments related to the uncertainty surrounding our recurring losses or accumulated deficit.

 

The Company currently has limited revenue and is experiencing recurring losses. These factors raise substantial doubt about its ability to continue as a going concern. Management has financed the Company's operations principally through loans from an affiliate of the Company’s former CEO, who is also one of the principal shareholders. Through June 30, 2013, the Company obtained its liquidity principally from approximately $582,000 of cash advances from an affiliate of the former Chairman and CEO and the Company's principal shareholder. The Company may need to continue borrowings from an affiliate of the former Chairman and CEO and the Company's principal shareholder and will also need to raise additional capital. However, management cannot provide any assurances that the Company will be successful in completing this financing and accomplishing any of its plans.

 

The ability of the Company to continue as a going concern is dependent upon continued financial commitments from related parties and eventually secure other sources of financing in addition to those funds provided by its affiliate and attain profitable operations. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 R13.xml IDEA: PENDING ACQUISITION 2.4.0.80013 - Disclosure - PENDING ACQUISITIONtruefalsefalse1false falsefalseFrom2013-01-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-01-01T00:00:002013-06-30T00:00:001true 1simh_NotesToFinancialStatementsAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2simh_PendingAcquisitionTextBlocksimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Prime Time Medical:</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 26, 2013, the Company entered into a Stock Purchase Agreement (the &#147;Stock Purchase Agreement &#148;) with Prime Time Medical, Inc., a Florida corporation (&#147;Prime Time&#148;) and Mark R. Miklos, the sole equity holder of Prime Time (&#147;Miklos&#148;). Prime Time is a Durable Medical Equipment provider of home medical equipment servicing consumers throughout West Central Florida.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Stock Purchase Agreement, at the closing Miklos will transfer to the Company all the outstanding shares of capital stock of Prime Time for an aggregate purchase price of up to $3,100,000, subject to certain adjustments as summarized herein. The purchase price will be paid in a combination of cash, promissory notes and shares of the Company&#146;s common stock</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On the closing date, the Company will make a total cash payment to Miklos as follows: (a) if the closing occurs on or prior to May 26, 2013, the Company shall pay $950,000 at closing, (b) if the closing occurs after May 26, 2013 but on or prior to June 26, 2013 the Company shall pay to Seller $1,050,000 at closing, and (c) if the closing occurs after June 26, 2013, the Company shall pay to Seller $1,150,000 at closing. The Purchase Agreement requires total deposits of $400,000 to be paid towards the purchase price, to be paid by June 26, 2013. As of June 30, 2013 the Company has paid $300,000 and recorded an accrual for $100,000. Subsequently the company paid an additional $50,000, which has resulted in the seller granting the Company additional time to close.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, at closing, the Company will issue two additional promissory notes (the &#147;Prime Time Notes A and B&#148;) to Miklos in the aggregate principal amount of $1,000,000.&#160;&#160;Prime Time Note A in the principal amount of $500,000 will bear interest at 5% per annum, with monthly payments of principal and interest, and will mature three years after the closing date.&#160;&#160;Prime Time Note B in the principal amount of $500,000 will bear interest at 5% per annum, with annual payments of interest and principal payable annually over two years from the date of closing provided; however, that the principal balance of Prime Time Note B (and the respective annual payment) shall be reduced if: (i) the earnings before income taxes, depreciation and amortization (&#147;EBITDA&#148;) for the fiscal year ended December 31, 2013 is less than $975,000; and/or (ii) the EBITDA for the fiscal year ended December 31, 2014 is less than $975,000. At Miklos&#146; option, Prime Time Note B can be paid in shares of common stock of the Company on terms acceptable to Miklos and the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total consideration also includes $750,000 in the form of shares of restricted common stock of the Company (the &#147;Shares&#148;), with the number of Shares to be issued to be determined at closing by dividing $750,000 by the average of the highest bid and lowest asked prices for the Company&#146;s common stock as quoted on the OTC Bulletin Board, the OTC Pink Sheets or other similar quotation system, as applicable, at the end of the trading day immediately preceding the closing (the &#147;Original Issuance Price&#148;). If as of the first anniversary of the closing Miklos has not received at least $1,500,000 of the purchase price in the form of cash (including from the payment of principal on Prime Time Notes A and B and the sale of Shares in the public market), then, following such first anniversary, Miklos may put, and Company shall promptly purchase from Miklos in cash, such number of Shares equal to the difference between such cash payments and $1,500,000 divided by the Original Issuance Price.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Purchase Agreement also requires the Company to enter at closing into an employment agreement with the Seller for certain management services and; also contains a covenant of the Seller not to compete with the Company for a two year period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Purchase Agreement further provides that the Company will engage its independent registered public accounting firm to prepare an audit of Prime Time&#146;s financial statements for the years ended December 31, 2011 and 2012. If, for any reason the audit cannot be concluded, the Company will not be required to pay any amounts due under Notes A or B and such notes will be cancelled. The Company, however, has no right to receive a refund of the cash portion of the purchase price as tendered or to effect a cancellation of the Shares. In addition, if Prime Time&#146;s total asset value at December 31, 2012 as determined in accordance with the audited financial statements is less than the value set forth on the financial statements previously provided to the Company, the purchase price will be reduced by such amount on a dollar for dollar basis through a return of a number of Shares equal to such deficiency, and, if the deficiency is greater than the Original Issue Price, through a set off of the amount which will be due under Note A.</p>falsefalsefalsenonnum:textBlockItemTypenaCustom ElementNo definition available.false0falsePENDING ACQUISITIONUnKnownUnKnownUnKnownUnKnowntruefalsefalseSheethttp://sanomedics.com/role/PendingAcquisition12 XML 53 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONVERTIBLE NOTES PAYABLE (Details Narrative) (USD $)
3 Months Ended 6 Months Ended
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Dec. 31, 2012
Debt Instrument [Line Items]          
Convertible note payable $ 31,250   $ 31,250   $ 12,500
Beneficial conversion features of convertible debts     125,365 0  
Interest expense 30,898 0 54,337 0  
On August 24, 2012 [Member]
         
Debt Instrument [Line Items]          
Convertible note payable 31,250   31,250   12,500
Percentage of interest rate on convertible note 9.00%   9.00%   9.00%
Unamortized discounts 43,750   43,750   62,500
On December 6, 2012 [Member]
         
Debt Instrument [Line Items]          
Convertible note payable 0   0   4,688
Percentage of interest rate on convertible note 8.00%   8.00%   8.00%
Unamortized discounts $ 37,500   $ 37,500   $ 32,812
XML 54 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
NOTES PAYABLE -RELATED PARTY (Tables)
6 Months Ended
Jun. 30, 2013
Notes Payable -Related Party Tables  
Schedule of Notes payable

    June 30,     December 31,
    2013     2012
           
Notes Payable consists of the following:          
           
Secured Convertible Promissory Note - CLSS Holdings, LLC, dated September 30, 2010. Note accrues interest at 9% per annum, due and payable on October 1, 2013(A)   $ 181,000     $ 181,000
Secured Convertible Promissory Note - CLSS Holdings, LLC, dated March 12, 2011. Note accrues interest at 9% per annum, due and payable on October 1, 2013 (A)     367,000       367,000
Secured Convertible Promissory Note - CLSS Holdings, LLC, dated September 30, 2011. Note accrues interest at 9% per annum, due and payable on September 30, 2013(A)     220,000       220,000
Secured Convertible Promissory Note - CLSS Holdings, LLC, dated March 12, 2011. Note accrues interest at 7.5% per annum, due and payable on October 1, 2013 (A)     334,787       334,787
Convertible Promissory Note-Officer, dated June 17, 2013. Note accrues interest at 9% per annum, due and payable on March 30, 2015, net of discount of $703,339 (B) Refer to Note 5     -       -
               
Total     1,102,787       1,102,787
               
Other advances from CLSS Holdings, LLC, not evidenced by a promissory Note (A)     858,132       276,640
      1,960,919       1,379,427
               
Less: Current portion     858,132       1,379,427
Notes Payable-related parties   $ 1,102,787     $ -

XML 55 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8
PENDING ACQUISITION (Details Narrative) (USD $)
Jun. 30, 2013
Pending Acquisition Details Narrative  
Purchase price paid $ 300,000
Accrual amount 100,000
Purchase price paid an additional $ 50,000
XML 56 R15.xml IDEA: NOTES PAYABLE -RELATED PARTY (Tables) 2.4.0.80015 - Disclosure - NOTES PAYABLE -RELATED PARTY (Tables)truefalsefalse1false falsefalseFrom2013-01-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-01-01T00:00:002013-06-30T00:00:001true 1simh_NotesPayableRelatedPartyTablesAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2us-gaap_ScheduleOfShortTermDebtTextBlockus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00<p style="margin: 0pt"></p> <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>June 30,</b></font></td> <td nowrap="nowrap" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt"><b>December 31,</b></font></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2013</b></font></td> <td nowrap="nowrap" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2012</b></font></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td></tr> <tr style="vertical-align: bottom"> <td><font style="font-size: 10pt">Notes Payable consists of the following:</font></td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%; text-align: justify"><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated September 30, 2010. Note accrues interest at 9% per annum, due and payable on October 1, 2013(A)</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">181,000</font></td> <td nowrap="nowrap" style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; text-align: right"><font style="font-size: 10pt">181,000</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated March 12, 2011. Note accrues interest at 9% per annum, due and payable on October 1, 2013 (A)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">367,000</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">367,000</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated September 30, 2011. Note accrues interest at 9% per annum, due and payable on September 30, 2013(A)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">220,000</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">220,000</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Secured Convertible Promissory Note - CLSS Holdings, LLC, dated March 12, 2011. Note accrues interest at 7.5% per annum, due and payable on October 1, 2013 (A)</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">334,787</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">334,787</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Convertible Promissory Note-Officer, dated June 17, 2013. Note accrues interest at 9% per annum, due and payable on March 30, 2015, net of discount of $703,339 (B) Refer to Note 5</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Total</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,102,787</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,102,787</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Other advances from CLSS Holdings, LLC, not evidenced by a promissory Note (A)</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">858,132 </font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">276,640 </font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,960,919</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,379,427</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Less: Current portion</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">858,132</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,379,427</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Notes Payable-related parties</font></td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,102,787</font></td> <td nowrap="nowrap">&#160;</td> <td>&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td></tr> </table> <p style="margin: 0pt"></p>falsefalsefalsenonnum:textBlockItemTypenaTabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false0falseNOTES PAYABLE -RELATED PARTY (Tables)UnKnownUnKnownUnKnownUnKnowntruefalsefalseNoteshttp://sanomedics.com/role/NotesPayable-RelatedPartyTables12 XML 57 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
DERIVATIVE LIABILITIES (Details Narrative) (USD $)
Jun. 30, 2013
Dec. 31, 2012
Derivative Liabilities Details Narrative    
Fair value of derivative liabilities $ 1,847,560 $ 40,697
XML 58 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8
Document and Entity Information
6 Months Ended
Jun. 30, 2013
Aug. 16, 2013
Document And Entity Information    
Entity Registrant Name Sanomedics International Holdings, Inc  
Entity Central Index Key 0001501972  
Document Type 10-Q  
Document Period End Date Jun. 30, 2013  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Is Entity a Well-known Seasoned Issuer? No  
Is Entity a Voluntary Filer? No  
Is Entity's Reporting Status Current? Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   26,508,609
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2013  
XML 59 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
STOCKHOLDERS' DEFICIT (Details Narrative) (USD $)
3 Months Ended
Jun. 30, 2013
Stockholders Deficit Details Narrative  
Stock compensation $ 38,842
XML 60 R1.xml IDEA: Document and Entity Information 2.4.0.80001 - Document - Document and Entity Informationtruefalsefalse1false falsefalseFrom2013-01-01to2013-06-30http://www.sec.gov/CIK0001501972duration2013-01-01T00:00:002013-06-30T00:00:002false falsefalseAsOf2013-08-16http://www.sec.gov/CIK0001501972instant2013-08-16T00:00:000001-01-01T00:00:00sharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli01true 1simh_DocumentAndEntityInformationAbstractsimh_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 2dei_EntityRegistrantNamedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Sanomedics International Holdings, Incfalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:normalizedStringItemTypenormalizedstringThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false03false 2dei_EntityCentralIndexKeydei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse000001501972falsefalsefalse2falsefalsefalse00falsefalsefalsedei:centralIndexKeyItemTypenaA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1 false04false 2dei_DocumentTypedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse0010-Qfalsefalsefalse2falsefalsefalse00falsefalsefalsedei:submissionTypeItemTypestringThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".No definition available.false05false 2dei_DocumentPeriodEndDatedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse002013-06-30falsefalsetrue2falsefalsefalse00falsefalsefalsexbrli:dateItemTypedateThe end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.No definition available.false06false 2dei_AmendmentFlagdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:booleanItemTypenaIf the value is true, then the document is an amendment to previously-filed/accepted document.No definition available.false07false 2dei_CurrentFiscalYearEndDatedei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00--12-31falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:gMonthDayItemTypemonthdayEnd date of current fiscal year in the format --MM-DD.No definition available.false08false 2dei_EntityWellKnownSeasonedIssuerdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Nofalsefalsefalse2falsefalsefalse00falsefalsefalsedei:yesNoItemTypenaIndicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.No definition available.false09false 2dei_EntityVoluntaryFilersdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Nofalsefalsefalse2falsefalsefalse00falsefalsefalsedei:yesNoItemTypenaIndicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.No definition available.false010false 2dei_EntityCurrentReportingStatusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Yesfalsefalsefalse2falsefalsefalse00falsefalsefalsedei:yesNoItemTypenaIndicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.No definition available.false011false 2dei_EntityFilerCategorydei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Smaller Reporting Companyfalsefalsefalse2falsefalsefalse00falsefalsefalsedei:filerCategoryItemTypestringIndicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.No definition available.false012false 2dei_EntityCommonStockSharesOutstandingdei_falsenainstantfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalse2truefalsefalse2650860926508609falsefalsefalsexbrli:sharesItemTypesharesIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.No definition available.false113false 2dei_DocumentFiscalPeriodFocusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00Q2falsefalsefalse2falsefalsefalse00falsefalsefalsedei:fiscalPeriodItemTypenaThis is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.No definition available.false014false 2dei_DocumentFiscalYearFocusdei_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse002013falsefalsefalse2falsefalsefalse00falsefalsefalsexbrli:gYearItemTypepositiveintegerThis is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.No definition available.false0falseDocument and Entity InformationUnKnownNoRoundingUnKnownUnKnowntruefalsefalseSheethttp://sanomedics.com/role/Documentandentityinformation214